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General Introdution
Cervical cancer 
Cancer of the uterine cervix is a major cause of death worldwide. In 2000 cervical 
cancer was the second most common cancer in women accounting for more than 
11% of all feminine cancers. Annually, an estimated 490,000 women are diagnosed 
with invasive cervical cancer globally.1 The majority of the cases occur in developing 
countries, where it is frequently second in magnitude, with a lifetime risk of 1.5%.2 
In developed countries it accounts for 3.6% of the new cancers, with a lifetime risk 
of 0.8%. In the developed parts of the world cervix cancer is only seventh in 
magnitude with fewer cases than cancer of the corpus uteri and ovary.1 Fortunately, 
mortality rates are substantially lower than the incidence rates. Globally the 
mortality to incidence ratio is 0.47, still accounting for more than 230,000 deaths 
yearly. In the Netherlands, incidence declined from 762 in 1989 to 584 in 2003, see 
Figure 1. The age-standardized mortality rate decreased as well from 3.3 deaths per 
100,000 women in 1989 to 2.0 deaths per 100,000 women in 2003.3 Most probably 
the influence of the population-based screening programme contributes to these 
declines.1 The reductions are solely observed in squamous cell carcinomas, the 
incidence of adenocarcinomas appears to increase especially in young women aged 
15-29.4 Apart from non-specific symptoms like intermenstrual and post-coital 
bleeding the development of cervical cancer usually occurs without symptoms. 
Cervical cytological changes can be detected in an early and pre-invasive stage of 
the disease. Detection and treatment of these precursor lesions can effectively 
prevent cervical cancer.5 
Cervical cancer is believed to have a co-factorial aetiology in which human 
papillomavirus (HPV) infections are considered the most important factor.6,7 The risk 
of acquiring an HPV infection is highly associated with early sexarche, promiscuous 
precarious sexual behaviour, and sexual contact with promiscuous partners.7 The 
cofactors, i.e. long-term oral contraceptive use, high parity, other sexually transmitted 
infections, cigarette smoking, and viral cofactors as viral load, integration, genotype 
and variants influence the likelihood of HPV persistence and progression towards a 
(pre-)malignant cervical lesion.8 
Anatomy of the uterine cervix
Non-keratinising squamous epithelium covers the ecto-cervical area (i.e. the external 
part of the cervix), whereas the endo-cervix (i.e. the internal part of the cervix) is 
covered with glandular columnar epithelium. The border between these two 
epithelia is called the squamo-columnar junction (SCJ). From puberty onwards 
columnar epithelium is replaced by squamous epithelium in a physiological process 
of metaplastic transformation. The SCJ is shifted more towards the endo-cervix thus 
forming a new SCJ. The transformation zone (TZ) is the area between the original 
and new SCJ. Due to the high cell-turnover rate, this zone is presumably more 
susceptible to oncogenic influences.9 The majority of all (pre) malignant lesions 
develop in this particular area.10 Generally, cervical lesions are detected using cervical 
cytological, i.e. cervical scrapes or smears. Colposcopy and histological examination 
are performed respectively to identify and finally diagnose the lesion. 
1
Figure 1  Incidence and mortality of cervical cancer in The Netherlands
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Detecting, identifying, and diagnosing cervical lesions
Carcinoma in situ of the uterine cervix had already been acknowledged a precursor 
of invasive cervical cancer in 1932 by Broders.11 Subsequently, Pap Anicolaou and Traut 
demonstrated that exfoliative cytology could be used to detect both in situ and 
invasive carcinomas of the uterine cervix.12 Cervical lesions potentially progressing 
towards invasive carcinoma were initially diagnosed as dysplasia characterized by a 
disturbed epithelial architecture and cellular atypia of the epithelial cells. In the late 
60’s Richart hypothesized that cervical cancer develops from non-invasive stages, 
thereby introducing the terminology of cervical intraepithelial neoplasia (CIN).13 
Decades later it is generally accepted that CIN precedes squamous cell carcinoma of 
the uterine cervix. The pre-malignant CIN lesions are classified solely by 
histomorphological criteria, i.e. nuclear atypia, presence, frequency and localization 
of mitotic figures and the loss of polarity of the nuclei. According to the thickness of 
the epithelium involved in dysplastic alterations, CIN is hereby subdivided in low-
grade lesions CIN 1 (involvement of less than one third of the epithelial layer), and 
high-grade lesions CIN 2 (one to two thirds involved) and CIN 3 (up to the full 
thickness is involved). CIN 1 is considered equivalent to mild dysplasia, CIN 2 to 
moderate dysplasia, and both severe dysplasia and carcinoma in situ are equal to CIN 3. 
Twenty years after the introduction of Richart’s CIN nomenclature the Bethesda 
System for reporting results of cervical cytology was developed.14 The objective of 
this uniform system of terminology was to provide clear guidance for the improvement 
of patient management through the establishment of an optimal differentiation 
between lesions with a low- and high-risk of progression to carcinoma. The 
classification’s final revision in 2001 intended an even more standardized approach 
in women with equivocal cervical smears.15 Although, the Bethesda system and its 
local versions are used frequently, various other nomenclatures for the cytological 
and histological description of cervical abnormalities circulate and are sometimes 
used interchangeably. In the Netherlands for instance a modified Papanicolaou 
system, the CISOE (in Dutch KOPAC) classification was used since the introduction of 
the nationwide cytological screening in 1988. In this system five items are scored 
according to the acronym Composition, Inflammation, Squamous epithelium, Other 
abnormalities and endometrium and Endo-cervical columnar epithelium. The S, O, 
and E are the only parameters specifying the smear classification as used in the other 
nomenclatures concerning cytological pathology. In 1996 this classification system 
was revised, resulting in CISOE-A (in Dutch KOPAC-B), where the A stands for the 
adequacy of the cervical smear.16 Due to the revisions, cytology and histology are 
more concordant. Borderline nuclear changes resulting from inflammatory epithelial 
changes or from atrophic cells for instance are now classified as Pap 1 (i.e. normal 
pap-smear) instead of Pap 2. This has led to a significant decrease in Pap 2 smears 
diagnosed in the Dutch population-based screening programme from 9.8% in 1990 
to 1.9% in 2000 (P<0.001), without any changes in the detection rate of high-grade 
cervical lesions (stable at 0.9%).17 Simultaneous to the revision concerning the Pap 2 
smears, screening-age limits, interval-time between recommended smears, and 
repeat and referral recommendations were changed. This caused a decrease in total 
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Table I  Overview of the most frequently used cytological and histological  
classification systems, modified from Bulk, et al. (with permission).17
Bethesda 2001  WHO CIN BSCC  CISOE-A Pap
Squamous Glandular    S O E
Unsatisfactory    Inadequate 0 0 0 Pap 0
NILM  Normal  Normal  Normal  1 1 1-2 Pap 1
BCC/NILM/Atrophy      1 2 1-2 
ASC-US/ASC-H AGC   BNC 2-3 3 3 Pap 2
LSIL  Mild CIN 1 Mild 4 4 4 Pap 3a
   dysplasia  dyskaryosis 
  AGC favour  Moderate CIN 2 Moderate 5 5 5 Pap 3a
  neoplastic dysplasia   dyskaryosis    
HSIL  Severe   Severe 6 6 6 Pap 3b
   dysplasia  dyskaryosis 
   AIS Carcinoma  CIN 3  7 - 7 Pap 4
   in situ   
Invasive carcinoma Adeno- (Micro-) Carcinoma Invasive 8-9 7-8 9 Pap 5
  carcinoma  invasive   carcinoma
   carcinoma
WHO: World Health Organization; CIN: cervical intraepithelial neoplasia; BSCC: British Society Clinical Cytology; 
CISOE-A: the Dutch cervical cytology classification; S: Squamous epithelium; O: Other abnormalities and 
endometrium; E: Endocervical columnar epithelium; Pap: Papanicolaou classification; BCC: benign cellular  
changes; NILM: negative for intraepithelial lesion or malignancy; ASC-US: atypical squamous cells of  
undetermined significance; ASC-H: atypical squamous cells cannot exclude HSIL; HSIL: high-grade squamous 
intraepithelial lesion; AGC: atypical glandular cells; BNC: borderline nuclear changes; LSIL: low-grade squamous 
intraepithelial lesion; AIS: Endocervical adenocarcinoma in situ
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number of smears (approximately 27%), although the number of regular screening 
smears increased (approximately 10%). In Table I the most frequently used cytological 
and histological classification systems are listed and related next to one another.
The current population-based screening programme
Non-invasive abnormalities of the uterine cervix are generally detected through 
cervical smears. Opportunistic or non-organised screening can reduce cervical 
cancer rates, but it may not adequately cover the targeted population, thereby 
specifically missing those at highest risk.18 Large-scaled organised detection of 
cervical pathology i.e. population-based screening programmes (PSP), perform 
substantially better than non-organised programmes.19 Depending on the screening 
interval and the age range of target group, PSP could establish a decline in mortality 
rate of 80-95%, providing that the participation rate is maximal.20 Screening interval 
and accordingly lifetime number of recommend smears varies significantly 
throughout Europe, from 5-yearly interval and 7 smears in Lithuania, Finland, and 
parts of France, to yearly interval and more than 60 smears in Germany and 
Luxembourg.21 Since, liquid based cytology is at least as good as conventional 
cytology22, the present Dutch cervical cancer screening is based on either method 
supported by screening laboratory. In general, family doctors perform the cervical 
smears. It consists of a 5-yearly screening of women aged 30-60 years, leading to a 
recommended lifetime number of 7 smears. Approximately 70% of the invited women 
actually participate in the Dutch screening programme, this leads to a mortality 
reduction of 56%.23 Optimising the sensitivity of the screening method and the 
screening interval, and increasing the participation rate of the target population to 
100%, the mortality reduction rate will increase to 70%. This could for instance be 
achieved by adding a high-risk human papillomavirus test with a sensitivity of 100%.23 
According to the consensus guidelines from 1996, cytology indicating either atypical 
squamous cells of undetermined significance (ASC-US) or a low-grade squamous 
intraepithelial lesion (LSIL) (also BMD; borderline and mild dysplasia) need to be 
repeated after 6 months. In case of persistent cytological abnormalities the patient 
is referred to the gynaecologist for colposcopic examination, whereas normalised 
cervical smears are repeated 12 months later. Patients with smears more severe than 
LSIL are immediately referred for a similar assessment. Based on the latest guidelines 
of the Dutch Pathology Association approved and published in July 2006, all BMD 
smears are repeated after 6 months and tested for presence of Human papillomavirus 
(HPV)24, see “HPV assessment in screening” below. 
Management and natural behaviour of abnormal cytology 
Colposcopy guided biopsy samples are obtained to histologically diagnose a cervical 
abnormality; this is considered the gold standard. Adequate colposcopic images 
visualize the entire transformation zone, the impressions are enhanced by application 
of a 3% acetic acid solution. The classification of colposcopic impressions is a 
prediction of the expected histopathological findings. The quality of estimating the 
extent and severity of the lesion is related to experience and skills of the colposcopist 
and can thus be highly biased. Average inter-observer agreement for instance 
appeared to be moderate (52.4%) in experienced colposcopists, the level of 
agreement interpreting CIN 1 and CIN 2 lesions was lower than the agreement in no-
CIN and CIN 3 lesions.25 Ideally, a biopsy ought to be taken from all colposcopically 
suspected areas. However, generally a biopsy is only taken from the most severe or 
susceptible lesion visible. This could lead to misclassification of the underlying CIN 
lesion due to sampling error of multifocal lesions or histologically heterogeneous 
lesions.26 
Subsequent to colposcopy and biopsy, various treatment options for high-grade CIN 
are available depending on the preference and experience of the gynaecologist. 
Regardless of the ablative therapy method used, the risk of an invasive cancer of the 
uterine cervix is reduced by 95% during the first 8 years following a successful 
treatment of pre-malignancies. Nonetheless, the chance of developing invasive 
cancer of the cervix for a treated woman is still increased five times compared to 
healthy individual.27 To date, there is no convincing evidence suggesting a superior 
surgical treatment technique for high-grade CIN.28,29 However, for several decades 
the large loop excision of the transformation zone (LLETZ) has been the most widely 
used method treating cervical pre-malignancies.30-33 Using the LLETZ, CIN lesions are 
in general adequately eradicated, while anatomy and function of the cervix are 
maintained.31,34
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Since, this multiple step strategy has increased the number of colposcopy 
appointments, time between referral and definite diagnosis, and subsequently 
expenses, Bigrigg and colleagues introduced a one-step protocol.35 In case colposcopic 
assessment revealed a high-grade CIN lesion LLETZ was immediately performed. In a 
patient-control study, the histological diagnosis of the “see-and-treat” procedure 
has recently shown to be highly comparable with the diagnostic findings of the 
multi-step procedure.36 Using the one or three step large loop excision treatment 
success rates varying from 81% to 98% can be achieved.28,31,33,34,37,38 
Unfortunately, over-treatment of low-grade CIN is the penance for the accessibility 
and the low specificity of the LLETZ procedure. For achieving adequate and well-
deliberate treatment, knowledge on the pro- and regressive behaviour of squamous 
intraepithelial cervical lesions is compulsory. In a review Östör showed that CIN 1 will 
progress to CIN 3 in 10% of the cases and to invasive cancer in only 1%.39 CIN 3 lesions 
on the other hand will advance to invasive carcinomas in 12%, whereas spontaneous 
regression will occur in 33%.40 Projections by Peto and colleagues, however implied 
that without a screening programme around 40% of the CIN 3 cases would eventually 
progress to invasive cancer if left untreated.5 Of the women diagnosed with a single 
ASC-US smear only 7% have shown progression to a high-grade CIN lesion within 24 
months, while 68% normalised.41 Uncertainty however endures about the exact 
timescale of pro- and regression of “any-grade” CIN. If in defensive medicine all 
women with abnormal or persistently abnormal smears would be referred for 
colposcopy, this would irrevocably lead to a substantial overkill. Especially, since a 
large proportion of the women with ambiguous cervical cytology (i.e. Borderline and 
mild dysplasia (BMD) smears) will never develop cervical cancer.42-44 Nevertheless, 
the risk of developing cervical cancer in BMD smears should not be underestimated, 
but should be carefully deliberated in the light of unfavourable health effects as 
unnecessary referrals, high anxiety levels45,46, and cost effectiveness.47 A not 
insignificant factor in the decision-making is that neither cyto- nor histomorphological 
markers of cervical intraepithelial abnormalities can predict the biological behaviour 
of CIN. Recently however, several studies found that abnormal cytology in women 
who tested negative for high-risk human papillomavirus will definitely not 
progress.42,44 
Human papillomavirus (HPV)
A large body of clinical, molecular and epidemiologic studies have shown that a 
persistent infection with high-risk human papillomavirus (hr-HPV) is needed for 
the development of both cervical cancer and its high-grade non-invasive 
precursors.43,44,48-53 This association is unique in cancer epidemiology, since it is the 
largest association ever identified.43,52
Papillomaviruses (PVs) are small, nonenveloped viruses with 55 nm diameter 
icosahedral capsids that contain double-stranded DNA genomes of approximately 
8,000 base pairs. Based on their capsid structure and biochemical composition these 
microorganisms were originally lumped with the polyomaviruses in one family, the 
Papoviridiae. Since taxonomic classifications should reflect natural relationships, it 
was concluded that these viruses form two separate families. The International 
Committee on the Taxonomy of Viruses (ICTV) has recognised this and separated the 
families accordingly, Papillomaviridae and Polyomaviridae.54 
Papillomaviruses are widely spread throughout the animal kingdom, each of those 
viruses being highly specific for their respective hosts. They specifically infect 
squamous epithelia and cause a generation of warts.55 The infectious aetiology of 
warts was first described by Chandler in 1845. While removing a large circular 
condyloma, he accidentally injured his assistant beneath the thumbnail. “There 
appeared after a short time a wart, which was repeatedly destroyed, but reappeared, 
until the nail of the injured thumb was removed” (cited in Ullmann).56 Two hundred 
years ago genital warts and even cervical carcinoma were regarded manifestations 
of venereal diseases not uncommon for the era.57 In 1917, this assumption was 
abhorrently disputed by exposing extracts of a penile condyloma on sites of the 
forearm of a researcher and the genital mucosa of a “virgo intacta”. The unfortunate 
subjects respectively developed flat warts and genital condylomata.58 In the 30s of 
the last century several experiments had shown that the warts transmitted from 
cottontail rabbits to domestic rabbits were susceptible to malignant progression in 
the domestic animals.59,60 
Regardless of their small size, the molecular biology of PVs is very complex. It consists 
of a ‘late region’, a non-coding long control region, and an ‘early region’. The two late 
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region open reading frames (ORFs) L1 and L2 encode two structural proteins 
composing the major and minor capsid proteins, respectively. The non-coding region 
contains regulatory elements. The early region ORFs encode proteins that are 
supposed to be expressed before the onset of viral DNA replication. Three of the 
early ORFs are the oncogenes E5, E6, and E7, modulating the transformation process. 
Moreover, there are two regulatory proteins, E1 and E2, modulating replication and 
transcription. Moreover, E2 negatively influences the expression of E6 and E7.55 
Although human papillomavirus was already identified as crystalline virus-like 
particles in 194961, it took approximately 30 years before HPV DNA from condylomata 
acuminata was characterised and cloned.62-64 Eventually, this has led to the discovery 
of associated HPV sequences in cervical cancer.65 In the following years the full 
genomes of various papillomviruses became available. Presently, the complete 
genomes of almost all isolated papillomavirus types have been fully sequenced.54 
The rapid increase in number of PVs identified, uttered the need for a taxonomic 
classification. Using phylogenetic criteria the taxonomic levels ‘family’, ‘genus’, 
‘species’, ‘types’, ‘subtypes’, and ‘variants’ evolved. Since the L1 ORF is the most 
conserved gene within the genome, it has together with the E6 and E7 ORFs been 
used for identification of new papillomavirus types, subtypes and variants for the 
last two decades.54 In order to identify a new type, the L1, E6, and E7 ORFs should 
differ by more than 10% from the closest type known. Differences of 2-10% lead to 
detection of a new subtype, whereas differences of less than 2% need to be observed 
in case of intratype variants. 
The papillomavirus genotypes infecting humans can be divided in cutaneous and 
mucosotropic types, based on their tissue preferences. This variability in local tissue 
tropism is probably explained by the presence of type-unique binding sites for 
cellular factors on the non-coding region of the viral genome.66 The cutaneous types 
are found in the skin and cause common warts. The mucosotropic HPV types infect 
the mucous epithelium of the oropharynx and anogenital tract. Approximately 40 
different genotypes exhibit a tropism for the mucosa of the anogenital tract. 
Considering their carcinogenicity these anogenital HPV types have been subdivided 
into low-risk types (lr-HPV), probable high-risk types and high-risk types (hr-HPV)67, 
although some controversy remains regarding the probable high-risk genotypes.68 
Almost all squamous cell cervical cancers harbour hr-HPV types.52 High-risk HPV 16 
alone accounts for 50% of the cervical cancer cases worldwide.69 Other predominating 
types are HPV 18, 31, and 45. Together with HPV 16 they account for 80% of the cases.6 
In a pooled analysis of multiple case-control studies the IARC estimated an odds 
ratio of 158 for the association between cervical cancer and the presence of HPV.67 
Although the evidence of HPV induced carcinogenesis is strongest for cervical 
cancer, HPV infections have, with lesser evidence, also been associated with 
carcinoma of de vagina, vulva, penis, anus, skin, and oropharynx.70 
HPV mediated carcinogenesis 
Persistently hr-HPV positive women with abnormal cytology are reported to have a 
327 times increased risk of developing high-grade lesions.43 And although a genital 
HPV infection can occur in an early stage, persistence of a type-specific hr-HPV 
infection is considered a necessary requirement in the carcinogenesis of cervical 
cancer.71 The established key-event of HPV-induced oncogenesis is the integration of 
viral-DNA in the human genome.55 
The expression of the viral proteins is very tightly regulated and dependent on cell 
differentiation. Once the integrity of the basal layer is compromised due to micro-
traumata or environmental changes HPV can infect the epithelium. Recently it was 
suggested that following absorption to the cell surface, capsomeric structure 
remains largely unchanged for many hours.72 Uncoating may be facilitated by the 
disassembly of intracapsomeric interpentamer disulphide bonds in the reducing 
environment of the cell’s cytoplasm hereby allowing transportation of viral DNA into 
the nucleus.73 The viral genome is maintained as low copy number episomes in the 
basal layer of the epithelium. Vegetative DNA amplification occurs only in squamous 
epithelial undergoing terminal differentiation. Viral mRNA can be detected in low 
levels in the infected basal cells, but transcription of the viral genome is predominantly 
increased in the differentiated layers.74 Papillomaviruses completely depend on the 
host cell’s replication mechanism for DNA synthesis. Preservation of viral DNA as an 
episome is however most likely done by expression of E1 and E2.75
Frequently, hr-HPV DNA integrates near common fragile sites of the host genome76, 
and this is believed to occur somewhere in the gradual process of progression of a 
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CIN lesion. Integration not infrequently results in the disruption of the viral E2 
region, inducing an over-expression of viral E6 and E7 oncoproteins.77,78 Whereas in 
low-grade CIN E6 and E7 are expressed in low levels in the basal layer, the expression 
increases throughout all epithelial layers in high-grade CIN lesions and cervical 
cancer. The proteins encoded by E6 and E7 show high resemblance with oncoproteins 
of other DNA tumour viruses. Successively, the oncoproteins interfere with two 
crucial mitosis-regulating pathways of the host cell, the p53-pathway and pRb-
pathway, respectively. The E6 protein targets the p53 protein, which normally 
induces growth arrest or apoptosis. The binding of E7 to the active form of the 
retinoblastoma protein (pRb) causes inactivation of pRb and subsequent release of 
the host transcriptional factor E2F. This factor will eventually disrupt the cell cycle 
regulation. Accordingly, E6/E7-induced inactivation of these pathways results in 
hyperproliferation (E7 related) and genetic instability, numerical and structural 
chromosome aberrations and immortalization (all E6 related) (reviewed by Zur 
Hausen).79 
In cervical carcinomas E6-induced chromosomal aberrations as deletions, transloca-
tions and inversions have been reported in chromosomes 1, 3, 6, 9, 11, and 17.80 
Structural rearrangements of chromosome 1 for instance have been described in 
90% of the cervical cancers.81 Also, the mean number of chromosome copies per 
nucleus, i.e. chromosome index (CI), for chromosome 1 shows a significant positive 
correlation with CIN grading.82,83 E7-induced hyperproliferation expresses the prolife-
ration-associated Ki-67 antigen that is recognized by the monoclonal antibody 
MIB1.84 The Ki-67 labelling index (percentage of MIB1 positive cells) has been 
propound a promising alternative method for classification of CIN lesions.85-87 As 
opposed to cyto- or histomorphological markers of a CIN lesion, the parameters 
related to aberrations of chromosome 1 and those related to cell proliferation are 
suggested to have predictive value regarding the natural behaviour of CIN.
HPV detection and genotyping
Since HPV cannot be cultured in conventional cell cultures and serological assays are 
of limited value as they are not able to distinguish between present and past 
infection, accurate diagnosis of HPV infections relies on the detection of viral nucleic 
acid (NA).88 HPV DNA can be detected in cytological smears and histological samples 
by a number of methods that have been developed over the past 25 years. Amongst 
these techniques are i) non-amplified NA hybridisation methods as Southern Blot, ii) 
signal-amplified, immunoassay-based NA hybridisation methods as the Hybrid 
Capture assay, and iii) a variety of target-amplification systems like type-specific 
polymerase chain reaction (PCR) and consensus-primer PCR techniques. The non-
amplified NA hybridisation methods are insensitive89 and very laborious. To overcome 
these problems and to increase both sensitivity and specificity various amplification 
methods were developed (see for review Molijn, et al.).88 These NA amplification 
techniques could also enlarge the appropriateness for mass screening. Snijders, et al. 
recently stated that the efficacy of population based screening programmes solely 
using cervical cytology could benefit from adding hr-HPV testing.90 Accordingly, 
many ongoing international research projects have been assessing the feasibility of 
introducing hr-HPV tests in the available routine screening. 
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Figure 2  The outline of the HPV-DNA genome, presented in linear form with  
the positions of the early (E) and late (L) genes, and untranslated 
regions (UTR) indicated, as well as the positions and size of the four 
most widely used primer-sets for HPV detection/genotyping.  
Adapted form Molijn, et al. (with permission).88
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Apart from categorising the tests based on the technique used, contemporary tests 
can be divided according to their actual purpose, i.e. hr-HPV detection or HPV 
genotyping. Tests distinguishing high-risk HPV infections from no HPV infection for 
instance could be specifically valuable for mass-screening purposes. Especially, since 
merely hr-HPV genotypes are essential in the carcinogenesis of the uterine cervix. 
The non-radioactive signal-amplification method Hybrid Capture II (hc2, Digene 
Corp., Gaithsburg, Maryland, USA) and the recently developed target-amplification 
method Roche Amplicor® HPV Test (Roche Molecular Systems, Inc., Branchburg, NJ, 
USA) are two of these alleged “hr-HPV plus/minus” screening methods which are 
currently commercially available, CE marked and frequently used. The hc2 test is 
however the only FDA registered HPV screening assay.91 Since, both tests only 
differentiate between an infection with one (or more) of 13 hr-HPV genotypes and 
no hr-HPV infection, neither one of the assays allow individual identification of 
specific genotypes, nor do they have the ability to identify infections harbouring 
multiple genotypes. This is regrettable as recent studies have provided evidence for 
a difference in oncogenic potential between the different hr-HPVs92 arguing for the 
importance of HPV genotyping in a clinical setting. Outside of the clinical setting, 
HPV genotyping is a key-characteristic of studies evaluating i) the epidemiology of 
HPV infections worldwide93-95, ii) HPV vaccination/surgical treatment trials 88,96-100, 
and iii) cervical cancer screening and triage.43,90,101,102
In order to detect and genotype HPV DNA in a single sample using type-specific (TS) 
primers, multiple polymerase chain reactions ought to be used separately. However, 
particularly if multiple genotypes are present this method is too laborious. 
Additionally, the type-specificity of each PCR TS primer set should be validated. As an 
alternative, a broad spectrum of HPV types can be amplified using consensus or 
general primers. Predominantly these primers target a section within the most 
conserved region amongst HPVs, the L1 ORF.88 Various primer designs are available 
for HPV assessment. The most commonly used are the GP5+/6+ PCR system, the 
Roche Amplicor®, the PGMY primer set, and the SPF10 primer set. These PCR primer 
sets vary substantially in their design and the size of the PCR product they amplify, 
see Figure 2. Generally, the PCR efficiency is dependent on the amplimer size; the 
larger the product the less efficient the reaction. Formalin-fixed and paraffin-
embedded samples frequently show DNA degradation, therefore HPV assessments 
using primer sets generating large PCR products are inappropriate and their 
efficiency is considerably lower than primer sets generating smaller PCR products.103 
In contrast the various consensus primer assays show comparable results in 
detecting HPV in liquid-based cytology samples. Subsequent to the amplification of 
HPV DNA, reverse hybridisation of the amplicon to multiple oligonucleotides 
provides the possibility to simultaneously type up to 37 different low-risk, possible 
high-risk and high-risk HPV genotypes. The oligonucleotide probes which recognize 
the different genotypes are frequently tailed with poly(dT) and immobilised as 
parallel lines to membrane strips. The assays called line blot assay (LBA), line probe 
assay (LiPA) or LINEAR ARRAY (LA) require only little amount of PCR product. A range 
of scientific papers have assessed and, on occasion, compared the various tests. 
Generally these tests are judged advantageous in the ability to rapidly genotype 
HPVs present in samples with high sensitivity and specificity.104-108 Thereby, minimizing 
the possibility of misclassification.104 
Besides the importance of specific HPV genotypes in the risk of (pre-)malignant 
deterioration of cervical lesions92, other viral cofactors as viral load and viral 
integration appear to influence the progression likelihood.8 Real-time PCR techniques 
have been developed to quantify HPV in clinical samples. However, due to low 
multiplicity for different hr-HPV types, real-time PCR methods are not (yet) suitable 
as a high-throughput screening tool.109 Moreover, the Hybrid Capture II provides a 
semi-quantitative measurement of HPV-DNA. The estimated hc2 load correlates well 
with the precise load generated by real-time PCR.110 Abnormal cervical smears with 
high viral loads have been suggested to have an increased risk to progress.111-115 These 
conclusions however could not be verified by other studies.116-118 The physical status 
of HPV DNA, i.e. episomal, mixed, or integrated, measured through the real-time PCR 
evaluation of the HPV 16 E2/E6 ratio is suggested a potential diagnostic marker for 
progressive cervical lesions.119,120 In general, the frequency of viral integration 
increased in parallel with the severity of the lesion. However, several studies have 
already reported a lack of sensitivity of this specific assay.121,122 Moreover, a study by 
Arias-Pulido and co-workers showed that exclusive viral integration occurs in 8.7% of 
the carcinomas in situ and only in 15.2% of the cervical cancers, whereas mixed 
infections were detected in 29.4% and 45.7% of the cases, respectively.121 This 
suggests the existence of other potential sites for HPV integration.76 Whether the 
E2/E6 ratio real-time PCR for HPV integration is already usable in routine detection 
of HPV integration remains questionable.
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HPV assessment in screening
As mentioned previously hr-HPV infection plays the key role in the multi-step 
carcinogenesis of cervical cancer. The sensitivity of hr-HPV testing for the detection 
of high-grade lesions is approximately 95%.123 The negative predictive value (NPV) of 
hr-HPV testing for the detection of high-grade CIN, i.e. the proportion of patients 
with negative hr-HPV test results who are correctly diagnosed not having nor 
developing high-grade CIN, is almost as high as 100%.124,125 This by far exceeds the 
sensitivity of conventional smears and liquid based cytology, respectively 58% and 
84%.124 HPV assessment could therefore play a significant role in population based 
screening programmes for cervical cancer, i.e. detecting of abnormal cervical 
cytology126, management of equivocal smears42,127, and follow-up management of 
women treated for high-grade CIN.128,129
However, the specificity of a positive high-risk HPV DNA test for high-grade CIN is 
lower than that of both conventional and liquid based cytology. Also, the positive 
predictive value (PPV) of hr-HPV assessment for the detection of high-grade cervical 
lesions -i.e. the proportion of patients with a positive hr-HPV test who are correctly 
diagnosed with a high-grade CIN- is low compared to the PPV of cytology.124,125 
Insignificant positive HPV test results are especially inconvenient for sexually active 
young women who experience the highest HPV prevalence. Providing an adequate 
immune response, the vast majority of these women will clear the HPV infection 
within 12-24 months.130,131 Moreover, 70% of the HPV induced low-grade CIN will 
regress spontaneously, whereas the regression rate is 100% in hr-HPV negative 
women.102 Viral clearance often precedes the cytological normalisation. In countries 
provided with a well-organised screening programme, this natural behaviour of HPV 
infections and the absence of a proper test discriminating persistent and transient 
infection, are responsible for the scepticism replacing cytology with HPV testing.132 
Introducing such an all-exclusive HPV detection strategy could however be a 
promising alternative to a cytological assessment in countries lacking an organised 
population based programme. 
Adding high-risk HPV detection to the conventional cytological screening could 
safely lengthen the interval period by 2-5 years in the Netherlands.133 Which would 
lead to a substantial decrease in the recommended lifetime number of smears. 
Particularly for countries with an opportunistic screening policy and therefore high 
numbers of recommended smears (e.g. Germany and Luxembourg) this could reduce 
costs considerably. The NPV of double negative tests, i.e. normal cytology and no 
presence of high-risk HPV, is close to 100%.134 Moreover, in several studies progression 
towards high-grade CIN lesions was not detected in women with an HPV-negative 
borderline and mild dysplasia (BMD) smear.127,135 Providing that all hr-HPV negative 
BMD women (65% of all BMD women) have their subsequent smear taken at the 
next screening round (after 5 years) and all hr-HPV positive women are reassessed 
after 6 months, referral to the gynaecologist for colposcopic assessment of this 
group could be markedly reduced. Berkhof and colleagues have recently shown that 
this approach is cost-effective.136 
Not to trivialize is the suggestion that incorporating HPV assessment would have a 
positive impact on the detection of glandular lesions,137 these rare but aggressive 
lesions are easily missed through regular cytological screening.132 High-risk HPV 
assessment might be helpful in detection of these lesions.138,139 
Since primary and exclusive HPV testing will lead to too many false positive referrals 
and HPV assessment combined with cytology will increase screening cost (especially 
if a liquid based approach has to be introduced simultaneously), triage management 
could be highly valuable. Considering triage, either abnormal cytological smears 
could be triaged using HPV assessment or persistently hr-HPV positive women could 
be triaged using cytology. The prospective, randomised clinical ALTS (ASCUS-LSIL 
Triage Study) trial concluded that HPV triage in ASC-US women is at least as sensitive 
as immediate colposcopy-guided biopsy for detecting CIN 3.140 For the LSIL smears 
the ALTS-trial was not able to determine a useful triage strategy, these smears were 
best management by direct colposcopy.141 More recently however Bias et al. 
suggested that hr-HPV negative persistent borderline and mild dysplasia smears will 
not develop cervical cancer, do therefore not need to be referred and can thus be 
followed in the regular population based screening programme.42 Based on repetitive 
positive high-risk HPV test colposcopy referrals could be reduced by approximately 
50% in BMD smears.42,44,127,140,142 Too high levels of HPV positivity however will 
negatively affect a triage management, in a UK study for instance 80% of the BMD 
smears appeared to be HPV positive.143 Since HPV predominantly affects young 
women, age could be a determining factor in triage. Cuzick and colleagues suggested 
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using HPV testing for primary screening in women older than 30 years, thereby using 
cytology to triage HPV-positive women. This approach could potentially improve 
detection rates of high-grade CIN without increasing the colposcopy referral rate.127 
How to manage the triage of younger hr-HPV positive women remains however 
equivocal. 
The previously described HPV assays generally detect 13 of the 15 most common hr-
HPVs. Adding more high-risk and probable high-risk genotypes will probably be of 
too little relevance for cervical cancer. Moreover, the possible increased sensitivity 
will be at the costs of a marked specificity loss.68 Recently, Castle, et al. discovered 
that hr-HPV 16 positive women had a significant five fold increased risk for 
developing high-grade CIN compared to women infected with any other high-risk 
HPV genotype.92 This suggests that, the clinical implications of HPV genotyping can 
be even more significant than HPV detection. However, HPV genotyping is too 
expensive to introduce as a routine screening tool. 
Following the introduction of high-risk HPV assessment in the USA, other countries 
will eventually implement hr-HPV testing. Only recently (July 2006) the Dutch 
Pathology association (NVVP) for instance has approved the new guidelines 
considering the triage of persistent BMD smears.24 In case of an initial BMD smear, 
cytology is repeated after 6 months. If the repeated smears indicated moderate 
dysplasia or worse, the women is immediately referred for colposcopic examination, 
whereas in all other cytological diagnoses hr-HPV is tested and recommendations 
are as indicated in Figure 3. For the countries still awaiting implementation of HPV 
testing, the most obvious questions rising are; which strategy and which assay to 
use and what are the costs? Regarding cost-effectiveness, both HPV DNA testing 
strategies, HPV triage and combination testing, appeared to be more effective than 
status quo screening policy in the UK, France, Italy and the Netherlands.144 The cost-
effectiveness of HPV genotyping as risk assessor has not been studied yet. 
In addition to the discussion on which HPV assessment strategy to use, the issue of 
the most appropriate detection method has risen. Particularly the dramatic variation 
in HPV prevalence in healthy women (normal cytology) probably depending on the 
assessment moment and on the HPV assay used has contributed to this debate. 
Herein, difficulties concerning analytical versus clinical sensitivity and specificity 
need to be overcome. The analytical performance measures refer to the proportion 
of HPV positive and negative women who are correctly classified by a given assay. 
The clinical sensitivity refers to the proportion of affected women (≥ CIN 3) who are 
correctly identified by a positive hr-HPV test, whereas the clinical specificity signifies 
the women without a lesion who are correctly classified negative by a given test.90 
In case a specific test is able to distinguish as little as 10 HPV DNA copies per sample, 
this could be very relevant from an analytical perspective. Both the virologist and the 
epidemiologist would welcome an assay with such a high analytical sensitivity, i.e. 
always detecting the virus if present. Thereby not taking the clinical implication of 
the test result in to account; in a sample that is barely hr-HPV positive, it is highly 
unlikely a high-grade CIN is detected. Recent studies have for instance shown that 
HPV 16 viral load measured using quantitative real-time PCR methods is proportional 
related to the severity of CIN lesions.104,115 These data support the concept that an 
increased HPV viral load in normal cytology increases the risk of developing pre-
malignant cervical lesions. Persistently high viral loads are subsequently associated 
with progression of the lesion, whereas clearance of a lesion is preceded by a 
decrease in viral load (Figure 4).90 
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Figure 3  Flow chart of the new policy of the Dutch pathology association 
(NVVP) regarding the follow-up of abnormal cytology and  
the HPV triage, modified from “de praktijkrichtlijn versie 2.0”.24
Hr-HPV: high-risk Human papillomavirus; PSP: population-based screening programme; 
BMD: borderline and mild dysplasia
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As previously mentioned, the observed variations in HPV prevalence and the 
following risk estimates for high-grade lesions may be partly attributed to the HPV 
assay used. Based on existing experiments, Snijders and colleagues concluded that 
of the most widely used consensus HPV test, the Hybrid Capture II assay has the 
lowest analytical sensitivity and the SPF10 the highest. Both the GP5+/6+ and the 
PGMY primer sets have intermediate analytical sensitivities.90 The relation between 
analytical and clinical sensitivity of the four different assays is schematically 
represented in Figure 4. 
Physicians ought to be aware of the stated differences and should be able to use and 
translate this information to the management of the individual patient. Accurately 
studying both the epidemiology of HPV and the global impact of HPV infections, and 
monitoring the HPV vaccination trials however, require a test with the highest 
analytical sensitivity possible.90 
Self-sampling
The participation rate of the Dutch population-based screening programme (PSP) is 
approximately 70%. Tragically, half of the cervical cancers are diagnosed in the 
remaining non-participating 30%. The reason why women do not participate varies 
from being afraid of the procedure or the possible diagnosis to having a too busy 
schedule. Although hr-HPV testing might have a beneficial effect in general patient 
management, the viral infection is often presented as or associated with sexually 
transmitted diseases. Implementing or adding an HPV test might affect a woman’s 
sexual relationship in terms of trust, fidelity and blame if a positive result is found, 
this could in turn negatively influence the compliance rate.23 Especially, if the general 
practitioner performing the test is acquainted with the partner involved. Genital 
self-sampling is a more anonymous and user-friendly alternative method for the 
collection of vaginal material. Since it is virtually impossible for a woman to obtain a 
desired cervical scrape of the transformation zone, self-sampled material is not 
suitable for cytological diagnoses. Material from vaginal lavages or self-sampling 
brushes is however highly representative for the cervical HPV status.145-147 Recently, 
Brink and colleagues have described a paper in preparation in which 1.6% of the PSP 
non-responders with a valid self-sample test appeared to have a high-grade cervical 
intraepithelial lesion.109 This is significantly higher than the high-grade CIN prevalence 
in the POBASCAM trial.148 These results not only show that women who do not 
participate in a well-organised screening programme indeed have a higher risk 
developing cervical cancer109,145,146, but also that hr-HPV testing on self-sampled 
materials might be a promising opportunity increasing the efficiency of population-
based screening programmes worldwide.109 Moreover, it illustrates the need for HPV 
tests with both high enough sensitivity and specificity and subsequent adequate 
patient management, in order to detect and subsequently treat high-grade cellular 
abnormalities of the uterine cervix in an early stage thereby reducing the risk of 
cervical cancer development. 
1
Figure 4  The concept of HPV load in cervical smears in relation to biological 
behaviour and the schematic representation of the relationship  
between the analytical sensitivity and the potential clinical sensitivity 
levels (for lesions ≥CIN 3) for normal and abnormal cervical smears. 
Modified from Snijders, et al. (with permission).90
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Aim and outline of this thesis 
The management of abnormal cervical cytology and pre-malignant cervical lesions 
has been debated for many decades. Traditionally, cytological and histological 
examinations were used for the screening, diagnosis, and follow-up of cervical 
abnormalities. However, since it is now widely accepted that high-risk human 
papillomavirus (hr-HPV) infections play a significant, but not sufficient, role in the 
development of virtually all cervical carcinomas worldwide, HPV assessment has 
become increasingly more issued. This sexually transmittable infection (STI) is highly 
prevalent in the general population, especially in sexually active young adults. 
Previous investigations have shown STI are more prevalent in subfertile patients. 
Chapter 2 describes the distribution of normal and abnormal cervical cytology in 
women eligible for In vitro fertilisation (IVF) and compares these smears with the 
smears of women in the population-based screening programme for cervical cancer. 
In chapter 3, cervical cytology is studied with regard to the follow-up of women who 
underwent a LLETZ procedure for a high-grade cervical lesion in a retrospective 
study. Chapter 4 reports the presence and persistence of (high-risk) HPV genotypes 
in histological samples, and cytological follow-up samples of women who were 
treated for a high-grade CIN. Accurate genotyping of HPV is essential when studying 
i) the epidemiology of HPV, ii) evaluating the efficiency of HPV vaccines or surgical 
procedures of the cervix, and iii) cervical screening and triage. A recently developed 
HPV genotyping assay is compared with a more established assay in chapter 5. Not 
every HPV positive women will eventually develop a (pre-) malignancy of the uterine 
cervix. Assessment of various proliferation markers in cervical smears could triage 
progressive and regressive CIN lesions in case of HPV positivity. This is studied in 
chapter 6. The worldwide advance and influence of HPV assessment assays is irrever-
sible and also self-sampling will become customarily. Chapter 7 reports the efficiency 
of HPV detection using a new method of sample storage and transportation. And 
finally in chapter 8, future directions are discussed in general, based on the results of 
the studies presented in this thesis.
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Abstract 
Chlamydia trachomatis is more prevalent in subfertile women than in the general 
population and is the leading cause of tubal factor subfertility. As C. trachomatis 
infections are sexually transmitted, it can be expected that infections with human 
papillomavirus (HPV) are also more prevalent in this group of women. HPV is a 
necessary cause for the development of cervical (pre-)malignancies. We therefore 
hypothesized that subfertile women are more likely to have HPV-induced cervical 
abnormalities compared to the general population. In this retrospective case-control 
study, all cervical smears of women visiting the fertility clinic for IVF (cases) and of 
women attending the population-based screening programme for cervical cancer 
(controls) were retrieved from an electronic database and assessed. The cases 
(n=669) showed significantly more abnormal cervical smears compared to the 
controls (n=77 055) (6.1 and 3.9%, respectively, P < 0.02). The probability that 
subfertile women eligible for IVF are diagnosed with a high-grade cervical lesion is 
almost twice as high compared to women in the general population. We therefore 
suggest to take a cervical smear from all women referred for fertility problems.
Introduction
Sexually transmitted infections (STIs) in adolescents and young adults (i.e. 10-19 and 
20-24 years of age, respectively) are a significant burden for health care worldwide. 
In the United States this age group represents approximately 25% of the sexually 
active population; however, they account for more than 65% of all registered STIs.1,2 
Chlamydia trachomatis and human papillomavirus (HPV) infections are STIs of 
specific interest because of the high prevalence rates and the association with tubal 
factor subfertility and cervical cancer, respectively. Both can be considered a marker 
reflecting promiscuous, precarious sexual behaviour noticeably increasing in the 
general population.3 
Prevalence of C. trachomatis infections varies from 5% in asymptomatic women in 
the general population4 to 24% in women assessed for fertility problems.5 Adolescence, 
nulligravidity, promiscuity and unmarried state are independently associated with 
an increased risk for Chlamydia infection.4 In a small percentage of infected women, 
an ascending infection will lead to pelvic inflammatory disease and ultimately to 
tubal factor subfertility, the third cause of subfertility in industrialized countries.6 
The estimated lifetime risk of contracting a genital HPV infection is 80%, whereas 
50% of the sexually active women will be infected within 2 years following the 
sexarche.7 Molecular and epidemiologic studies have shown that a persistent 
infection with high-risk HPV is the most important risk factor for the development 
of both cervical cancer and its precursors.8-10 Close to all of the cervical cancers11, 84% 
of high-grade cervical intraepithelial neoplastic lesions (CIN) and 74% of low-grade 
CIN lesions harboured the high-risk virus.12 Recent studies have shown that HPV 
persistence is associated with concurrent Chlamydia infection13 and that C. 
trachomatis antibodies were associated with a significant increase of squamous cell 
cervical cancer.14 
The presumed increase in promiscuous, precarious sexual behaviour results in 
sexually active adolescents who are at risk of acquiring HPV and C. trachomatis 
infections unaware of the fact that (tubal factor) subfertility and (the treatment of) 
severe cervical pathology could negatively affect family planning even many years 
following an infection. Because women with fertility problems have the highest 
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Chlamydia prevalence, suggesting promiscuous, precarious sexual behaviour and 
thus possible HPV infections, we hypothesize that women visiting fertility clinics are 
more likely to harbour high-grade cervical lesions than women in the general 
population. This study was undertaken to study this hypothesis. 
Materials and methods
In this retrospective case-control study, the cases were women who consulted the 
fertility clinic of the Department of Obstetrics and Gynaecology of the Radboud 
University Nijmegen Medical Centre in the period from 1 January 2000 to 31 
December 2003 and who had had either in vitro fertilisation (IVF) or intracytoplasmic 
sperm injection (ICSI) treatment. According to the policy of the department, cervical 
smears were taken before starting IVF or ICSI. The controls comprises women who 
had had a cervical smear taken within the population-based screening programme 
for cervical cancer in the same period. These smears were taken by a general practi-
tioner. Because, both fertility clinic and screening programme operated in the same 
region, demographic features of both cases and controls were considered 
comparable.
Women aged 29-42 years were included. The upper limit was applied since IVF is not 
performed in women older than 42 years, whereas the lower limit is based on the age 
of the first screening within the population-based screening programme. Although 
this programme starts at age 30, some women have their first smear taken at 29 
years of age, explained by the fact that women are generally invited in the year they 
are turning 30. Applying these criteria led to the inclusion of 669 cases and 77 055 
controls. 
The cytological results were retrieved from the local pathology database and were 
classified using the Dutch CISOE-A classification.15 This classification system 
discriminates between normal cytology, borderline nuclear changes (BNC), mild 
dyskaryosis, moderate dyskaryosis, severe dyskaryosis, carcinoma in situ, and 
carcinoma. Smears diagnosed equal to or more severe than BNC were considered 
abnormal. Furthermore, it is hospitals policy to perform colposcopy guided histology 
in all smears indicating ≥ moderate dyskaryosis. Smears showing BNC or mild 
dyskaryosis are repeated after 6 months and are referred for colposcopic evaluation 
in case of persistence. On the basis of classification system guidelines, all cervical 
smears classified as ‘insufficient quality for reliable diagnosis’ were repeated within 
6 weeks. Presuming that all ‘insufficient’ smears were reiterated, all cervical smears 
classified accordingly were excluded from the controls. With regard to the cases, 
‘insufficient’ smears were identified and replaced by the first consecutive cervical 
smear of sufficient quality. In case the only available smear was ‘insufficient’, the 
woman was excluded from the study. 
To study the relation between the incidence of abnormal smears and the primary 
cause of subfertility, additional data were collected from the electronic database of 
the fertility clinic. Only the most important subfertility diagnosis was listed in the 
database and thus taken into consideration. All women of subfertile couples, 
irrespective of age and fertility treatment modality, who had had a cervical smear 
and who were diagnosed with subfertility were taken into account. For this part of 
the study 1629 women were included. 
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Figure 1  Age distribution of 669 cases and 77 055 controls.
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Statistics
The chi-square test was used to test for significant differences between cases and 
controls in categorical nominal variables. Fischer’s exact test was used in case of two 
by two tables. Univariate logistic regression analysis was used to test differences in 
the incidence of severe abnormalities between groups. The (crude) odds ratio (OR) 
with 95% confidence interval (95% CI) is presented. Multivariate logistic regression 
was used to test differences in the incidence of severe abnormalities between 
groups adjusted for age. The adjusted odds ratio (adj OR) with 95% CI is presented. 
All test results with a probability (P) of <0.05 were considered to be statistically 
significant. The statistical analyses were performed with SAS version 8.2 software.
Results 
Meeting the inclusion criteria, that is age between 29 and 42 years and cervical 
smear taken of sufficient quality, the cases consisted of 669 women aged 34±3 
years, whereas the mean age of the 77 055 controls was 35±4 years. Age distribution 
for cases and controls is shown in Figure 1. 
The distribution of cervical cytology in the two groups is summarized in Table I. In 
comparison to the cases, the control group showed more normal smears. Smears 
indicating BNC and the smears showing moderate dyskaryosis or more severe were 
more frequently observed in the cases. The percentage of abnormal cytology (BNC 
or more severe) as observed in the cases was significantly different from the 
abnormal cytology as expected based on the findings in the control group (P=0.014; 
chi-square test). 
From moderate dyskaryosis onwards, it is compulsory to evaluate and verify the 
cytological abnormalities using (colposcopy-guided) histology. Table I summarizes 
that significantly more cases (1.95%) than controls (1.01%) had a cytological diagnose 
equal to or more severe than moderate dyskaryosis (P=0.017; OR 1.94 [95% CI = 1.12-
3.37]). Although the age distribution in the cases differed from the distribution in the 
controls (Figure 1), this did not affect the significant difference (adj OR 1.77 [95% CI 
= 1.19-2.65]). 
To study a possible association between cytological abnormalities and the various 
diagnoses of subfertility, the cervical smears of all women at the fertility department 
who had been diagnosed concerning their subfertility were assessed (disregarding 
age or IVF-status), as is summarized in Table II. In 38.6% of the women having an 
abnormal smear, subfertility was explained by female factors being menstrual cycle 
problems, cervical factor, tubal/uterine factor, and endometriosis (see Table II). 
However, the vast majority (61.4%) of cervical abnormalities equal to or more severe 
than BNC were found in women of couples diagnosed with male factor subfertility, 
couples with sexual problems and unexplained subfertile couples. 
The results of the diagnoses of the smears of women with tubal factor subfertility 
were compared with those of women with subfertility of other origin (excluded is 
male subfertility) (Table III). Although, smears indicating BNC, mild and severe 
dyskaryosis, and carcinoma in situ appeared more frequently in the women suffering 
tubal factor subfertility, the differences were not statistically significant (P=0.356; 
Fischer’s exact test). 
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Table I  Percentage of the distribution of cervical cytology in the  
cases (n=669) and the controls (n=77055) 
Cytology Cases Controls  
Normal  93.87 96.06
BNC 3.74 2.36
Mild dyskaryosis 0.45 0.56
Moderate dyskaryosis 0.60 0.34
Severe dyskaryosis 0.75 0.38
Carcinoma in situ  0.45 0.27
Carcinoma 0.15 0.02
BNC: borderline nuclear changes 
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Discussion 
In this study, abnormal cytology (i.e. ≥ BNC) was observed significantly more often 
in women eligible for IVF treatment (i.e. the cases) as compared with the women in 
the population-based screening programme for cervical cancer (i.e. the controls) 
(6.1% and 3.9%, respectively [chi-square test, P<0.02]). These results are in contrast 
to the observations by Lundqvist and colleagues. In a similar study, they found 
abnormal cytology in 2.3% of women admitted for IVF and in a corresponding 4.1% 
of the healthy control women from a screening programme.16 However, in the latter 
study, both case and control group were substantially smaller, encompassing just 214 
and 197 women, respectively. In contrast to this study, Lundqvist, et al. did not apply 
age limits -the cases were aged 20-40 years whereas the controls were aged 25-59 
years. Moreover, the results could neither be interpreted scientifically nor compared 
to our results since statistical analyses were not performed. 
The most important factor known in the development of CIN and cervical cancer is 
a persistent type-specific high-risk HPV infection.8-10 Because this study is entirely 
based on electronic data, HPV status was not and could not be included. Hormonal 
stimulation promotes HPV replication in vitro17 and in vivo.18 Long term exogenous 
oestrogen exposure in humans has shown an increased detection rate of HPV19 and 
appeared to be a risk factor for high-grade cervical lesions.20  
 
However, because the cases in our study consisted of nonpregnant women eligible 
for IVF, who neither used oral contraceptives nor received hormonal treatment at 
intake, higher hormone levels were considered unlikely to explain the observed 
difference. Moreover, Strehler and colleagues did not find a significant difference in 
cervical HPV DNA prevalence between infertile women undergoing ovarian hormonal 
stimulation and healthy control women.21 In addition, the study of Lundqvist and 
co-workers did not report significant differences in hr-HPV genotypes prevalence in 
IVF women compared to healthy controls (7% and 9.1%, respectively).16 Even 
cumulative HPV prevalence rates in infertile and healthy women do not seem to be 
significantly different. Van Ham and colleagues found a cumulative HPV prevalence 
of 75% in infertile women with normal cytology22, whereas Brown and colleagues 
found 82% in healthy adolescents.1
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The pathogenesis of cervical intraepithelial neoplasia is however not solely dependent 
on HPV. Smoking, promiscuity, early sexarche, long-term contraceptive use and 
immunosuppres-sion have been proposed as co-factors. Moreover, an independent 
role for the most prevalent STI, i.e. C. trachomatis was suggested by several 
epidemiologic and case control studies.14,23-25 Although endocervical glandular cells 
are the targets for C. trachomatis, the association between Chlamydia and cervical 
carcinoma was only applicable to squamous cell carcinomas.14 However, the 
association is modest in comparison with the strong effect of HPV infections. 
Possibly, a C. trachomatis infection might increase the host susceptibility to HPV or 
enhance the effects of HPV.26,27 Because, C. trachomatis-seropositive women appear 
to elicit a humoral-mediated rather than a cell-mediated immune response to 
particular antigens they may have an impaired ability to clear HPV.28 This hypothesis 
is supported by the finding that a self-reported history of previous Chlamydia 
infection was the most significant risk factor for the persistence of a HPV infection.29 
Therefore, it remains unlikely that C. trachomatis individually acts as a carcinogen of 
the cervix, but it may act as a trigger or an enhancer for HPV-mediated carcinogenesis 
of the uterine cervix. Both microorganisms are however sexually transmittable and 
evidently related to promiscuous, precarious sexual behaviour.
Another consequence of persistent C. trachomatis infections is a significant increase 
in the likelihood of developing tubal pathology and, subsequently, tubal factor 
subfertility.30 In addition to the association between Chlamydia infection and 
cervical pre-malignancies, we expect a higher frequency of abnormal smears in 
subfertile women suffering from tubal pathology. However, despite one case of 
moderate dyskaryosis, three cases of severe dyskaryosis and one case of carcinoma 
in situ in the ‘tubal pathology’ group, the data of this study do not support this 
hypothesis, because the majority of the abnormal cytological results were found in 
the ‘unexplained subfertility’ and the ‘male subfertility’ groups. This latter group is 
of specific interest since HPV has been found in substantial proportions of the sperm 
cells of patients who attended fertility clinics31,32 and in the vas deferens of 
vasectomized middle-aged men.33 Moreover, HPV negatively affects sperm cell 
motility, and the incidence of asthenozoospermia appears associated with sperm 
harbouring HPV.34 Although insufficiently studied, this work emphasizes the 
interesting possibility of sperm cells as a carrier for HPV transmission in unprotected 
sexual intercourse, eventually leading to cervical (pre-) malignancies. 
Two other or alternative confounding factors could however explain the observed 
differences in the present study: i) an urbanization trend and ii) intra- and 
interobserver variability. Squamous and glandular cell abnormalities were observed 
more frequently in cities exceeding 250 000 inhabitants in comparison to towns of 
20 000 - 250 000 inhabitants and villages of less than 20 000 inhabitants.35 This 
positive urbanization trend has also been described in association with HPV, bacterial 
vaginosis and Gardnerella infection.35,36 However, both the case and the control 
groups of women assessed in this study populate the same geographical area that 
encompasses only towns and villages. The town/village ratio was assumed to be 
equally distributed over the cases and controls. Several studies have described a 
significant intra- and interobserver variability in subclassification of squamous and 
glandular pre-malignancies based on cytology37-40 and histology.41 Although all 
patients in this study lived in the same area, the control group smears were taken by 
a different group of healthcare workers (i.e. general practitioners) and the smears 
were assessed by various laboratories in the district, whereas all smears from the 
cases were taken by gynaecologists and subsequently evaluated by the pathology 
department of the Radboud University Nijmegen Medical Centre. 
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Table III  The number (percentages) and totals of the distribution of cervical  
cytology in women diagnosed with tubal/uterine factor subfertility 
(n=188) and women diagnosed otherwise considering subfertility (n=753) 
Cytology Tubal/uterine factor Other factors Total
  [n (%)] [n (%)] [n (%)]
Normal  167 (88.8) 704 (93.5) 871 (92.6)
BNC 14 (7.4) 34 (4.5) 48 (5.1)
Mild dyskaryosis 2 (1.1) 3 (0.4) 5 (0.5)
Moderate dyskaryosis 1 (0.5) 5 (0.7) 6 (0.6)
Severe dyskaryosis 3 (1.6) 5 (0.7) 8 (0.9)
Carcinoma in situ  1 (0.5) 1 (0.1) 2 (0.2)
Carcinoma 0 (0.0) 1 (0.1) 1 (0.1)
Total 188 (100) 753 (100) 941 (100)
Male factor subfertility was not included in the groups.  BNC: borderline nuclear changes
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The higher prevalence of severe abnormal cytology in subfertile women visiting the 
outpatient clinic because of IVF treatment compared to the general population in 
the same geographical area suggests that sexually transmitted diseases are more 
present in subfertile women. Because, pathologists might be influenced by the 
clinical origin of a cervical smear, thereby judging smears from cases in a more 
enquired perspective, a possible bias could be considered. Provided that the results 
of this study are validated in a prospective randomized investigation with 
standardized sampling and assessment methods, we suggest to structurally perform 
cytological examination of the uterine cervix in all women assessed for fertility 
problems. Especially since cytological abnormalities are induced or enhanced by 
highly prevalent STIs that are related to promiscuous, precarious sexual behaviour 
and appear to be more common in patients visiting subfertility clinics. 
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Abstract 
Early treatment of cervical intraepithelial neoplasia (CIN) significantly reduces the 
risk of invasive cancerous progression. Residual and recurrent high-grade CIN should 
be detected and retreated in an early phase. Therefore, a post-surgery cytological 
follow-up protocol was introduced at 3, 6, 9, and 12 months and yearly thereafter for 
5 years. The aim of this study is to evaluate the long-term experience in treating 
high-grade CIN using large-loop excision of the transformation zone (LLETZ). 
Additionally, the long-term follow-up in this study gains the opportunity to 
document the pattern of disease recurrence beyond 5 years. The average follow-up 
of the 1696 women included in this study was 6.5 years. Overall, 8.5% of the patients 
who underwent LLETZ showed a high-grade repetitive CIN and three patients had 
invasive carcinoma. Eighty percent of those lesions were probably residual, whereas 
20% of all high-grade repetitive lesions appeared more than two years after initial 
surgery and were considered recurrent lesions. Half of the recurrent lesions occurred 
more than 5 years after LLETZ. 
Introduction 
Cancer of the uterine cervix is a major cause of death. In developed countries 
population-based screening programmes for cervical cancer to identify precursor 
lesions have significantly contributed to a reduction in mortality and morbidity of 
this disease. However, worldwide annual incidence and mortality rates are still high, 
respectively 500 000 and 230 000.1 
Using any form of cervical ablative therapy, the risk of an invasive cancer of the 
cervix is reduced by 95% during the first 8 years subsequent to successful treatment 
of high-grade cervical intraepithelial neoplasia (CIN 2/3). Nonetheless, the chance of 
developing invasive cancer of the cervix for women conservatively treated for CIN is 
still increased five times compared to the general population.2 To date, there is no 
convincing evidence suggesting a superior surgical technique for treating CIN.3,4 
However, for decades, one of the most widely used conservative methods is the 
large-loop excision of the transformation zone (LLETZ).5,6 Using the LLETZ, CIN lesions 
are in general adequately eradicated, while anatomy and function of the cervix are 
maintained.7-9 
Treatment success of LLETZ -defined as not having recurrence in the follow-up 
period of 24 months- varies from 81% to 98%.3,7,8,10-12 The vast majority of treatment 
failures transpires during the first two years following the procedure.13 Repetition of 
CIN may be due to inadequate treatment of the initial lesion (residual) or development 
of a new lesion (recurrence).10 In order to verify the adequacy of the treatment 
cytological follow-up is performed. Dutch guidelines from 1998 recommend 
cytological follow-up at 6, 12 and 24 months after a LLETZ procedure with 
histologically proven high-grade CIN lesion, after which the patient is referred back 
to the population-based screening programme for cervical cancer.14 
Prior to its introduction as treatment modality by Prendiville in 198912, we had 
already adopted the technique of the large loop excision. Preponderantly for 
scientific purposes, the Radboud University Nijmegen Medical Centre had formulated 
guidelines, posing cytological follow-up was to be executed at 3, 6, 9, 12 and 24 
months after LLETZ. Subsequently, the patients’ general practitioners were advised 
to perform a cervical smear annually during 5 years. Thereafter, the patients were 
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sent back to the cervical cancer-screening programme (cervical smear every 5 years 
to age 60). The purpose of this early and frequent collection of cervical cytology is 
particularly important in order to obtain sufficient data to document the effectiveness 
of the treatment15 and to evaluate our policy regarding ‘LLETZ and follow-up’ for the 
future. Therefore, the objective of this study was to present and evaluate our 22 
years of experience in treating high-grade cervical intraepithelial lesions using 
diathermy loop excision. Additionally, the long-term follow-up in this study gains the 
opportunity to document the pattern of disease recurrence beyond 5 years as 
suggested by Flannelly and colleagues.15
Materials and methods
Retrospectively, we have assessed all 2579 cases who underwent LLETZ at the 
outpatient clinic of the Department of Obstetrics and Gynaecology of the Radboud 
University Nijmegen Medical Centre from January 1981 to December 2001. Background 
information, data, and diagnoses of all patients were retrieved from an electronic 
database. From this group we have included only the patients (n=1696) having a 
diagnoses histologically proven high-grade CIN (2 or 3) using the primary loop 
excision. The latter inclusion date (December 2001) was used so that all patients 
could have had a follow-up of at least 2 years. 
Follow-up was done by cervical smear 3, 6, 9, 12, and 24 months after the initial 
procedure. Subsequently, the patients were referred back to their general practitioner 
carrying an advice to have a cervical smear performed yearly during 5 years, after 
which the patient was send back to the population-based screening program for 
cervical cancer. The follow-up cytology was classified according to the Pap-
classification. In case the follow-up cytology indicated a supposed high-grade 
squamous or glandular lesion (i.e. diagnosed as equal to or more severe than 
moderate dysplasia or moderate atypia), the patient would return for colposcopic 
assessment and re-treatment, if necessary. 
Cervix and transformation zone were visualized by colposcopy at our outpatient clinic. 
Assessment of the transformation zone was enhanced using a 3% acetic acid solution. 
If an abnormality, suggestive for high-grade CIN, was identified on the cervix, 
immediate excision of the whole transformation zone would follow using low-voltage 
diathermy loop excision under local anaesthesia, as previously described by our group.7 
As commonly used in literature we defined residual lesions as high-grade CIN or 
carcinoma occurring up to 2 years post-treatment, while recurrent lesions occur from 
2 years onwards.
Results
From January 1, 1981 to December 31, 2001, a total of 1696 women underwent a LLETZ 
for high-grade CIN (2 or 3). The mean age was 34.9 years (standard deviation 7.8 
years). The youngest patient was 18 years, while the eldest was 74 years. 80% of the 
women pertained to the age group of the population screening for cervical cancer 
(30-60 years), 19% was younger than 30 years and 1% exceeded the age related 
eligibility for screening. Histological examination of the 1696 excised samples 
revealed 443 cases of moderate dysplasia, 802 cases of severe dysplasia, and 451 
cases of carcinoma in situ. Therefore, CIN 2/3 distribution was 26/74%. 
The mean follow-up of the total group was 78 months, with a maximum follow-up 
of 22 years. Approximately 90% of the 1696 women completed a follow-up period of 
1 year, 80% a follow-up of 2 years. Of the 361 women failing to complete 2 years of 
follow-up, 2 had died, 36 had had a hysterectomy, 11 had moved out of our district or 
abroad, 5 had not yet shown up for their follow-up, 90 had unintentionally been send 
back to the population-based screening for cervical cancer, and 217 had been lost for 
follow-up.
A second procedure was performed in 268 cases: 179 re-LLETZ, 48 hysterectomies, 26 
biopsies, 11 conisations, and 4 endocervical curettages. In 1 biospy sample and 1 
Re-LLETZ specimen insufficient material resulted in indefinite diagnose, whereas in 
9 biopsies, 4 cone biopsies, 34 hysterectomies, and 24 re-LLETZ samples no 
histological abnormalities were found. In 144 cases (8.5%), histology after the second 
procedure revealed high-grade lesions, 3 patients had an invasive cervical cancer, 
and low-grade (LG) lesion was detected in 48 cases. High-grade and LG histological 
distribution per procedure is summarized in Table I. 
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Hysterectomies showing normal histology (n=34) were performed for various 
reasons: 4 cases of uterine prolapse, 13 cases of menorrhagia, 2 high-grade follow-up 
cytology, and 15 for an indeterminate cause. The cone biopsies, showing normal or 
LG histology (n=5) were performed because of high-grade cytology in follow-up in 2 
occasions; the reason for the others remains unclear. The re-LLETZ (63), biopsies (5) 
and curettages (1), showing no or a low grade histological abnormality, were 
performed because of involved margins in 2 cases, colposcopic findings in 3 cases, 
stenosis of the cervix in 5 cases, high-grade cytology in 47 cases, and unknown/low-
grade cytology in 27 cases. 
In case histology of the second procedures revealed a lesion equal to or more severe 
than high-grade CIN (n=147), 2 samples recorded involved margins, 10 cases of low-
grade follow-up cytology with suspected lesions at colposcopy, and 135 patients had 
a high-grade cytology somewhere in the follow-up period with a certain sampling 
date. 
In more than 50% of the 147 patients the residue/recurrence high-grade lesion or 
invasive cancer was detected within 4 months after the initial procedure, whereas 
within 2 years following LLETZ 80.3% of all high-grade residual lesions were detected 
and treated. Moreover, an additional 9.5% was identified between 2 and 5 years after 
the initial surgery. The remaining 10.2% of recurrences was detected longer than 5 
years after LLETZ (Figure 1). The disease-free interval between initial procedure and 
high-grade recurrence varied from 63 to 159 months. This included one invasive 
cancer that was detected 137 months subsequent to LLETZ. This patient had attended 
neither the follow-up regimen nor the population-based screening programme. She 
had a macro-invasive squamous cell carcinoma of the cervix, FIGO stage IIB, and was 
treated with chemoradiation. The two remaining cervical malignancies were 
detected at the first follow-up moment and subsequently treated successfully. Both 
patients underwent a hysterectomy. Histology revealed malignant micro-invasive 
growth in the cervix. The resection margins were not involved. The initial LLETZ 
specimens of the 3 patients having carcinoma had been reassessed and were once 
again diagnosed as carcinoma in situ.
Discussion
The LLETZ technique has been used and studied extensively since the initial reports 
by Cartier16 and Prendiville and colleagues.12 The treatment has shown to be 
innovative, cost-effective7,17, time-conserving17-19, successful3,7,8,10-12, and causing low 
morbidity.3 
The technique of LLETZ allows histological examination of the entire transformation 
zone, thus facilitating confirmation of diagnosis and detection of involvement of the 
excision margins. Assessment of these borders is of importance to determine the risk 
of recurrence, since incomplete excision of the CIN lesion is related to an increased 
prevalence of neoplasia.6,8,15,20-22 However, according to Buxton, et al. abnormal 
cytology is a better prognostic indicator than histologic examination of excision 
margins.23 Therefore, pathologists in our unit did not assess involvement of the 
excision margins. Moreover, larger lesions are removed in multiple fragments, so 
that orientation of the specimen, and therefore assessment of completeness of 
excision, is virtually impossible.24,25 
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Table I  Distribution of 2nd procedures and abnormal histology  
(percentages of 268) 
  LG lesions High-grade lesions
  CIN 1 CIN 2 CIN 3 Carcinoma Total
  [n (%)] [n (%)] [n (%)] [n (%)] [n ]
Biopsy  7 1 7 1 16
Curettage  1 1 2 0 4
Cone biopsy  1 0 6 0 7
Hysterectomy 0 2 11 1 14
Re-LLETZ 39 39 75 1 154
Total 48 (17.9) 43 (16.0) 101 (37.7) 3 (1.1) 195
LG: low-grade; CIN: cervical intraepithelial neoplasia; LLETZ: large loop excision of the transformation zone
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This study describes 22 years of experience in treating high-grade CIN in 1696 
women. The average follow-up was 6.5 years, which is 11 months more than the most 
extended trial described thus far.8 In case of reappearance of a high-grade CIN, the 
lesion was detected at the first follow-up moment within 4 months after LLETZ in 
more than half of the cases. Moreover, 80.3% of all repetitions were identified within 
24 months by strictly monitoring the patients; according to literature these are 
considered the residual lesions. Additionally, 9.5% (n=14) of the recurrent lesions 
became apparent from the third to the fifth year subsequent to LLETZ. The remaining 
10.2% (n=15) high-grade lesions recurred after 5 years of follow-up, showing a 
variation from 62 to 159 months. Our results show that 119 women have had a second 
procedure, histologically showing no abnormality or a low-grade cervical lesion. 
Our early-onset cytological follow-up is debatable. The effects of tissue regeneration, 
i.e. reparative changes, often visible subsequent to surgical treatment at the cervix, 
can result in over-estimative diagnoses. Colgan et al., for instance reported false-
positive diagnoses of high-grade CIN or even carcinoma in 3% of the selected smears 
classified as benign cellular changes with typical reparative change.26 In order to 
reduce this chance of overestimating smears with reparative changes, we have 
qualified cytology as aberrant if it was diagnosed equal to or more severe than 
moderate dysplasia or moderate atypia. This in contrast to other studies that have 
classified all cytology abnormal from mild dysplasia onwards. 
As previously suggested, long-term follow-up has to be executed in order to 
document the pattern of disease recurrence beyond the 5 years of follow-up.15 The 
enduring follow-up after LLETZ achieved in this study creates the opportunity to 
illuminate this issue. According to our data approximately 20% (29/147) of the high-
grade repetitive CIN lesions occurred after 2 years of normal follow-up; 9.5% (14/147) 
until the fifth year, and 10.2% (15/147) after 5 years of follow-up. Although arbitrarily, 
literature utters that residual lesions occur up to 2 years post-treatment and 
recurrence lesions from 2 years onwards. Therefore, the approximate 20% repetitive 
lesions after 2 years are all recurrences, resulting in a residue-recurrence ratio of 4:1. 
High-risk Human papillomavirus (hr-HPV) genotypes have great oncogenic potential; 
hr-HPV infection causes squamous and glandular intraepithelial lesions that can 
progress to invasive cervical carcinoma. The overall HPV prevalence in cervical 
cancers worldwide is 99.7%.27 An effective LLETZ procedure of CIN lesions is 
suggested to result in the eradication of hr-HPV types.28 Therefore, persistence of 
CIN requires perseverance of the hr-HPV infection.29 Consequently, de novo 
development of pre-malignancies would require re-infection with the same or other 
hr-HPV-types. Since, predictive value of a positive high-risk HPV test post treatment 
was higher than conventional abnormal smear, including hr-HPV tests in the follow-
up of women treated for high-grade CIN lesions was suggested.30 However, it was 
also reported that high-risk HPV detection in early follow-up after LLETZ has low 
positive predictive value.31 Moreover, sensitivity and specificity of the conventional 
follow-up cytology remain the highest 100% and 96%, respectively.31 So, currently 
there is no unambiguous opinion in routine follow-up screening HPV. 
Conclusively, this study shows that the majority of repetitive lesions can be detected 
within the first 4 months following LLETZ. Particularly interesting are the recurrent 
lesions after 5 years of follow-up, since the pattern of disease recurrence beyond five 
years has not been described in detail. 
3
Figure 1  Detection of 147 high-grade residual or recurrent CIN lesions  
in follow-up
CIN: cervical intraepithelial neoplasia; mo: months; yr: years
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Abstract 
Large loop excision of the cervical transformation zone (LLETZ) is a well-established 
treatment for high-grade cervical intraepithelial neoplasia. It has even been 
postulated that LLETZ is responsible for the elimination of the infectious agent, 
human papillomavirus (HPV), causing the lesion. Most studies on HPV detection 
after LLETZ have focussed on the persistence of high-risk (hr-)HPV to identify women 
at risk for residual or recurrent disease. Therefore, the appearance and or significance 
of hr-HPV types newly detected after surgical treatment has not been studied 
extensively so far. The presence of hr-HPV in 85 high-grade squamous cervical LLETZ 
biopsies and in the first follow-up smear was determined. In 80 (94%) of the LLETZ 
biopsies hr-HPV was detected in contrast to 30 (35%) hr-HPV positive follow-up 
scrapes. Twenty of the 80 hr-HPV positive women (25%) had the same hr-HPV 
genotypes in their follow-up cervical smears as was found in the corresponding 
biopsies. In the follow-up smear of 13 women a new hr-HPV genotype was detected 
and HPV 18 was newly detected in 8 of them. The remarkably high presence of newly 
detected HPV 18 genotypes may argue for a release or re-activation of this virus from 
proximal layers of the cervical canal incised during surgery.
Introduction 
Carcinoma of the cervix is the most common type of cancer in the developing world 
and the leading cause of death from cancer among women.1 In women with cervical 
cancer, malignant cells usually develop from cytologically abnormal tissue that can 
range from mildly dysplastic (“cervical intraepithelial neoplasia” CIN 1) to moderately 
or severely dysplastic (CIN 2/3). Women with cervical abnormalities indicative of HPV 
infection have a much higher incidence risk of cervical cancer than do those with 
normal cytology.2,3 Virtually all cervical carcinomas are associated with an infection 
by one of the high-risk HPV genotypes.4 Studies towards the oncogenic potential of 
these HPV types clearly support a causal relationship with cervical cancer 
carcinogenesis.5-7 To date, over 120 distinct HPV genotypes have been identified. 
About 30 of the known HPVs, and even a higher number of variants, have been 
detected in genital mucosa. These genital HPVs can be divided subsequently into 
groups based on frequency of association with malignant tumours, and thus 
presumed oncogenic potential. Thirteen HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68) are classified as high-risk types, directly associated with invasive 
cervical cancers.8
Large loop excision of the cervical transformation zone (LLETZ) is a well-established 
method of treatment of high-grade CIN lesions and has shown to be highly 
effective.9,10 It has even been suggested that effective surgical treatment of CIN also 
eliminates the HPV infection responsible for the lesion.11-13 Most studies on HPV 
detection after treatment for high-grade CIN have focussed on either the persistence 
of hr-HPV in general or type-specific persistence to identify women at risk for 
residual or recurrent disease.14-17 The appearance of new hr-HPV types after surgical 
treatment, however, has not been studied in detail so far.
To obtain more insight into this phenomenon, hr-HPV detection and genotyping was 
performed both on high-grade squamous cervical biopsies from 85 women treated 
with a large loop excision of the transformation zone (LLETZ), and on the 
corresponding first follow-up smear taken within 6 months after treatment.
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Materials and methods
All women, visiting the outpatient colposcopy clinic of the Radboud University 
Nijmegen Medical Centre between April 1997 and October 1999 and treated for high-
grade squamous cervical intra-epithelial neoplasia with a LLETZ, were eligible for the 
study. A high-grade squamous cervical lesion was histologically defined as CIN 2 or 
worse. All patients were first time referrals from the population-based screening 
programme for the prevention of cervical carcinoma. The referral cervical scrape 
indicating a high-grade lesion was performed by the general practioner and was 
unavailable for HPV assessment. The participants gave written informed consent 
after approval of the local ethical committee. The LLETZ procedures were undertaken 
by an experienced gynaecologic oncologist. 
The cervix and transformation zone were visualized by colposcopy. Assessment of 
the transformation zone was enhanced using a 3% acetic acid solution. If an 
abnormality, suggestive for CIN 2 or worse, was identified on the cervix immediate 
electrosurgical excision of the whole transformation zone would follow. After local 
infiltration of the paracervical tissue with 1 mL of 2% lidocainehydrochloride with 
epinefrine in every quadrant, an ERBE (Tubingen, Germany) ectrosurgical unit was 
used, together with a wire loop of appropriate size to excise the transformation 
zone, as described previously.9,10 
Within 6 months after the LLETZ procedure cervical scrapes were collected using the 
Cervex brush® (Rovers Medical Devices B.V., Oss, The Netherlands) and processed 
using a liquid-based approach (ThinPrep®, Cytyc Corp., Marlborough, MA, USA). 
An experienced pathologist, blinded for the results of the HPV test, performed 
histopathological and cytological examination. 
HPV detection was performed on the LLETZ biopsies as well as on the liquid-based 
cervical scrapes, using a broad-spectrum short fragment polymerase chain reaction 
(SPF10 PCR) assay as previously described.
18 In case of a positive HPV test, subsequent 
HPV genotyping was performed via a reverse hybridization line probe assay (LiPA), 
allowing for simultaneous typing of all hr-HPV genotypes. 
The SPF10-LiPA assay has proven to be sensitive, specific, effortless, and reproducible 
in the assessment of HPV in cervical scrapes and histological samples, and has been 
clinically validated.18-21 The assay has also shown to be highly comparable to other 
frequently used primer-sets.19,21 
Specimen preparation
A single 3µm thick section of every LLETZ-biopsy specimen was put into a reaction 
tube and incubated overnight at 56ºC in 200µL 10mM Tris-HCl with 1mM EDTA, 0.2% 
Tween-20 and proteinase K (0,3mg/mL). Proteinase K was inactivated by a 10 min 
incubation at 100ºC for nucleic acid isolation. The sample was centrifuged for 10 min 
at 11,000 rpm and 10µL were directly used for PCR analysis. 
The MagnaPure LC Isolation station (Roche Diagnostics GmbH, Molecular 
Biochemicals, Mannheim, Germany) was used for nucleic acid isolation of the 
cervical scrapes in liquid cytology media, was used; 200µL of material was isolated 
using the Total Nucleic Acid isolation kit (Roche Diagnostics GmbH, Molecular 
Biochemicals, Mannheim, Germany), as described by the manufacturer. Nucleic acid 
was resuspended in a final volume of 100µL; 10µL were used for PCR analysis. A water 
blank control was processed with each batch of 10 samples. After isolation of DNA, 
samples were tested for the presence of HPV by the SPF10-LiPA HPV detection/
genotyping assay. 
SPF10-LiPA HPV detection/genotyping
PCR amplification of HPV DNA
Broad-spectrum HPV DNA amplification was carried out using a short PCR fragment 
assay (SPF10-LiPA detection/genotyping assay system). This assay amplifies a 65-bp 
fragment of the L1 open reading frame, and allows detection of at least 43 different 
HPV types.18-20 SPF10-PCR system was carried out in a final reaction volume of 50mL, 
containing 10mL of the isolated DNA sample, 10mmol/L Tris-HCL (pH 9.0), 50mmol/L 
KCl, 2.0mmol/L MgCl2, 0.1% Triton X-100, 0.01% gelatin, 200mmol/L of each 
deoxynucleoside triphosphate, 15pmol each of the forward and reverse primers 
tagged with biotin at the 5’ end, and 1.5 units of AmpliTaq Gold® (Applied Biosystems, 
Foster City, Ca, USA). The mixture was incubated for 9 min at 94ºC, 40 cycles of 30 s 
at 94ºC, 45 s at 52ºC and 45 s at 72ºC, with a final extension of 5 minutes at 72ºC. 
Appropriate negative and positive controls were used to monitor the performance of 
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the PCR method in each experiment. The presence of HPV DNA was determined by 
hybridization of SPF10 amplimers to a mixture of general HPV probes recognizing a 
broad range of HPV genotypes, in a microtiter plate format, as described previously.18
Hr-HPV genotyping by reverse hybridization 
The HPV-genotyping assay was performed as described previously.19 Briefly, equal 
volumes (10mL each) of the biotinylated PCR products and denaturation solution 
(400mmol/L NaOH, 10mmol/L EDTA) were mixed in test troughs and incubated at 
room temperature for 5 minutes, after which 1mL of pre-warmed (37ºC) hybridization 
solution (3x SSC [1x SSC is 0.15mol/L NaCl plus 0.015mol/L sodium citrate], 0.1% SDS) 
was added, followed by the addition of one strip per trough. Hybridization was 
performed for 1 hr at 50±0.5ºC in a closed water bath with back-and-forth shaking. 
The strips were then washed twice with 1mL of wash solution (3x SSC, 0.1% SDS) at 
room temperature for 20 s, and once at 50ºC for 30 min. Following this stringent 
washing, strips were rinsed twice with 1mL of a standard rinse solution. Strips were 
then incubated on a rotating platform with an alkaline phosphatase-labeled 
streptavidin conjugate diluted in a standard conjugate solution, at 20–25ºC for 30 
minutes, after which strips were washed twice with 1mL of rinse solution and once 
with standard substrate buffer; colour development was initiated by the addition of 
5-bromo-4-chloro-3-indolylphosphate and nitroblue tetrazolium to 1mL of substrate 
buffer. After 30 minutes incubation at room temperature, the colour reaction was 
stopped by aspiration of the substrate buffer and addition of distilled water. The 28 
oligonucleotide probes which recognize 25 different types (including 13 hr-HPV 
genotypes) were tailed with poly(dT) and immobilised as parallel lines to membrane 
strips (Labo Bio-medical products B.V. Rijswijk, The Netherlands). The LiPA strips 
were manually interpreted using provided reference guide. The samples that tested 
positive using DNA Enzyme Immuno Assay but showed no results on the LiPA strip 
were considered to be HPV X-type, i.e., genotypes not available on the LiPA strip. 
Every hr-HPV genotype found in the follow-up scrapes, which was not detected in the 
LLETZ biopsy was considered as a non-identical hr-HPV type and further defined as 
“new” HPV type. Assessment of hr-HPV genotypes in the follow-up samples, identical 
to those found in the histological specimens were defined as “identical” types. 
Statistical analysis was performed by the McNemar’s test where appropriate; all test 
results with a probability (P) of <0.01 were considered to be statistically significant.
Results
Ninety women, treated for a high-grade squamous cervical lesion with a LLETZ, were 
eligible for the study. In 5 cases no follow-up smear was performed within 6 months 
after treatment therefore these women were excluded from the study group. The 
remaining 85 women had a mean age of 36 years (range 26-58 years) and had 
undergone at least one follow-up smear within 6 months (range 2-6 months) after 
the LETTZ procedure. 
High-risk HPV prevalence in the LLETZ biopsies
In 20 cases (24%) the LLETZ biopsy showed CIN 2 on histopathological examination 
and 65 cases (76%) had CIN 3 or worse (2 cases of micro-invasive carcinoma). In 80 
(94%) of the histopathological specimens, at least one hr-HPV genotype was found. 
In 4 of 85 (5%) biopsies a single low-risk (lr-) HPV type was detected and in one (1%) 
case no HPV DNA was detected. This HPV negative case was diagnosed histologically 
as CIN 3.
Multiple infections with at least one hr-HPV were present in 31 of 80 positive 
patients (39%), single hr-HPV infections were found in 49 of 80 patients (61%). The 
most common hr-HPV genotypes (as a single or as part of a multiple infection) 
detected in the biopsy were HPV 16 (56%), followed by HPV 31 (20%), HPV 52 (11%), 
HPV 33 and HPV 18 (both 9%), HPV 51 and 58 (both 8%), HPV 39, HPV 45 and HPV 56 
(all 4%). An overview is shown in Table I.
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Table I  Distribution of hr-HPV types in 80 hr-HPV positive LLETZ biopsies 
hr-HPV genotype
Infection 16 18 31 33 39 45 51 52 56 58
Single  28 4 4 3 1 1 3 4 1 0
Multiple  17 3 12 4 2 2 3 5 2 6
Total  45 7 16 7 3 3 6 9 3 6
Due to multiple HPV infections, the overall percentage of hr-HPV types exceeds 100%
80 81
High-risk HPV prevalence in the follow-up cervical scrapes
In 55 of 85 (65%) follow-up cervical scrapes, made after the LLETZ procedure, the hr-
HPV status was negative. In 8 of these hr-HPV negative cases, the cytological 
diagnosis revealed a mild disorder defined as atypical squamous (4 cases) or 
glandular (3 cases) cells of undetermined significance (ASC-US resp. ASG-US) and 1 
case as low-grade squamous intraepithelial lesion (LSIL), whereas the remaining 47 
cases had a normal cytological. In 30 of 85 (35%) of the follow-up scrapes hr-HPV was 
detected, which is statistically lower than the 94% hr-HPV positive biopsy samples 
(McNemar’s test, P<0.01). An overview of the results is shown in Table II. In 21 of 
these 30 hr-HPV positive cases a normal cytological result was found, whereas 4 
cases showed ASC-US, two cases LSIL and three cases showed a high-grade squamous 
intraepithelial lesion (HSIL).
Identical hr-HPV genotypes
Twenty of the 80 (25%) women with a hr-HPV DNA positive biopsy showed identical 
hr-HPV genotypes in their follow-up cervical smear. In 3 of these 20 patients 
additional new HPV types were detected in the follow-up scrapes (Table III). 
Cytological examination of the 20 scrapes showed a normal result in 13 cases, ASCUS 
in 3 cases, LSIL in 2 cases, and finally HSIL in another 2 cases.
New hr-HPV genotypes
In the follow-up smear of 13 of the 85 patients (15%) a new hr-HPV type was detected, 
which was not present in the LLETZ biopsies of these patients; in 3 cases multiple hr-
HPV infections and in 10 cases a single hr-HPV infection were found. HPV 16, HPV 31, 
HPV 39, HPV 51 and HPV 52 were all newly detected once in the follow-smears. HPV 
18, on the other hand, was newly detected in 8 of these 13 women (62%) (Table III). 
Cytological examination of these 13 cases revealed a normal result in 11 cervical 
scrapes, ASC-US in one scrape, and high-grade squamous intraepithelial lesion (HSIL) 
in one scrape.
Discussion
Both epidemiological and molecular studies have now clearly established that high-
risk human papillomaviruses (hr-HPV) are the causative agents for the development 
of malignant lesions of the cervix and their precursors (CIN). Although, effective 
4
Table II  Distribution of hr-HPV types in 30 hr-HPV positive cervical smears  
after LLETZ  
Table III  Thirteen cases with a new hr-HPV genotype in the first follow-up  
smear after LLETZ  
Infection    hr-HPV genotype
  16 18 31 33 39 45 51 52 56 58
Single  7 4 0 1 1 0 1 1 1 1
Multiple  5 5 3 0 0 0 1 1 0 1
Total  12 9 3 1 1 0 2 2 1 2
Due to multiple HPV infections, the overall percentage of hr-HPV types exceeds 100%
Case hr-HPV in  hr-HPV after Follow-up Cytology after
 LLETZ biopsies LLETZb (months) LLETZ
1 16 18 6 Normal 
2a 16 16 18 3 Normal 
3 45 18 6 Normal 
4 51 31 6 Normal 
5 52 16 2 Normal 
6 - 18 4 ASCUS
7 16 39 18 3 Normal 
8 16 52 18  3 Normal 
9 16 18  4 Normal 
10a 16 58 16 51 3 Normal 
11 33 35 18 3 Normal 
12 16 52  39 4 HSIL
13a 31 31 52 3 Normal 
a  in 3 cases not only a new hr-HPV type but also an identical hr-HPV type was found
b  new hr-HPV genotypes are underlined
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therapeutic options to treat the viral infection are not yet available, LLETZ has shown 
an effective therapy for high-grade CIN lesions.9,10 Moreover, surgical treatment is 
suggested to eliminate the infection causing the cervical abnormality.11-13 This study 
also shows that 65% (55/85) of the women treated with LLETZ harboured no hr-HPV 
DNA in their follow-up cervical scrapes, suggesting that the surgical treatment 
eliminated the HPV infection.
However, hr-HPV DNA was still detected in 30/85 follow-up scrapes (35%) taken 
within 6 months after the treatment. In 20 patients (24%) an identical hr-HPV 
genotype was found in both the follow-up scrape and the LLETZ biopsy specimen. As 
suggested in the literature this could reflect non-eliminated persistent hr-HPV 
infections increasing the risk for residual or recurrent disease. Indeed, residual CIN 
can be detected in up to 16% of the patients after treatment of CIN. Adding hr-HPV 
detection could thus be used as a prognostic marker to identify women at risk for 
residual CIN.14-17
However, hr-HPV genotypes were also detected in the follow-up scrapes of 13/85 
women (15%) that were not detected in the preceding LLETZ biopsy. These newly 
detected HPV genotypes were either found as part of a multiple infection, containing 
also the same hr-HPV genotype found in the LLETZ biopsy (three women), or as a 
single new hr-HPV genotype different from the hr-HPV genotype found in the biopsy 
specimen (nine women). In one woman a new hr-HPV genotype was found in the 
scrape while the LLETZ biopsy showed no evidence of hr-HPV presence. 
Although data on newly detected hr-HPV genotypes in women treated for high-
grade CIN are rare, this phenomenon has been reported previously. Mann, et al. 
reported a new HPV genotype in the cervical follow-up smear in 10% of 152 women 
treated for high-grade CIN after a median follow-up period of 12 months.13 Bollen and 
colleagues even found new HPV genotypes in 19% of the follow-up smears in a study 
comprising 91 women treated with two different treatment modalities for high-
grade CIN.22 
In the present study a remarkably high percentage of newly detected hr-HPV 18 
genotypes was observed in cervical smears taken after surgical treatment; in 8 of the 
13 women (62%) with new hr-HPV genotypes, HPV 18 DNA was detected. In the hr-
HPV positive LLETZ specimens HPV 18 was detected in only 9%. This latter percentage 
is comparable to the 7% precalence of HPV 18 published recently in an extensive 
meta-analysis of 4338 squamous high-grade lesions.23
How can we explain this finding? First, the results could be explained due to a coinci-
dental finding related to the relatively small number of newly detected hr-HPVs in 
the follow-up cervical scrapes influencing the outcome of the analysis. However, as 
only 7 of the LLETZ biopsies were HPV 18 positive, this explanation, although it 
cannot be excluded, does not seem plausible. Newly acquired HPV infection of the 
cervix by sexual intercourse after the LLETZ procedure could also be an explanation 
for the appearance of new HPV types. However, it is very unlikely that the relatively 
high appearance rate of specifically HPV 18 could only be explained by sexual 
transmission, also because of the very low rate of HPV 18 in the LLETZ biopsies as 
indicated above. 
Another possible explanation for the appearance of new HPV types is that after 
elimination of the lesion, i.e., the HPV-infected epithelium, other types which were 
not detected previously may fill the niche.13 In fact, many women are infected with 
multiple HPV genotypes and genotypes can remain undetectable due to differences 
in viral load. After eradication of the prominent HPV types with the highest viral 
loads, HPV types with lower viral loads are no longer dominated by prominent types 
and will start shedding again24 becoming detectable after treatment.
But again, how does this may affect the presence of specifically HPV 18?
During the LLETZ procedure the transformation zone is excised and as a result of 
which the proximal layers of the endocervical canal are incised which may result in a 
release or re-activation of HPV from these layers of the cervical canal. HPV infections 
detected after LLETZ may therefore represent HPV genotypes that are more 
prevalent in the proximal layers of the cervix. Interestingly, from this point of view, 
it has been demonstrated clearly that although almost 100% of the cervical 
carcinomas are hr-HPV DNA positive4, the prevalence of specific hr-HPV genotypes 
detected in squamous cell carcinomas and adenocarcinomas of the cervix clearly 
differ indicating a potential malignant tropism of different hr-genotypes. For 
example, HPV 16 is found in over 60% of cervical squamous cell carcinomas and in 
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about 20% of the cervical adenocarcinomas, while, HPV 18 is detected in only 10% of 
the cervical squamous cell carcinomas but in more than 50% of the cervical 
adenocarcinomas.5,25-27 As HPV 18 seems to play a more prominent role in the 
development of cervical adenocarcinomas HPV 18 may have a local preference site in 
the endocervical canal. After removal of the transformation zone of the cervix by the 
LLETZ procedure, certain genotypes of HPV in the proximal layers of the cervix, as 
HPV 18, may become detectable. As HPV 18 seems to play a predominant role in this 
specific histological type of cervical cancer, studies towards comparison of different 
cervical sampling devices for ectocervical cell sampling and endocervical cell 
sampling are warranted, to investigate its potential to detect HPV 18 in the proximal 
layers of the cervix and to determine the risk of HPV 18 associated abnormalities.
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Abstract 
The need for accurate genotyping of human papillomavirus (HPV) infections is 
becoming increasingly important, since (i) the oncogenic potential among the high-
risk HPV genotypes varies in the pathogenesis of cervical cancer, (ii) monitoring 
multivalent HPV vaccines is essential to investigate the efficiency of the vaccines, 
and (iii) genotyping is crucial in epidemiologic studies evaluating HPV infections 
worldwide. Various genotyping assays have been developed to meet this demand. 
Comparison of different studies that use various HPV genotyping tests is possible 
only after a performance assessment of the different assays. In the present study the 
SPF10 LiPA version 1 and the recently launched Roche LINEAR ARRAY HPV genotyping 
assays are compared. A total of 573 liquid-based cytology samples were tested for 
the presence of HPV by a DNA enzyme immunoassay; 210 were found to be positive 
for HPV DNA and were evaluated using both genotyping assays (163 with normal 
cytology, 22 with atypical squamous cells of undetermined significance (ASCUS), 20 
with mild/moderate dysplasia, and 5 with severe dysplasia). Comparison analysis 
was limited to the HPV genotype probes common to both assays. Of the 160 samples 
used for comparison analysis 129 (80.6%) showed absolute agreement between the 
assays (concordant), 18 (11.2%) showed correspondence for some but not all 
genotypes detected on both strips (compatible), and the remaining 13 (8.2%) 
samples did not show any similarity between the tests (discordant). The overall 
intertest comparison agreement for all individually detectable genotypes was 
considered very good (κ-value, 0.79). The genotyping assays were therefore highly 
comparable and reproducible. 
Introduction
Molecular and epidemiologic studies have shown that a persistent infection with 
high-risk human papillomavirus (hr-HPV) is the most important risk factor for both 
cervical cancer and its precursors.1-4 Approximately 40 different HPV types can infect 
the mucosa of the anogenital tract. Based on their carcinogenicities these anogenital 
HPV types have been subdivided into low-risk HPV (lr-HPV) types, probable high-risk 
types and high-risk (hr) HPV types 5, although some controversy remains regarding 
the probable high-risk genotypes.6 Almost all squamous cell cervical cancers 
worldwide harbour hr-HPV types.7 Moreover, high-risk HPV DNA can be detected in 
74% of the pre-malignant low-grade cervical intra-epithelial neoplasia (CIN) and 
approximately 84% of the high-grade CIN lesions.8 Consequently, the efficacy of 
population based screening programmes solely using cervical cytology could benefit 
from adding hr-HPV testing.9 Accordingly, many ongoing international research projects 
assess the feasibility of introducing hr-HPV tests in the available routine screening. 
For these screening purposes, several tests have been developed in order to 
distinguish high-risk HPV infections from no HPV infection. Amongst those are the 
signal amplification method Hybrid Capture II (hc2, Digene Corp., Gaithsburg, 
Maryland, USA) and the recently developed target amplification method Roche 
AMPLICOR® HPV Test (Roche Molecular Systems, Inc., Branchburg, NJ, USA).10 
Although both tests are commercially available and Conformité Européenne (CE) 
marked, hc2 is currently the only FDA registered HPV screening assay.11 Both tests 
differentiate between an infection with one or more of 13 hr-HPV genotypes (16, 18, 
31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68), and no hr-HPV infection; a “hr-HPV plus/
minus” screening. Although these tests are not designed to detect the recently 
described probable hr-HPV, or any lr-HPV infections, some cross-reactivity outside of 
the spectrum of 13 hr-HPV genotypes has been reported for the hc2 assay.12 Neither 
hc2 nor AMPLICOR HPV assays allow identification of specific genotypes13 nor do 
they have the ability to identify infections involving multiple genotypes. 
However, recent studies have provided evidence for a difference in oncogenic 
potential between the different hr-HPVs14, arguing for the importance of HPV 
genotyping in addition to the “hr-HPV plus/minus” screening. Outside of the clinical 
setting, HPV genotyping is a key-characteristic of studies evaluating the epidemiology 
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of HPV infections worldwide. Although a number of HPV genotyping assays have 
been used in such studies a reliable comparison between the diagnostic and 
epidemiological data generated is difficult, since data on the inter-test comparisons 
between the different genotyping assays are limited. 
The SPF10-INNO LiPA assay is capable of amplifying up to 43 different genotypes and 
providing type-specific genotype information for 25 different HPV genotypes 
simultaneously, has been extensively tested, and has proven to be highly sensitive 
and specific.8,15 The Roche LINEAR ARRAY (LA) HPV Genotyping Test (Roche Molecular 
Systems, Inc., Branchburg, NJ, USA) is a recently launched new HPV genotyping assay 
able to genotype 37 HPV types, concurrently assessing human ß-globin. The full 
spectrum of HPV genotypes amplified by the PGMY primer system16 used in the 
Roche LINEAR ARRAY HPV Genotyping Test has not been assessed beyond the probed 
37 genotypes. In essence, both assays could be used for genotyping analysis.
This study was designed to compare these two well-known and commonly used 
commercially available genotyping assays with HPV DNA positive samples. 
Materials and Methods
Cervical scrapes were obtained from 573 women attending the Department of 
gynaecology for routine cervical screening. Specimens were collected using the 
Cervex-Brush® (Rovers Medical Devices B.V., Oss, The Netherlands) and processed 
using a liquid-based cytology medium (ThinPrep®, Cytyc Corp., Marlborough, MA, 
USA) that provides monolayer distribution for cytological assessment. Moreover, it 
offers the opportunity to isolate DNA for various HPV detection assays. This method 
has received U.S. FDA approval for clinical use.17,18 
Specimen preparation
For isolation of DNA from cervical scrapes in liquid based cytology medium, the 
MagNAPure LC Isolation station (Roche Diagnostics GmbH, Roche Applied Science, 
Mannheim, Germany) was used; 200µL of material was isolated using the MagNA 
Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics GmbH, Roche Molecular 
Biochemicals, Mannheim Germany), as described by the manufacturer. With each set 
of 28 cervical scrape samples 4 negative controls (distilled water) were used to 
monitor the DNA isolation procedure and to assess contamination. Nucleic acid was 
resuspended in a final volume of 50µL; 10µL were used for each of the various PCR 
analyses. 
SPF10-INNO LiPA HPV detection and genotyping (DNA enzyme immunoassay [DEIA] 
and LiPA)
(i) PCR amplification of HPV DNA
Broad-spectrum HPV DNA amplification was performed using a short PCR fragment 
assay (SPF10 HPV PCR, Labo Bio-medical products B.V. Rijswijk, The Netherlands). This 
assay amplifies a 65-bp fragment of the L1 open reading frame, and allows detection 
of at least 43 different HPV types.8,19 SPF10 PCR system was used in a final reaction 
volume of 50mL, containing 10mL of the isolated DNA sample and 40mL PCR mix, 
which contained 10mmol/L Tris-HCL (pH 9.0), 50mmol/L KCL, 2.0mmol/L MgCl2, 0.1% 
Triton X-100, 0.01% gelatin, 200mmol/L of each deoxynucleoside triphosphate (dATP, 
dCTP, dGTP, and dTTP), 15pmol each of the forward and reverse primers tagged with 
biotin at the 5’ end, and 1.5 units of AmpliTaq Gold® (Applied Biosystems, Foster City, 
CA, USA). Activation of AmpliTaq Gold for 9 minutes at 94ºC, was followed by 40 
cycles of 30 s at 94ºC, 45 s at 52ºC and 45 s at 72ºC, with a final extension of 5 
minutes at 72ºC. Appropriate negative and positive controls were used to monitor 
the performance of the PCR method in each experiment. 
(ii) HPV detection by DEIA
The presence of HPV DNA was determined by hybridization of SPF10 amplimers to a 
mixture of general HPV probes recognizing a broad range of high-risk, low-risk and 
possible high-risk HPV genotypes in a microtiter plate format, as described 
previously.8,15 All HPV DNA-positive samples (by SPF10 DEIA) were genotyped using the 
INNO-LiPA HPV genotyping assays and the Roche LINEAR ARRAY® HPV Genotyping 
Test as described below. Twenty randomly selected DEIA-negative samples, that had 
previously been tested negative by Roche AMPLICOR® HPV Test10 were also assessed 
using both genotyping assays. 
(iii) HPV genotyping by reverse hybridization using the INNO-LiPA HPV genotyping system 
The 28 oligonucleotide probes that recognize 25 different types (see table 1) 
were tailed with poly(dT) and immobilised as parallel lines to membrane strips 
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(Labo Bio-medical products B.V. Rijswijk, The Netherlands). The HPV genotyping 
assay was performed as described previously.15 The LiPA strips were manually 
interpreted using the reference guide provided. The samples that tested positive 
using the DNA Enzyme Immuno Assay but showed no results on the LiPA strip were 
considered to be HPV X-type, i.e., genotypes not available on the LiPA strip.
 
LINEAR ARRAY HPV Genotyping Test
The LINEAR ARRAY (LA) HPV Genotyping Test (Roche Molecular Systems, Inc., 
Branchburg, NJ, USA) is a new qualitative in vitro test for the determination of 37 
anogenital HPV DNA genotypes (table 1). The LA test was applied to all samples that 
tested positive for HPV by DEIA and to 20 randomly selected DEIA-negative samples. 
(i) PCR amplification of HPV DNA
The LA test uses biotinylated PGMY primers to amplify a 450-basepair fragment 
within the polymorphic L1 region of the HPV genome. The PGMY amplification 
system has been described previously.16 The PGMY primers are present in the ‘master 
mixture’ (containing: buffer, nucleotides [dATP, dCTP, dGTP, and dUTP], MgCl2, and 
<0.02% AmpliTaq® Gold DNA polymerase) and amplify HPV DNA from 37 HPV 
genotypes including 13 high-risk types (Table I). Amplicons incorporate dUTP, 
allowing the use of AmpErase® enzyme (urasil N-Glycosylase) which is included in 
the master mixture to prevent PCR carryover contaminations. Capture probe 
sequences are located in polymorphic regions of L1 bound by these primers. An 
additional primer pair targets the human ß-globin gene (268 bp amplicon) to provide 
a control for cell adequacy, extraction and amplification. 
PCR was performed in a final reaction volume of 100µL, containing 50µL HPV master 
mixture, 40µL PCR water and 10µL isolated DNA. The mixture was incubated for 2 
minutes at 50°C and 9 minutes at 95°C, followed by 40 cycles of 30 seconds at 95°C, 
1 minute at 55°C and 1 minute at 72°C, with a final extension at 72°C lasting from 10 
minutes to a maximum of 1 hour. The provided HPV positive and negative controls 
were used with each set of 10 samples to assess the performance of the reaction. 
(ii) Hybridization and Detection
Following amplification, the HPV and human ß-globin amplicons were denatured by 
immediately adding 100µL denaturation solution to each PCR tube. Hybridization 
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Table I  Distribution of HPV-genotypes in the LiPA and LA assays  
Oncogenic Potential5 HPV Genotype  Detected ina: 
  SPF10-LiPA LA 
 16 X X
 18 X X
 31 X X
 33 X X
 35 X X
 39 X X
High-risk 45 X X
 51 X X
 52 X X
 56 X X
 58 X X
 59 X X
 68 Xb X
 73 Xb X
 82  X
 26  X
Probable high-risk 53c X X
 66 X X
 6 X X
 11 X X
 34 X 
 40 X X
 42 X X
 43 X 
 44 X 
 54 X X
 55  X
 61  X
 62  X
Low-risk 64  X
 67  X
 69  X
 70 X X
 71  X
 72  X
 74 X 
 81  X
 83  X
 84  X
 IS39  X
 CP6108  X
a X: detected; LiPA: SPF10-INNO-LiPA test; LA: Roche LINEAR ARRAY HPV Genotyping test; 
b LiPA does not distinguish 
between HPV 68 and HPV 73, since both types are detected by a single probe; c Oncogenic potential of 
HPV 53 is controversial.6
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and HPV genotyping were performed as described by the manufacture (Roche Molecular 
Systems, Inc., Branchburg, NJ, USA). The strips were manually interpreted using the 
LINEAR ARRAY HPV Reference Guide, by reading the individual types down the length of 
the strip. Samples that were both SPF10-DEIA and LA-ß-globin positive, yet were not 
reactive to any of the genotype probes on the LA strip, were considered “LA negative”.
Design of the study
Previously the samples had been assessed in an analysis comparing only high-risk 
HPV types detected by the Roche AMPLICOR® HPV test and the INNO-LiPA HPV 
detection and genotyping assay.10 Since the present study compares two genotyping 
assays, only the DEIA HPV positive samples and 20 randomly selected DEIA (and 
Roche AMPLICOR®) HPV negative samples were assessed. In order to have the most 
accurate comparison between the two genotyping tests, only the HPV genotypes 
identified by both assays (i.e. lr-HPV 6, 11, 40, 42, 54, and 70; possible hr-HPV 53 and 
66; hr-HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) were considered for direct 
comparison of the individual HPV genotypes (Table I). These will be termed assay-
common genotypes. High-risk HPV genotypes 68 and 73 were not taken into account 
for individual comparison, since these types are identified by a single probe in the 
LiPA assay and can thus not be distinguished. Moreover, the classification of HPV 53 
as possible high-risk is currently disputed. When comparing the two genotyping 
assays, results were termed concordant, compatible or discordant, based on the 
following definitions. If the analyses yielded identical assay-common genotypes in 
both tests the results were termed concordant. Results were termed compatible if 
one or more additional assay-common genotypes were not detected by either one of 
the assays. Genotyping results were termed discordant if there were no similarities 
in the assay-common genotypes between the two tests. Assay results for HPV 
genotypes uniquely identified by each of these two assays (i.e. assay-unique HPV 
genotypes 34, 43, 44, and 74 only detected by the LiPA and the assay-unique HPV 
genotypes 26, 55, 61, 62, 64, 67, 69, 71, 72, 81, 82, 83, 84, IS39, and CP6108 solely 
detected by the LA) were not considered in determining concordant, compatible, or 
discordant status. 
From all compatible and discordant samples a re-extracted DNA sample was 
randomly retested in a blinded approach in a discrepancy analysis using both 
genotyping assays. Eleven concordant samples (6 single infections, 4 double and 1 
triple infections) and six double negative (i.e., DEIA-positive, LiPA X-type and LA 
negative) samples were used as positive and negative controls for both inter- and 
intra-assay performance control. 
All HPV tests were performed by investigators unaware of the results of the 
comparative HPV detection or genotyping tests.
Statistics 
All data were analyzed using SPSS version 12.0.1. for Windows. Agreement was 
measured by absolute agreement and Cohen’s kappa statistics, a measure of the 
agreement between two methods that is in excess of that due to chance.
Results
In total, 218 of the 573 DNA samples tested positive by SPF10 DEIA. These were 
considered suitable for analysis using the SPF10 LiPA and the LA HPV Genotyping 
assays. Eight samples were excluded from further analysis: 4 showed negative 
b-globin results in the LA test and from 4 other samples insufficient material was 
available to perform adequate assessment. Twenty randomly selected DEIA negative 
control samples were negative in both genotyping assays and were thus not taken 
into consideration for further analysis. Of the 210 DEIA positive samples 163 (77.6%) 
indicated normal cytology. Atypical Squamous Cells of Undetermined Significance 
(ASC-US) were detected in 22 samples (10.5%), mild/moderate dysplasia was 
observed in 20 samples (9.5%), and 5 samples (2.4%) showed severe dysplasia. 
Of the 210 DEIA-positive samples tested using both genotyping assays, 40 samples 
were excluded since either one of the tests was negative whereas the comparative 
test detected an assay-unique genotype or LA was negative and LiPA showed an 
X-type (Table II). 
In 132 of the remaining 170 samples, all detected genotypes that could have been 
identified by both assays. Of these samples harbouring only assay-common 
genotypes, 87/132 (65.9%) were concordant, 24 (18.2%) were compatible, and 21 
(15.9%) showed discordant results (Table III). Finally, in 38 cases, assay-unique 
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genotypes were detected in addition to assay-common genotypes. Of these samples 
25 (65.8%) had concordant results, 12 (31.6%) were compatible and one (2.6%) was 
discordant. In the final analysis of 170 samples these 38 samples were retained. The 
additional assay-unique genotypes found in these 38 samples were not taken into 
consideration. The outcome of the concordant, compatible, and discordant cases is 
described in detail below. 
Concordant cases
Of the 112 concordant cases (25 with and 87 without assay-unique genotypes) 69 
(61.6%) contained a single HPV genotype and the remaining 43 samples contained 
multiple genotypes. Thirty-two samples (28.6%) harboured two different genotypes, 
8 samples (7.1%) contained 3 HPV genotypes, and 3 samples (2.7%) contained 4 
genotypes. One or more high-risk genotypes were detected in 86.6% (97/112) of 
these samples, whereas 7 samples (6.3%) only contained low-risk genotypes and 8 
samples (7.1%) also harboured probable hr-HPV genotypes. 
Compatible cases
All 36 compatible cases were multiple infections. The LiPA assay did not detect a 
total of 41 genotypes in 30 separate clinical samples. In 23 cases, 1 type was missed; 
in 5 cases, 2 types were missed; and in 2 cases, 4 types (thirteen low-risk, 1 possible 
high-risk and 27 high-risk genotypes were not detected by the LiPA test). The LINEAR 
ARRAY assay on the other hand did not detect 12 genotypes in 8 separate samples. In 
6 cases, 1 type was missed; in 1 case, 2 types; and in 1 case, 4 types (2 low-risk, 1 
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Table II  Distribution of 40 excluded samples that either showed only assay- 
unique genotypes or were HPV DNA positive but genotype negative  
(i.e. LiPA X-type) 
Table III  Overview of the 170 included samples with assay-common genotypes  
Table IV  Overview of the 36 compatible and 22 discordant samples  
LA result   SPF10-LiPA Total
  LiPA X-type  Assay-unique genotype
  (No.)  (No.)  
Negative 9  7 16
Assay-unique genotype 24  0 24
Total 33  7 40
X-type: HPV DNA positive sample (DEIA) without results on LiPA strip
Assay-unique  Concordant  Compatible Discordant Total
genotypes (No.) (No.) (No.) 
None 87 24 21 132
LiPA 3 0 0 3
LA 20 12 1 33
LiPA and LA 2 0 0 2
Total 112  36 22 170
Oncogenic Potential Genotype  No. of specific genotypes not detected 
  Compatible samples Discordant samples
  LiPA LA LiPA LA 
 16 7   1
 18 2 1  
 31 2 2  
 33 1   2
 35    1
 39 3   
High-risk 45 2  1 
 51  1  4
 52 1 1  2
 56  3 1 1
 58 3   
 59 5   
 68/73 1 1  2
 53  1 1 3
Probable high-risk
 66 1   2
 6    2
 11 1 2  
Low-risk 42 4  1 
 54 8  2 1
 Total 41 12 6 21
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possible high-risk and 9 high-risk HPV types). Table IV gives an overview of the 
individual types not detected. Fifteen of the 16 cases in which LiPA missed a hr-HPV 
type were multiple hr-HPV infections and tested positive for another high-risk type 
which was also detected in the LA. 
Discordant samples 
In 22 (12.9%) of the 170 samples considered, no similarity was observed in the 
genotypes found in the two tests. These were predominantly single infections. An 
overview of the individual discordant cases is given in Table IV. Twenty-seven 
genotypes were discrepant between the two assays in 22 different samples. The LA 
test did not detect 13 hr-HPV, 5 probable hr-HPV and 3 lr-HPV types, that were found 
to be positive in the LiPA assay. The LiPA assay on the other hand failed to detect 2 
high-risk, 1 probable high-risk and 3 low-risk types, which were all found positive on 
the LA strip. 
The genotypes which were detectable by both assays of all 170 samples (112 
concordant, 36 compatible and 22 discordant) were individually compared as 
summarized in Table V. The overall strength of agreement between the two assays 
for the individual genotypes was considered good (κ = 0.792). Although HPV 16 was 
detected in 45 samples using the LA test and in 39 samples using the LiPA agreement 
between the tests was considered very good with a κ-value of 0.874. The agreement 
between the two assays for the other high-risk and probable high-risk genotypes 
varied between “good” and “very good”. The agreement between the two tests for 
the low-risk genotypes was “moderate” to “perfect”. The agreement for HPV 54 was 
moderate since LiPA and LA shared 8 samples harbouring the low-risk genotype 
whereas LA detected it in 10 additional samples. Also, the agreement for lr-HPV’s 11 
and 42 was moderate, while HPV 70 was detected in equal amounts by both assays. 
Low-risk HPV 40 was not detected in either one of the test, thus no agreement could 
be calculated. The difference in detection of lr-HPV 54 was statistically significant 
(P<0.05; McNemar’s test). Although the differences for hr-HPV 16, 51 and 59, and lr-
HPV 42 between the assays were large, they were considered not quite statistically 
significant (P>0.07 McNemar’s test). In the individual comparison of the other 
genotypes no statistically significant differences were detected. 
Discrepancy analysis
The compatible (n=36) and discordant (n=22) samples were reanalysed using the 
two genotyping assays in a discrepancy analysis. DNA was re-extracted from these 
58 compatible/discordant samples. As interassay test controls 11 previously 
concordant (6 single and 5 multiple infections) and 6 previously double negative 
samples (LiPA X-type and LA negative) were also included, these samples were used 
for method performance assessment only. All 6 double negative samples remained 
negative and all 11 concordant samples appeared identical in both second genotyping 
assays. These internal controls were not further considered in the discrepancy 
analysis. Of the 58 discrepant samples 10 were ß-globin negative in LINEAR ARRAY 
and were also negative by LiPA. Of these 10 samples, 6 had been concordant and 4 
had been discordant; these 10 samples were excluded from the discrepancy analysis. 
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Table V  Kappa values and the p-values of McNemar’s test for individual HPV 
genotypes detectable by both assaysa  
Oncogenic  Genotype  No. of genotypes  κ-value (95% CI)b P-value 
Potential  found positive by:   (McNemar’s test) 
  LiPA LA LiPA and LA  
 16 39 45 38  0.874 (0.788-0.959)* 0.08
 18 14 15 13  0.887 (0.760-1.014)* 1.00
 31 13 13 11  0.833 (0.672-0.995)* 0.62
 33 10 9 8  0.833 (0.645-1.020)* 1.00
 35 9 8 8  0.938 (0.817-1.059)* 1.00
High-risk 39 7 9 7  0.869 (0.687-1.050)* 0.48
 45 5 8 5  0.761 (0.492-1.029)$ 0.25
 51 16 11 11  0.799 (0.626-0.973)$ 0.07
 52 23 21 20  0.896 (0.795-0.997)* 0.62
 56 12 9 8  0.747 (0.528-0.965)$ 0.37
 58 8 11 8  0.833 (0.646-1.020)* 0.25
 59 6 11 6  0.692 (0.426-0.958)$ 0.07
 53 20 17 16  0.848 (0.718-0.979)* 0.37
Probable hr
 66 9 8 7  0.814 (0.606-1.023)* 1.00
 6 11 9 9  0.894 (0.748-1.040)* 0.48
 11 4 3 2  0.563 (0.072-1.053)+ 1.00
 40 0 0 0  
Low-risk
 42 2 7 2  0.434 (-0.055-0.923)+ 0.07
 54 9 18 8  0.562 (0.311-0.812)+ 0.02
 70 6 6 6  1.000 (1.000-1.000)**
a The results of 112 concordant, 36 compatible and 22 discordant samples after initial analysis are shown 
b CI; confidence interval 
Strength of agreement considered: **perfect, *very good, $good, +moderate
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The crude initial and discrepancy analysis results of the remaining 48 samples are 
shown in Table VI. Of the 30 compatible samples from the initial analysis 18 remained 
compatible after discrepancy analysis, while 8 appeared concordant and 4 discordant 
in a comparison of the second genotyping assays. Of the 18 discordant samples from 
the first test run, 9 remained discordant in the second analyses between LiPA and LA, 
whereas 4 appeared genotype concordant and 5 were concordant as LiPA X-type, LA 
negative. Thus, comparing the second LiPA and LA test, yielded 17 concordant, 18 
compatible and 13 discordant results.
Intra-assay comparisons taking these 48 samples and the 17 control samples in both 
initial and discrepancy analysis into account, show highly comparable results for 
both assays (Table VII). 
In conclusion, of the 160 samples considered for final analysis 80.6% (129/160) 
showed identical results, 11.2% (18/160) appeared compatible and 13 samples (8.2%) 
were discordant. 
Discussion
Based on this study, we can conclude that the SPF10-INNO LiPA and the LINEAR ARRAY 
HPV genotyping assays are highly congruent for the genotypes detectable in both 
assays. Moreover, manageability of both the SPF10-INNO LiPA and the LINEAR ARRAY 
assay is highly comparable, as is to a large extent the total runtime required for both 
assays, including amplification and preparation of all of the reagents. 
 
Generally, a separate screening is needed preceding genotyping in order to assess a 
sample’s HPV DNA positivity, i.e., an HPV plus/minus screening. An advantage of the 
LiPA is the usage of the same amplicon for both detection of 43 different lr-, probable 
hr-, and hr-HPV genotypes and genotyping of 25 different HPVs. For the LA, a pre-
screening test with the PGMY primers is available using a generic HPV probe labelled 
with digoxigenin in a microtiter plate-based assay as recently described.20 Without 
the need for further amplification, this amplicon can be directly used for the LINEAR 
ARRAY genotyping assay. However, the efficiency of such a combination has not 
been studied. The recently launched HPV Roche AMPLICOR® test for HPV plus/minus 
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Table VI  All genotyping and comparison results of the 35 initially compatible and 
discordant samples assessed discrepancy analysis  
Initial  HPV genotype (initial analysis)  Discrepancy HPV genotype (discrepancy analysis)
comparison
 LiPA_1 LA_1 
comparison
 LiPA_2 LA_2 
Compatible 35 33, 35 Concordant 33, 35 33, 35
Compatible 51 16, 39, 51 Concordant 51 51
Compatible 18, 33 18, 31, 33 Concordant 18, 33 18, 33
Compatible 33 16, 33 Concordant 33 33
Compatible 68/73 58, 73 Concordant 68/73 73
Compatible 39 16, 39 Concordant 39 39
Compatible 52, 53 52, 53, 54, 67 Concordant 52, 53, 54 52, 53, 54, 67
Compatible 35, 39, 70 16, 35, 39, 70, 81 Concordant 35, 39, 70 35, 39, 70, 84
Compatible 16 16, 59 Compatible 16 16, 59
Compatible 6, 51 6, 16, 18, 39, 51, 66 Compatible 6 6, 16, 18, 39, 51, 66
Compatible 51, 52, 53, 59 45, 51, 52, 53, 59, IS39 Compatible 53 42, 51, 52, 53, 59, IS39
Compatible 6, 33 6, 33, 58, 59, 72 Compatible 6, 31, 33, 58, 59 6, 33, 58, 59, 72
Compatible 6, 16, 52 6, 16, 42, 52 Compatible 6, 16, 52 6, 16, 42, 52
Compatible 52 16, 52 Compatible 6, 16, 52, 56 16, 52
Compatible 6 6, 59 Compatible 6 6, 59
Compatible 31, 70 31, 54, 62, 70 Compatible 6, 31, 70 62, 70
Compatible 54 54, 73 Compatible 54 54, 73
Compatible 16 11, 16, 59, 81 Compatible 16 11, 16, 59, 81
Compatible 56, 66, 68/73 39, 52, 56, 66, 68 Compatible 56, 66, 68/73 52, 56, 66, 68
Compatible 16, 52 16, 52, 54 Compatible 16, 52 16
Compatible 53 42, 53, IS39 Compatible 53 42, 51, 53, 59, IS39
Compatible 53, 66 16, 53, 66 Compatible 66 53, 66
Compatible 31, 33, 53 33, 42, 45, 53, 54, 59, 61, 83 Compatible 31, 33, 45, 53, 59 33, 42, 45, 53, 54, 59, 61, 83
Compatible 56, 58 54, 56, 58, 62 Compatible 56, 58 54, 56, 58, 62
Compatible 54, 56 54 Compatible 54, 56 54
Compatible 16, 31, 53, 58 16, 18, 53, 54, 62, CP6108 Compatible 16, 18, 31, 53, 58 16, 53, 54, 58, 62, CP6108
Compatible 33 33, 54 Discordant 33 54
Compatible 56, 66 66, 67 Discordant 56, 66 67
Compatible 56, 59 59 Discordant X-type 59
Compatible 51, 53 51, 53, 54, 62 Discordant 51, 53 62
Discordant 6 negative Concordant 6 6
Discordant 6, 53 negative Concordant 6, 53 6, 53
Discordant X-type 53 Concordant X-type negative
Discordant 16 negative Concordant 16 16
Discordant X-type 45, 61, 83 Concordant 45 45, 61, 83
Discordant 53 negative Concordant X-type negative
Discordant 52 negative Concordant X-type negative
Discordant 53 negative Concordant X-type negative
Discordant 52 54 Concordant X-type negative
Discordant 66 negative Discordant 66 68
Discordant 35 negative Discordant 35 negative
Discordant 56 negative Discordant 56 negative
Discordant X-type 42 Discordant X-type 42
Discordant 68/73 negative Discordant 68/73 negative
Discordant 51, 66, 68/73 negative Discordant 51 negative
Discordant X-type 56 Discordant X-type 56
Discordant 51 negative Discordant 51 negative
Discordant 51 negative Discordant 51 negative
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screening is not meant for a LA screen. It could also be used as pre-test, but the assay 
only detects high-risk HPV types.10 
In the initial comparison, i.e., prior to the discrepancy analysis, LiPA did not detect 27 
high-risk genotypes in 30 compatible cases. Evidently, all the cases involved were 
multiple infections, i.e., containing two or more HPV types. Apparently, if an infection 
encompasses multiple genotypes the SPF10-INNO LiPA assay is less sensitive than the 
LA. After finding analogous results using the LiPA assay, Van Doorn, et al. propounded 
the idea of PCR competition between genotypes in mixed infections and suggested 
a combined testing algorithm using broad-spectrum and type-specific PCRs for HPV 
16 and HPV 18 (L.J. van Doorn, A.C. Molijn, B. Kleter, W.G.V. Quint and B. Colau, Abstr. 
22nd IPV Conference., abstr. N-01, 2005). The complexity of assessing multiple 
genotypes was addressed previously.21 Amplification and identification of two 
genotypes present in equimolar amounts are likely possible. However, ‘primer 
competition’ between genotypes might occur in case one particular genotype is 
present in molar excess, out competing the other one.21 In the present study this is 
demonstrated by the samples harbouring multiple infections which were not 
identically genotyped by both assays. Also, LA detected hr-HPV 16 in 7 samples that 
were LiPA HPV 16 negative; after the second LA, however, 5 samples no longer 
showed HPV 16. Moreover, in a previous study Van Doorn and colleagues detected 
HPV 16 and HPV 18 using type-specific PCR in samples negative to these genotypes 
(but not for other genotypes) using general primer sets.21 In the present study we 
observed similar results (data not shown). Although viral load was not determined 
in the present study, low-copy-number samples have previously shown more 
discrepancy in intralaboratory and interlaboratory comparison.22 
The LA assay is unable to distinguish hr-HPV 52 from other high-risk genotypes (33, 
35, and 58). This can be inconvenient in future studies using the LINEAR ARRAY, since 
hr-HPV 52 is prevalent in approximately 5% of the HPV-positive women with normal 
cytology23 and causes 2.2% of all cervical cancers.5 In 19 samples of the present study 
hr-HPV 52 positivity could not be excluded based on LA genotyping. However, in 
these cases the comparative LiPA tests did not detect this specific genotype. Two 
samples were considered LINEAR ARRAY HPV 52 positive based on the LiPA results.
Among the 22 discordant cases, the number of hr-HPV genotypes detected by the 
LINEAR ARRAY was not higher than the number detected by LiPA. All but three of 
these samples were single infections, predominately HPV 33, HPV 51, and HPV 52. A 
higher inclusivity level has been observed for some high- and low-risk HPV genotypes, 
particularly hr-HPV 33 and hr-HPV 56, when the PGMY amplification system is used 
(see product insert for the CE-marked LINEAR ARRAY HPV Genotyping Test, European 
market). The inclusivity level equates to the lowest concentration (copies/mL) that 
shows a 100% positive hit rate in a replicate of 6 tests or the concentration that is 
the probit predicted 95% positive hit rate. This could explain some of the differences 
between the two assays observed in our study. Thus the LA seems to be less sensitive 
than the LiPA if a sample has a single infection with some specific HPV genotypes 
that are poorly amplified by PGMY. Even though the majority of samples was cytolo-
gically classified as normal, proper HPV assessment, including genotyping, remains 
essential particularly in healthy women with normal cytology10, especially since 
Wallin and colleagues observed a strong concordance between the HPV type found 
in baseline smear with normal cytology and the eventual type found in histological 
samples of invasive cancers.24 In the present study hr-HPV 51 was missed by LA in 4 
of the discordant cases; this genotype accounted for approximately 0.9% of all 
squamous-cell cervical cancer in previous studies.5 Curiously, the inclusitivity level 
for HPV 51 is lower than the level for HPV16 using PGMY primers, suggesting a highly 
sensitive detection (see product insert CE-marked LINEAR ARRAY HPV Genotyping 
Test European market). The observed difference in HPV 51 detection between the 
two assays cannot be explained by a lower efficiency of LINEAR ARRAY PGMY primer. 
After discrepancy analysis of the compatible and discordant cases, both LiPA and LA 
detected more concordance (Table VI). Some previously undetected genotypes for 
example appeared in the second test run, and vice versa. This could be due to low 
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Table VII  Intra-assay comparison overview of the 65 samples re-analysed in  
the discrepancy analysis, including the 17 control samples concordant  
in all four assays  
Test compareda Concordant  Compatible Discordant Total
 (No.) (No.) (No.) 
1st LiPA vs 2nd LiPA 48 11 6 65
1st LA vs 2nd LA 43 16 6 65
a 1st: initial comparison; 2nd: discrepancy comparison 
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copy numbers or sampling, as DNA re-extracts were used for the analysis. Also it 
could possibly indicate the suggested competition between genotypes present in 
more or lesser molar excess. However, results from a discrepancy analysis should 
generally be handled with care and interpreted carefully. Discrepancy analyses are 
not perfect, since an analysis is easily biased in favour of the new test, and hard and 
fast rules do not exist.25 Moreover, the interpretation of results that cannot be 
dichotomised (i.e. concordant, compatible and discordant) is less straightforward. 
Failing to detect genotypes will lead to underestimation of the prevalence of certain 
genotypes and causing false-negative results. Studies concerning (i) epidemiology of 
HPV, (ii) HPV vaccination/surgical treatment trials, and (iii) cervical cancer screening 
and triage, especially will be negatively affected by this. In epidemiologic studies 
genotyping is compulsory in order to evaluate type-specific HPV DNA prevalence 
among infected women26, to assess geographic heterogeneity in HPV type 
distribution23 and to study type-specific HPV concordance between sexual partners.27 
The importance of suitable algorithms for HPV detection and genotyping in addition 
to the introduction of type-specific antiviral therapies or monovalent vaccines, was 
already addressed by Koutsky and colleagues.28 Moreover, current extensive trials 
testing multivalent vaccines, comprising multiple commonly occurring HPV types, 
demand accurate, unequivocal, and sensitive methods and algorithms detecting 
and, specifically genotyping HPV.28-30 These algorithms are also compulsory for 
clinical trials monitoring surgical treatment of HPV induced CIN lesions13,31 or 
monitoring of persistent infections in consecutive smears, because persistence has 
been identified as important risk factor.32,33 Finally, according to Snijders and 
colleagues, adding general hr-HPV testing could be beneficial for the efficacy of the 
population based screening programmes for cervical cancer.9 Castle and colleagues 
however observed that ASC-US women infected with the hr-HPV 16 had a 2-year 
cumulative absolute risk for developing ≥ CIN3 of 32.5% compared to the 8.4% risk 
developing ≥ CIN3 for other high-risk HPV types.14 This underlines the potential 
importance of assessing the specific genotype causing the HPV infection. Triaging 
patients using cytology and genotyping assays might have a cost benefit over 
cytology combined with hr-HPV testing alone. The existence of triage management 
of ASC-US women in the United States solely depends on an accurate genotyping 
test.34 Both tests assessed in the present study could be suitable as triage test.
In addition to accurate genotyping, the appropriate detection of multiple infections 
seems to be an important application of tests when they are implemented into any 
format of population based screening for the prevention of cervical cancer, especially 
since the presence of multiple human papillomavirus genotypes in a single sample 
-suggesting repetitive exposure- is suspected to be associated with an increased risk 
for progressive disease.35 Moreover, mixed infections appear to be more frequent 
than previously expected; 35% of the HPV-positive samples and more than 50% of 
human immunodeficiency virus-positive women are infected with multiple HPV 
types.36,37 Multiple infections were less prevalent in cervical carcinomas.15 
In conclusion, both genotyping assays are handled equally well and have shown to 
be highly comparable. All of the HPV genotypes detected in either one or both of the 
assays, regardless the analytical or clinical sensitivity and specificity of the tests, 
should not be trivialized, since their natural behaviours and cancerous potentials in 
both single and mixed infections remain ambiguous. 
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Abstract 
Progression and regression of pre-malignant cervical lesions cannot be predicted 
using conventional cyto- or histomorphological parameters. However, markers as 
HPV or makers indicating proliferation, genetic instability and chromosomal 
aberration may be of predictive value assessing short-term biological behaviour of 
cervical intraepithelial neoplasia (CIN). In this paper we have studied the usage of 
logistic regression models with Ki-67 labelling index (LI), chromosome index (CI) and 
aneusomy for chromosome 1 in cervical smears to predict progressive and regressive 
behaviour of CIN lesions. Retrospectively, the intake-smears of 42 women showing 
regression in follow-up and of 31 women showing progression in follow-up were 
assessed. A multi-parameter logistic regression model containing the parameters Ki-
67 LI, CI#1, and the fraction of cells with 4 copies of chromosome 1 per nucleus 
appeared to be the best predicting model, overall correct classification of 93.2% 
(AUC 0.96±0.02). After cross-validation, the model correctly classified 66 of 73 
samples (90.4%). Moreover, the model predicted biological behaviour perfectly 
assessing the smear taken subsequently to the intake-smear of 46 women. Although 
measuring parameters indicating proliferation and chromosome 1 aberration is 
laborious, this study demonstrates that short-term pro- and regressive behaviour is 
highly predictable using a model combing these parameters. We also showed that in 
the triage management of high-risk HPV positive women with minimally abnormal 
smears applying a model as such can be useful. 
Introduction 
It is generally accepted that cervical intraepithelial neoplasia (CIN) precedes 
squamous cell carcinoma of the uterine cervix.1 According to the classification of the 
International Society of Gynecological Pathologists, these pre-malignant CIN lesions 
are classified solely by histomorphological criteria, i.e. nuclear atypia, presence, 
frequency and localization of mitotic figures and the loss of polarity of the nuclei. 
CIN is hereby subdivided in low-grade CIN 1 (mild dysplasia), and CIN 2 (moderate 
dysplasia) and CIN 3 (severe dysplasia and carcinoma in situ). 
High-grade CIN (CIN 2 and 3) can be successfully treated by large loop excision of the 
transformation zone of the cervix (LLETZ).2-4 Unfortunately, substantial over-
treatment of low-grade CIN is the penance for the accessibility of this procedure. 
For achieving adequate and well-deliberate treatment, knowledge on the pro- and 
regressive behaviour of squamous intraepithelial cervical lesions is compulsory. 
Östör showed in an extensive literature review that CIN 1 will progress to CIN 3 in 
only 10% of the cases and to invasive cancer in 1%.5 CIN 3 lesions on the other hand 
will advance to invasive carcinomas in 12%, whereas spontaneous regression will 
occur in 33%.6 However, ambiguity persists about the exact timescale of pro- and 
regression of “any-grade” cervical intraepithelial lesion. Moreover, neither cyto- nor 
histomorphological markers of cervical intraepithelial abnormalities can predict the 
biological behaviour of CIN. 
Genital infection with high-risk human papillomavirus (hr-HPV) is considered the 
most important factor in the carcinogenesis of cervical cancer.7 This significance is 
verified by the observations that almost all cervical cancers harbour hr-HPV 
genotypes8, and that 74% of CIN 1 and approximately 84% of high-grade CIN lesions 
harbour high-risk genotypes.9 The key event of HPV-induced oncogenesis is the 
integration of viral-DNA in the human genome.10 Frequently, hr-HPV16 DNA integrates 
near common fragile sites of the host genome11, and this is believed to occur 
somewhere in the gradual process of progression of a CIN lesion. Integration results 
in the disruption of the viral E2 region, inducing an over-expression of viral E6 and E7 
oncoproteins. Successively, these oncoproteins interfere with two crucial mitosis-
regulating pathways of the host cell, the p53-pathway and pRb-pathway, respectively. 
Normally the p53-pathway induces growth arrest or apoptosis while pRb regulates 
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the passage through the cell cycle. Accordingly, E6/E7-induced inactivation of these 
pathways results in hyperproliferation (E7 related) and genetic instability, numerical 
and structural chromosome aberrations and immortalization (all E6 related) 
(reviewed by Zur Hausen, 2002).12 
Structural aberrations as deletions, translocations and inversions in cervical 
carcinomas have been reported in chromosomes 1, 3, 6, 9, 11, and 17.13 E6-induced 
structural rearrangements of chromosome 1 have been described in 90% of the 
cervical cancers.14 Moreover, chromosome index (CI) -defined as the mean number of 
chromosome copies per nucleus- for chromosome 1 shows a significant positive 
correlation with CIN grading.15,16 
Monoclonal antibody MIB1 recognizes the proliferation-associated Ki-67 antigen.17 
The Ki-67 labelling index (percentage of MIB1 positive cells) has been propound a 
promising alternative method for classification of CIN lesions.18-20 
As opposed to cyto- or histomorphological markers of a CIN lesion, the parameters 
related to aberrations of chromosome 1 and those related to cell proliferation are 
suggested to have predictive value regarding the natural behaviour of CIN. The 
present study was designed to elucidate whether univariate and multivariate linear 
logistic regression models using Ki-67 labelling index, chromosome index for 
chromosome 1 and aneusomy for chromosome 1 assessed in cervical smears were 
able to predict progressive and regressive behaviour of CIN lesions. According to 
previous studies only women positive for high-risk HPV are at risk for the progression 
of a CIN lesion and should thus be followed more closely, hence the results of the 
predictors were assessed considering hr-HPV positive samples cytologically indicating 
borderline and mild dysplasia (BMD). 
Materials and methods
From a cohort of 800 women, all women referred to the Department of Obstetrics 
and Gynaecology of the Radboud University Nijmegen Medical Centre having two 
consecutive smears indicating atypical squamous cells of undetermined significance 
(ASC-US) or mild dysplasia, or one smear indicating moderate dysplasia were eligible 
for this study. All patients underwent colposcopy within one month of the intake. 
Preceding the colposcopy procedure a new cervical smear (“initial smear”) was 
obtained using the Cervex-Brush® (Rovers Medical Devices B.V., Oss, The Netherlands). 
The remnants of the cervical smear were fixed with Unifix® and processed into 
AgarCyto blocks as previously described21, allowing for multiple analysis. In case 
colposcopy was suggestive for high-grade CIN immediate excision of the transfor-
mation zone (LLETZ) would follow as previously described.2 These patients were not 
included in the present study. All referred patients whose colposcopy did not indicate 
a high-grade CIN were followed using cervical cytology. 
In case two consecutive follow-up smears would indicate normal cytology or 2 
grades less severe than the initial smear, the lesions were considered non-progressive 
or regressive. Women with an initial smear diagnosed ASC-US, mild or moderate 
dysplasia having a histologically proven CIN 3 lesion were considered progressive. In 
both progressive and regressive group the follow-up period required to be at least 3 
months. These two groups were used to obtain classifiers to facilitate the 
development of a logistic regression model for assessing the biological behaviour of 
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Table I  Classification of the two study groups
 
 Group Selection criteria Controls No 
BNC: borderline nuclear changes 
Initial smear: ASC-US, mild or 
moderate dysplasia 
Follow-up: two successive  
normal smears or two grades 
less severe than the initial smear
II
I
31
42
Initial smear: ASC-US, mild or 
moderate dysplasia
Treated by LLETZ ≥13 weeks and 
diagnosed CIN 3
Lesions with a negative short-
term follow-up with a low risk  
to progress towards CIN 3 
“Regressive lesions”
Lesions with a positive short-
term follow-up, corresponding 
with a high risk to progress into 
CIN 3. “Progressive lesions”
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CIN lesions (table 1). In the present study the classifiers were considered reliable if 
they had the ability to predict a negative short-term follow-up correctly within a 
high percentage of the women who did not develop CIN 3 in follow-up (group I). On 
the other hand, the classifiers would predict a positive short-term follow-up correctly 
in very high percentages of the women who developed a CIN 3 lesion in the follow-
up (group II). 
In order to test the classifiers, the model was supposed to predict initial smears as 
progressive in 7 under-diagnosed women who had had a LLETZ performed indicating 
a CIN 3 lesion, but whose initial smear taken 6 weeks prior to LLETZ procedure was 
under-diagnosed as moderate dysplasia (test group). Moreover, classifiers that 
correctly predicted the biological behaviour would perform as good or even better if 
applied to cervical smears taken subsequent to the initial smears whereupon the 
model is based, i.e. closer to the endpoint of pro- or regression. Therefore, 46 patients 
from groups I and II who had a subsequent follow-up smear taken after the initial 
smear were selected from the local pathology database and assessed in a similar 
way as the initial smears. These samples were used to validate the performance of 
the model. 
Since cervical cancer screening programmes can benefit most from any triage of 
minimally abnormal cervical smears, the logistic regression model best predicting 
biological behaviour was applied to the HPV positive minimally abnormal smears, 
the borderline and mild dysplasia (BMD) smears.
HPV genotyping 
For HPV detection a highly sensitive short fragment polymerase chain reaction 
(SPF10-INNO LIPA HPV genotyping assay, Labo Bio-medical products B.V. Rijswijk, The 
Netherlands) was performed on a section of the AgarCyto cellblock. A serial 6µm 
thick tissue section was put into a reaction tube and incubated overnight at 56ºC in 
200µL of 10mM tris-HCL with 1mM EDTA, 0.2% Tween-20, and proteinase K (0.3mg/
mL). Proteinase K was inactivated by 10 min incubation at 100º C. The sample was 
centrifuged for 10 min at 11,000 rpm and 10µL was directly used for PCR analysis. HPV 
DNA was amplified using the SPF10 PCR primer set. This assay amplifies a 65-bp 
fragment of the L1 open reading frame, and allows detection of at least 43 different 
HPV types. Each experiment was performed with separate positive and negative PCR 
controls. Samples positive for HPV DNA were assessed using reverse hybridization by 
a line probe assay (LiPA), allowing for simultaneous typing of 25 different HPV 
genotypes. This procedure for HPV detection and genotyping has been previously 
validated and considered highly sensitive.9,22-24 In this present study HPV genotyping 
of the samples was only used in order to differentiate between high-risk HPV 
infection and no-HPV infection. 
Immunohistochemistry
Detection of Ki-67 in AgarCyto cervical smear samples was performed using a 
standard immunocytochemical procedure, described in detail previously.25 Four µm 
thick paraffin sections of the tissue samples were mounted onto polylysinecoated 
slides and dried overnight at 58˚C. The sections were dewaxed in xylene and 
endogenous peroxidase was blocked using H2O2 in methanol for 15 minutes and the 
slides were rinsed three times in phosphate-buffered saline (PBS; pH 7,4) for 5 
minutes. The slides were placed in a citrate buffer (0,01M; pH 6,0), heated in a 
household microwave oven (3 min at 850W until boiling; followed by 10 min at 180W. 
The sections were allowed to cool down to room temperature (RT) and washed in 
PBS (10 minutes). The primary antibody was diluted in PBS and incubated overnight 
at 4˚C. All following antibodies were diluted in PBS with 1% bovine serum albumin 
(BSA; Sigma, St. Louis, Missouri, USA) and incubated for 30 min at RT. All interme-
diate wash steps were performed in PBS. Ki-67 was detected by MAb MIB1 (1:50; 
Dianova, Hamburg, Germany), followed by incubation with horseradish peroxidase-
conjugated rabbit anti-mouse (1:100; DAKO SA, Glostrup, Denmark). The slides were 
developed with 0.05% diaminobenzidine (DAB; Sigma, St. Louis, Missouri, USA) with 
0.15% H2O2 in PBS for 5 min at RT. Specimens were counterstained with Mayer’s 
hematoxylin, dehydrated in ethanol and xylene and finally mounted in Permount 
(Fisher Scientific; Fair Lawn, NJ, USA). The Ki-67 labelling index is defined as the 
fraction of Ki-67 positive nuclei. This labelling index was assessed in at least 100 
non-overlapping nuclei. 
In situ hybridization 
DNA-probe pUC1.77 for the centromere region of chromosome 1 was labelled by nick 
translation with biotin-16-dUTP according to the supplier’s instructions (Boehringer; 
Mannheim, Germany). The hybridizations protocol applied to AgarCyto sections have 
been previously described in detail.25 In short, AgarCyto sections were consecutively 
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dewaxed, blocked for endogenous peroxidase, and pre-treated with 1M NaSCN for 10 
min at 80ºC. Protein digestion was performed using 4000U/mL pepsin (Sigma; St. 
Louis, Missouri, USA) in 0.2M HCl for 5 min at 37ºC and the sections were dehydrated 
through an alcohol series and air-dried. DNA probe (2ng/µL) was dissolved in 15µL 
hybridization mix containing 60% formamide, 2x standard saline citrate (SSC), pH 
7.0, 10% dextran sulphate (Sigma; St. Louis, Missouri, USA), and 50ng/µL herring 
sperm DNA (Boehringer; Mannheim, Germany). The probe mix was applied to the 
sections, covered with a cover slip, and sealed with rubber cement. Probe and target 
DNA were heat-denatured simultaneously for 10 min at 80ºC and hybridized 
overnight at 37ºC in a moist chamber. Cover slips were removed by immersing the 
slides at 42ºC in 2xSSC, pH 7.0. Post-hybridization washes at 42ºC were carried out 
twice for 5 min in 60% formamide/2x SSC, pH 7.0, and twice for 5 min in 2x SSC, pH 
7.0. The slides were rinsed in phosphate buffered saline (PBS)/0.05% Tween-20 
(PBST). Hybridised DNA probes were detected by immunohistochemically using 
mouse anti-biotin (1:100; DAKO SA, Glostrup, Denmark), biotinylated horse anti-
mouse, and peroxidase-ABC as described for immunochemistry. Evaluation of ISH 
signals of non-overlapping and morphologically good preserved nuclei was performed 
as previously described.16 At least 100 nuclei per sample were assessed.
The chromosome index is defined as the mean number of chromosome copies per 
nucleus in the sample of measured nuclei. The CI measured in non-truncated diploid 
nuclei has a theoretical value of 2. In truncated nuclei, the CI measured in dipoloid 
cells, will be always smaller than 2. As pointed out in an earlier study, an aberrant CI 
was defined as any value exceeding 1.4 (mean value CI + 2.58 x SD, obtained from 
normal cervical epithelium in control subjects).15,16 In this study the chromosome 
index for chromosome 1 (CI#1) was assessed.
Statistics 
Between group I and II independent t-tests were performed to assess differences in 
the means of the various parameters measured. In order to select a subset of 
features to discriminate between the patients in group I and II a forward likelihood-
ratio stepwise logistic regression analysis was performed. Logistic regression 
analyses were also used to find the best multi-parameter linear predictor to allocate 
women in these groups, as is given by the formula: η=a0+a1·x1+...+an·xn in which ai are 
the regression coefficients of the corresponding predictor xi which are selected 
using forward stepwise logistic regression analysis. The conditional probability that 
a low-grade cervical lesion will progress to a CIN 3 if the value of the linear predictor 
η (as described above) is known, is given by the formula: P(progressionIη)= 1+en 
In case the progression probability is ≥0.5 the sample is classified progressive, a 
probability <0.5 means the sample is classified regressive. The same samples were 
used to construct as well as to evaluate the performance of selection criteria. 
The quality of the multi-parameter linear models’ probabilistic judgements was 
assessed using several quantitative methods: the Brier score, the area under the 
“receiver operating characteristic” (ROC) curve and the Hosmer and Lemeshow Test. 
The Brier score (B) is the mean-squared-error of chance expectancy, measuring the 
difference between a predicted probability of an event (Pi) and its corresponding 
observed response (Yi) for the ith observation, expressed as 0 or 1 depending on if 
the event has occurred or not B= 1 ∑ (Pi-Yi)2 . 
So, a Brier score value near zero corresponds to a nearly perfect prognosis by the 
model.26 The area under the ROC curve is a graphical plot of the sensitivity vs. (1 – 
specificity) for a binary classifier system as its discrimination threshold is varied. The 
curve represents the probability that a randomly chosen progressive sample is 
correctly rated with greater suspicion than a randomly chosen non-progressive 
sample. The greater the area under the curve, the better the prediction model. The 
Hosmer and Lemeshow test is a commonly used test for the goodness-of-fit based 
on grouping predicted probabilities into deciles and performing a χ2-test for the 
mean predicted probability against the observed fraction of events.26 The higher the 
P-values of the χ2-test the better the fit.
Classification results from this procedure may therefore be too optimistically biased. 
The leave-one-out cross-validation method was used in the logistic regression 
analyses to reduce this bias. Using this method one observation is omitted from the 
analytical process and the response for that observation is predicted using a model 
derived from the remaining n-1 observations.26 The statistical analyses were 
performed with SPSS version 12.0.1 for Microsoft Windows.
en
n
i=1
n
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Results
From a cohort of 800 women, 73 were allocated meeting the criteria defined in table I. 
The mean age at initial smear was 37.0(±9.4) years. Thirty-five of the 73 initial 
smears showed moderate dysplasia (47.9%), 14/73 (19.2%) of the women had a smear 
indicating mild dysplasia and in 24/73 (32.9%) the initial cytology was diagnosed 
ASC-US. Details of the distribution of the initial cytology per group are given in table II. 
Twenty-one of the 24 women having ASC-US (87.5%) showed regression towards 
normal epithelium in the consecutive smears, while progression to CIN 3 appeared in 
3/24 cases (12.5%). Eleven of the 14 women (78.6%) initially having mild dysplasia 
regressed to a normal smear, while progressive behaviour was observed in 3/14 cases 
(21.4%). Finally, of the 35 women demonstrating moderate dysplasia in their initial 
smear 4/35 (11.4%) regressed to a normal smear, 6/35 (17.1%) regressed towards an 
ASC-US smear and, 25/35 (71.4%) showed progression. 
The indicated follow-up time between initial smears and subsequent normal or two 
grades less severe smears (group I) and between initial smears and LLETZ procedures 
(group II) was at least 3 months. However, the actual mean (±SD) follow-up time in 
months for the two groups was prolonged, group I 8.7(±6.1) months and group II 
5.9(±5.0) months. 
High-risk HPV detection 
Forty-four of the 73 initial cervical smears (60.3%) harboured high-risk HPV 
genotypes, in the remaining 29 (39.7%) no hr-HPV types were detected using the 
SPF10-LiPA assay. Considering the initial cytological results 11/24 (45.8%) ASC-US 
smears, 7/14 (50%) mild dysplasia smears and 26/35 (74.3%) moderate dysplasia 
smears contained hr-HPV. Using the presence or absence of a hr-HPV infection to 
classify women in respectively group II (progression) and group I (regression) yielded 
a poor overall classification percentage of 63.0% (46/73), 52.4% (22/42) was correctly 
classified in group I and 77.4% (24/31) in group II. 
Ki-67 Labelling Index and numerical chromosome aberrations 
The mean values and standard deviations of the Ki-67 LI, the fraction of cells with 4 
copies of chromosome 1 per nucleus, and of the chromosome index for chromosome 
1 (CI#1) for groups I and II are given in table III. In group II the fraction of MIB1 
positively stained nuclei (e.g. Ki-67 LI) was more than 2 times greater than in group I 
(P<0.001, Student t-test). Also the CI#1 was significantly greater in group II than in 
group I (P<0.001, Student t-test). Moreover, compared to group I the fraction cells 
with 4 copies of chromosome per nucleus was significantly greater in group II 
(P<0.01, Student t-test).
Logistic regression model
Using forward likelihood-ratio stepwise logistic regression analysis with Ki-67 LI, 
CI#1, and the fractions of cells with 0, 1, 2, 3, 4, 5, 6, 7, and 8 copies of chromosome 1 
per nucleus a linear predictor (η1) based on three parameters was identified (data 
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Table II  Cytological classification of the initial smears in the two groups assessed 
Table III  Mean and SD for the biomarkers in the initial smear which appeared  
to be most suited for logistic regression and (multi)variate analysis   
Initial smear Total Group
   I II
   [n (%)] [n (%)]  
ASC-US 24 21 (50) 3 (12.5) 
Mild dysplasia 14 11 (26.2) 3 (21.4)
Moderate dysplasia 35 10 (23.8) 25 (59.5)
Total 73 42 31 
ASC-US: atypical squamous cells of undetermined significance
Parameter  Group I  Group II  P-value  Test group 
 (N=42) (N=31) Student t-test (N=7)
 Mean±SD Mean±SD  Mean±SD  
Ki-67 LI 0.19±0.15 0.43±0.15 <0.001 0.59±0.14
CI#1 1.32±0.21 1.86±0.35 <0.001 2.11±0.33
Fr 4 copies #1 0.01±0.03 0.04±0.05 <0.01 0.04±0.06
LI: Labelling index; CI#1: chromosome index for chromosome 1;  Fr 4 copies #1: fractions of cells with 4 copies of 
chromosome 1 per nucleus; SD: standard deviation
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not shown). The chromosome index for chromosome 1 (CI#1) was the best 
discriminating biomarker, followed by Ki-67 labelling index and the fraction of cells 
with 4 copies of chromosome 1 per nucleus (Fr4ISH). This led to the following logistic 
regression models; η(1) was based on the best discriminating biomarkers respectively 
Ki-67 LI, CI#1 and Fr4ISH, bivariate linear prediction model η(2) was based on Ki-67 LI 
and CI#1. Univariate linear prediction models η(3) and η(4) were solely based on CI#1 
and Ki-67 labelling index, respectively. 
η  ( 1 )= -19. 432+10.680 · Ki-67 LI +11.04 4· CI #1-57.511 · Fr4ISH
η  (2)= -11 . 479 +8.766 · Ki-67 LI +5 .559 · CI #1
η  ( 3 )= -10.853 + 6.893 · CI #1
η  (4)= -3 .712+10.955· Ki-67 LI
The results of the tests validating the models, i.e. Hosmer and Lemeshow Test, the 
area under the receiver operating characteristics (ROC) curve (AUC) and the Brier 
score, are listed in table 4. The highest AUC score and the lowest Brier score indicate 
that model η(1) is the best prediction model. Applying the models to the initial 
cervical smears of group I and group II multivariate logistic regression model η(1) 
generated correct predictions of >90% in both groups, whereas the other 3 models 
(η(2)- η(4)) predicted overall correct group membership substantially less, table IV. This 
was especially true for the samples in the progressive group II. 
Reducing optimistically biased results using the leave-one-out cross-validation 
procedure in model η(1) led to correct classification of 27/31 (87.1%) progressive 
samples and 39/42 (92.9%) regressive samples, all other models performed less 
good, table IV.
Validating model η(1) using the additional moderate dysplasia samples of the test 
group, led to correct classification of all 7 samples. Thus, using regression model η(1) 
all smears in the additional group were correctly classified progressive. 
Subsequent smears 
Since the cervical smears following the initial smear are taken closer to the imaginary 
endpoint of pro- or regression, the parameters indicating proliferation and 
chromosomal aberrations will have shown development toward the final diagnoses. 
Therefore, the classifiers described in our logistic regression model should perform 
as good or even better if applied to these consecutive cervical smears. 
Using the results of the biomarkers assessed in the selected 46 subsequent smears 
(see also Materials and Methods section), we were once more able to assess and 
validate the logistic regression models. Applying the initial samples of the 46 
selected smears to the best predicting model η(1), the percentages correctly classified 
samples were comparable with the percentages in the total group of 73 samples 
(93% vs 95% and 88% vs 90% for group I and II, respectively). The overall correct 
classification in these 46 initial smears using the other models was substantially 
less. Using the biomarkers assessed in the subsequent smears led to correct 
prediction of all members of the two groups using the prediction models η(1), η(2), and 
η(3), table V. 
HPV positive borderline and mild dysplasia (BMD) smears
In total 38 initial smears indicating BMD were assessed in the present study, 24 ASC-
US (i.e. borderline) smears and 14 mild dysplasia smears. Eighteen of the BMD smears 
(47.4%) were hr-HPV positive, 4 of the hr-HPV positive BMD smears showed 
progression. Of the 20 hr-HPV negative BMD smears 18 regressed and two showed 
progression. Applying logistic regression model h(1), to these BMD smears predicted 
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Table IV  Percentage correctly classified per group using the logistic regression 
models η(1)-η(4) and the results of the test validating the models 
     Percentage correctly classified
Logistic  H&L Test  ROC curve  Brier Group I Group II Cross Cross  
regression  (AUC±SE) score (N=42) (N=31) validation validation
model      Group I Group II
η(1)  0.572 0.96±0.02 0.07 95.2% 90.3% 92.9% 87.1%
η(2)  0.622 0.94±0.03 0.12 92.9% 80.6% 90.5% 80.6%
η(3)  0.544 0.91±0.04 0.14 95.2% 74.2% 92.9% 74.2%
η(4)  0.713 0.87±0.04 0.26 78.6% 67.7% 78.6% 67.7% 
H&L Test: Hosmer and Lemeshow test; ROC: Receiver operating characteristics; AUC: area under the ROC curve;  
SE: standard error 
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progression and regression correctly in all hr-HPV positive samples, 4/18 (22.2%) and 
14/18 (77.8%), respectively. One of the 20 (5%) hr-HPV negative BMD samples was 
classified progressive, while actually being regressive. The two hr-HPV negative BMD 
smears, which showed progression, were correctly classified progressive by the model. 
Discussion
This study shows the possibility to predict biological behaviour of cervical lesions 
using a logistic regression model based on Ki-67 labelling index and numerical 
aberrations for chromosome 1 assessed in cervical smears. Taking all samples into 
account, our model containing the proliferation marker Ki-67 LI, the chromosome 
index of chromosome 1, and the fractions of cells with 4 copies of chromosome 1 per 
nucleus predicted 40/42 (95.2%) of the regressive lesions and 28/31 (90.3%) of the 
progressive lesions correctly. Overall, the behaviour of the cervical lesion of more 
than 93% of the women referred to the gynaecologist as selected in this study could 
be correctly predicted using the parameters assessed from the smears obtained at 
intake. In only 5/73 patients the model did not predict the behaviour of the cervical 
lesion correctly; 2 women were predicted progressive while being regressive (i.e. 
false positive), leaving 3 patients as false negative (predicted regressive while being 
progressive). If patient management would be solely based on the best predicting 
model the false negative results would have possibly lead to under-treatment. After 
reducing optimistically biased results using the leave-one-out cross-validation 
procedure, the biological behaviour of 66/73 (90.4%) samples was correctly predicted. 
Validating the model using the 46 follow-up smears taken subsequent to the initial 
smear, led to correct prediction of all 17 progressive and all 29 regressive samples. 
Since the 46 smears were obtained closer to the endpoint of pro- or regression, the 
parameters assessed were indeed involved in progression. The initial smears of the 7 
additional moderate dysplasia samples (test group) were also predicted correctly 
progressive by the model. Since, the time to progression was short (i.e. <6wks), these 
initial samples ought to be considered cytologically under-diagnosed CIN 3. 
High-risk HPV is associated with an increased risk in the development of cervical 
carcinoma. Supposing regressive or progressive behaviour of the lesions assessed in 
this study was predicted solely based on the absence or presence of hr-HPV 
genotypes, respectively, only 63% (46/73) of the samples would have been correctly 
classified; 22 (of 42) hr-HPV negative samples were predicted regressive and 24 (of 
31) hr-HPV positive samples progressive, whereas 27.4% (20/73) would have been 
incorrectly predicted to be progressive and 9.6% (7/73) would have been incorrectly 
predicted to be regressive. This suggests that hr-HPV testing is inappropriate as a 
prediction marker for progressive behaviour and that this parameter can be merely 
valued as a risk indicator in case of screening patients susceptible to developing 
high-grade CIN and/or cervical cancer. Previously, high negative predictive values of 
HPV DNA tests for identifying high-grade CIN and cancer and the questionable 
clinical relevance of a single positive hr-HPV test have been extensively reviewed and 
debated in literature.27,28 
Previous studies have already shown a significant positive correlation between 
structural rearrangements of chromosome 1 and CIN lesions15,16,29,30 and between 
MIB1 and CIN lesions.18,19,31 This is the fist study successfully assessing chromosome 
indexes and Ki-67 labelling index simultaneously in serial sections of cervical smears. 
Although MIB 1 is suggested an excellent neoplasm proliferation marker and 
aneusomy for chromosome 1 seems to be a promising surrogate marker for the 
prediction of biological behaviour of low-grade CIN lesions, the combination of 
parameters appears an even better method predicting CIN behaviour. Large-scale 
implementation, e.g. population based screening programmes might however be 
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Table V  Percentage correctly classified by (multi-)parameter logistic regression 
models η(1)-η(4) based on initial and subsequent smear   
Logistic  Initial smear  Subsequent smear 
regression
 Group I Group II Group I Group IImodel
 (N=29) (N=17) (N=29) (N=17)  
η(1)  93.1% 88.2% 100% 100%
η(2) 89.7% 82.4% 100% 100%
η(3) 48.3% 88.2% 100% 100%
η(4) 75.9% 76.5% 100% 94.1%
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restricted. Especially since assessments of Ki-67 LI and of rearrangements of 
chromosomes are time-consuming, require expertise, are expensive, and need to be 
performed under strict standardised conditions and laboratory settings. Moreover, 
the thickness of the dissected sample is influenced by various uncontrollable factors, 
e.g. barometric pressure. Since, the chromosome index measured in truncated nuclei 
is dependent on the fraction of the nuclear volume that is enclosed in the tissue 
section, reliable measurement of CI requires standardised thickness of the assessed 
sections.32 Although, all parameters in this study were measured in AgarCyto blocks, 
assessing the parameters in liquid based cytology (LBC) samples is also possible. 
MIB-1 for instance has lately shown to be of promising value as surrogate marker in 
a cervical cancer screening setting using LBC.33 In addition to a clinical use our 
multiple-parameter logistic regression model can be used for the validation of and 
correlation to new biomarkers which might be discovered in the future and are 
associated with progressive or regressive behaviour of CIN. 
However, the model could also be used more practically, i.e. in the triage of women 
with minimally abnormal cervical cytology, like ASC-US and mild dysplasia (i.e. the 
borderline and mild dysplasia (BMD) smears). Approximately 5% of the women 
participating in the population-based screening for cervical cancer are diagnosed 
having a BMD smear. The management of patients having these minimal abnormal 
cervical smears has been a clinical problem for a long time.34 At this moment women 
with two consecutive BMD smears are referred to the gynaecologist for colposcopic 
assessment. Since, cytology is not able to predict the pro- or regressive behaviour 
and HPV DNA testing alone has a too low positive predictive value for identifying 
high-grade CIN and cancer, additionally assessing HPV in the triage of repetitive 
BMD smears is recommended by the American Society for Colposcopy and Cervical 
Pathology (ASCCP) and other (inter)national medical societies. This triage will 
improve the management of BMD women at risk for developing cervical cancer.35-37 
Further triaging the BMD HPV positive smears using the progression makers 
described in our model, could improve management even more. Indeed, in the 
present study 18 of the 38 BMD (47.4%) smears were hr-HPV positive, which is 
consistent with other studies.37,38 So, using the proposed hr-HPV triage only 50% of 
the minimally abnormal cervical smear would be referred to the gynaecologist. 
In our follow-up 4/18 hr-HPV positive BMD smears (22.2%) showed progression, while 
the remaining 14 hr-HPV positive smears showed regression. Using the multiple 
parameter prediction model (η(1)) all progressive lesions were predicted correctly and 
only 1 observed regressive lesion was misclassified. This suggests that our prediction 
model works very well and that subsequent to the hr-HPV triage in borderline and 
mild dysplasia the hr-HPV positive smears can be assessed using Ki-67 LI and 
rearrangements of chromosome 1 to reliably predict the behaviour of the lesion. In 
this (small-numbered) study it would mean that of a total number of 38 BMD smears 
only 4 (10%) should have been referred to the gynaecologist since the model correctly 
predicted progression. However, of the 20 hr-HPV negative BMD smears 2 showed 
progression. According to the ASCCP triage guidelines for hr-HPV in BMD smears 
these women would not have been referred to the gynaecologist, nevertheless our 
model did predict these progressive lesions correctly. Since, the general dogma 
states that progression to ultimately cervical cancer will only occur in hr-HPV 
positive lesions, the behaviour of the lesions in these two women should however be 
considered non-progressive.
Our data demonstrate that short-term progressive and regressive behaviour is highly 
predictable. In case high-risk HPV is detected in a borderline and mild dysplasia 
smear, one should consider to determine the biological behaviour of the cervical 
lesion by using proposed the logistic regression model with Ki-67 LI, chromosome 1 
aberration parameters. This could significantly improve patient management.
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Abstract 
High-risk human papillomavirus (HPV) testing in cervical cancer screening has a 
beneficial effect in patient management and can increase the success rate of 
population-based screening programmes. Women not participating in these 
programmes have a higher risk of developing cervical cancer. The introduction of 
cervicovaginal self-sampling might increase the participation rate and can thus 
reduce cancer incidence. This study assesses the possibility to use self-sampled 
genital smears subsequently applied to specific filter papers (Dried Fluid Spots) 
allowing easy storage and transport. Fifty women obtained a self-sampled genital 
smear, which was applied to a filter paper and assessed for (probable) high-risk HPV 
genotypes by the HPV SPF10 Line Blot 25 assay. The HPV results were compared to a 
cervical smear taken by a trained physician. Twenty-five (50%) of all self-obtained 
samples were positive for (probable) high-risk HPV. Of these samples 23 also tested 
positive in the physician obtained smear. Twenty-four of the 50 samples (48%) were 
negative to (probable) high-risk HPV genotypes in both self-collected and physician 
smear. The overall agreement between self- and physician obtained sample was 96% 
(κ-value: 0.92). This study shows that HPV detection and genotyping in self-obtained 
genital samples that are subsequently applied to Dried Fluid Spots is very well 
possible. Moreover, this method shows a high overall agreement with HPV detection 
and genotyping in physician-obtained cervical smear. Compared to other self-
sampling devices the Dried Fluid Spot method is not dependent on liquid storage 
methods that are potentially inflammable, hazardous and are not always allowed 
regular mailing.
Introduction 
The clinical value of human papillomavirus (HPV) testing is increasingly recognized.1 
If used as primary screening method, HPV assessment has a higher sensitivity and a 
higher negative predictive value, but a lower specificity for the detection of pre-
invasive disease than cervical cytology.2,3 In the U.S., the Food and Drug Administration 
(FDA) has authorized high-risk HPV (hr-HPV) assessment in women aged 30 and 
older for primary screening, in addition to cytological screening, and for the triage of 
ASC-US smears. The Dutch Pathology association (NVVP) has recently approved 
additional hr-HPV testing in all follow-up smears after the detection of a first-time 
borderline or mild dysplasia (BMD) smear. So, high-risk HPV testing already has a 
beneficial effect in patient management. Most likely this will increase in case hr-HPV 
assessment replaces cytology as primary screening tool. 
Improving the sensitivity of cervical cancer screening methods through the 
implementation of hr-HPV testing may increase the success rate of population-
based screening programmes. Maximizing the participation-rate could improve this 
success even more.4 In the Dutch screening programme approximately 70% of the 
invited women are actually taking part.5 Tragically, half of the cervical carcinomas are 
diagnosed in the remaining group of non-responders.6,7 Cervical cancer incidence 
would decrease significantly if these non-responders can be reached, providing that 
they do participate.4 Women do not respond or participate for various reasons; being 
afraid of the procedure or the possible diagnosis, having a too busy schedule, or 
general unawareness. Genital self-sampling could be an easy accessible, user-friendly 
and timesaving alternative for the physician-based collection of cervicovaginal 
material. 
Material from vaginal lavages or self-sampling brushes is highly representative for 
the cervical HPV status.8-14 In a review, Brink and colleagues described a study in 
which 1.6% of the population-based screening non-responders with a valid and 
hr-HPV positive self-sample test, appeared to have a high-grade cervical intraepithelial 
lesion.15 This is significantly higher than the high-grade CIN prevalence observed in a 
population-based randomized controlled trial for implementation of hr-HPV testing 
in cervical screening, i.e., the Dutch POBASCAM trial.16 These results not only show 
that women who do not participate in a well-organised screening programme 
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indeed have a higher risk of developing cervical cancer9,11,15, but also that hr-HPV 
testing on self-sampled materials might be a promising opportunity to increase the 
efficiency of population-based screening programmes worldwide.8,15 Moreover, non-
responding women do actually participate in self-sampling projects, leading to an 
increased participation rate of population based screening programmes and thus a 
higher rate of success. 
The vast majority of studies assessing self-sampling have used methanol-buffered 
solutions or other liquid transport media in liquid based cytology (LBC) vials, i.e. 
PreservCyt® solution, and ThinPrep®. Since these samples can be inflammable, 
hazardous, and infectious, careful handling is required and in The Netherlands 
regular mailing is not allowed. This severely hampers the introduction of liquid based 
cervicovaginal self-sampling methods. 
In this study we have assessed the possibility to use self-sampled genital smears 
applied on filter paper, i.e., Dried Fluid Spots (Figure 1) allowing easy storage and 
transport for HPV DNA testing. The self-sampling material was compared to a 
cervical smear obtained for diagnostic purposes by a trained physician in the 
outpatient clinic. 
Materials and Methods
The participants were recruited between May and September 2006 at the Department 
of Obstetrics and Gynaecology of the Radboud University Nijmegen Medical Centre. 
The patients had initially been referred to the gynaecologist because of two 
subsequent smears indicating borderline or mild dysplasia (BMD). They had had a 
colposcopic examination and were followed using an expectative management, 
allowing spontaneous regression of the lesion.17 In this expectative management 
study setting, the patients were cytologically assessed every 6 months for 2 years at 
our outpatient clinic. Smear specimens were collected using the Cervex-brush® 
(Rovers Medical Devices B.V., Oss, The Netherlands), and processed using a liquid-
based approach (Thinprep®, Cytyc corp. Boxborough MA, USA) that provides 
monolayer distributions for cytological assessment and the possibility of isolating 
DNA for HPV detection and genotyping assays. This method has received approval 
for clinical use from the U.S. FDA.18,19
All patients were informed and the participants willing to participate were asked to 
sign a written informed consent. A specific illustrated explanation was developed to 
instruct the women on how to obtain a genital self-sample. Briefly, a Viba-brush® 
(Rovers Medical Devices B.V., Oss, The Netherlands) was inserted 10 cm into the 
vagina and rotated 5 times. Subsequently the brush was applied to a specific filter 
paper (Primagen Holding B.V., Amsterdam, The Netherlands), Figure 1. The Dried Fluid 
Spot was dried to air, placed in an envelope, and sent to the Department of Medical 
Microbiology for further processing and HPV assessment. After self-sampling, a 
vaginal speculum was inserted and the physician obtained a cervical smear using a 
Cervex-brush® (Rovers Medical Devices B.V., Oss, The Netherlands) that was rinsed in 
a Thinprep® vial (Cytyc corp. Boxborough MA, USA). Regular liquid-based cytological 
(LBC) examination was performed at the Department of Pathology and 0.5mL LBC 
medium was used for HPV assessment at the Department of Medical Microbiology. 
In order to have the samples assessed anonymously and in a blinded approach, all 
self-obtained samples and cervical LBC samples were sent to the laboratory with a 
unique code that could only be encoded by the principal investigator. 
7
Figure 1  Original Primagen Dried Fluid Spot filter paper with 6 separate  
spots including return envelope and Viba-brush self-sampling brush.  
In this study only 1 spot per paper was used per patient
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Specimen preparation LBC
For isolation of DNA from cervical scrapes in liquid-based cytology medium, the 
MagNAPure LC Isolation station (Roche Diagnostics GmbH, Roche Applied Science, 
Mannheim, Germany) was used; 500µL of material was isolated using the MagNA 
Pure LC Total Nucleic Acid Isolation Kit (Roche Diagnostics GmbH, Roche Molecular 
Biochemicals, Mannheim Germany), as described by the manufacturer. With each set 
of 28 cervical scrape samples 4 negative controls were included. Nucleic acid was 
resuspended in a final volume of 50µL; 10µL were used for PCR. 
Specimen preparation DFS
The dried fluid spots (DFS) were punched out of the filter paper using a sterilised 
perforator specifically designed for the DFS papers. DNA was isolated using the 
QIAGEN® DNeasy Tissue Kit (QIAGEN Inc, Valencia, CA, USA), as described by the 
manufacturer. Subsequently, HPV DNA assessment was performed identically as for 
the liquid based cytology specimens, as described below. 
SPF10 Line Blot 25 HPV detection and genotyping 
Broad-spectrum HPV DNA amplification was performed using a short PCR fragment 
assay (HPV SPF10 Line Blot 25, Labo Bio-medical products B.V. Rijswijk, The Netherlands). 
This assay amplifies a 65-bp fragment of the L1 open reading frame, and allows 
detection of at least 43 different HPV types.20,21 The presence of HPV DNA was 
determined by hybridization of SPF10 amplimers to a mixture of general HPV probes 
recognizing a broad range of high-risk (hr), low-risk (lr) and possible hr-HPV 
genotypes in a microtiter plate format, as described previously.21,22 
Twenty-eight oligonucleotide probes which recognize 25 different types were tailed 
with poly(dT) and immobilised as parallel lines to membrane strips (Labo Bio-
medical products B.V. Rijswijk, The Netherlands). The HPV genotypes detectable are 
hr-HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68/73 and 2 probable hr-HPV 
types (53 and 66). The HPV genotyping assay was performed as described previously.23 
The LiPA strips were manually interpreted using the provided reference guide. Since 
HPV assessment in screening and triage is solely based on (probable) high-risk 
genotypes, the comparison in this study is focussed on these genotypes.
As a quality control for the presence of DNA and absence of PCR inhibitors in the 
isolated material a ß-globin PCR was performed, as recently described by Snijders 
and colleagues.24,25
In all HPV 16, 18, 31, and/or 33 positive samples the viral load for the individual 
genotypes was assessed using real time PCR methods as previously described.24,25 We 
have indicated the viral load as copies per scrape. 
Statistics 
All data were analyzed using SPSS version 12.0.1 for Windows. Agreement was 
measured by absolute agreement and Cohen’s kappa statistics, a measure of the 
agreement between two methods that is in excess of that due to chance.
Results 
Fifty women were included in this study. The median age of the women was 35 years 
(range, 22 to 56). All women were initially referred to the gynaecologist for 2 
subsequent equivocal smears, i.e., borderline and mild dysplasia (BMD). The LBC 
cervical smears taken by the physician showed normal cytology in 60% (30/50) of 
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Table I  High-risk HPV detection for corresponding genital self-sampled  
smears and MD obtained cervical smears 
MD-sampling Self-sampling Agreement, κ-value and 95% CI
    Positive Negative
Normal  Positive 8 0 
cytology Negative 3 19 
 Total 11 19 90%, 0.77 (0.53-1.02)*
BMD  Positive 9 1 
cytology Negative 0 6 
 Total 9 7 93.8%, 0.87 (0.63-1.12)†  
>BMD   Positive 4 0 
cytology Negative 0 0 
 Total 4 0 100%, 1.00 (1.00-1.00)‡
Overall  Positive 21 1 
 Negative 3 25 
 Total 24 26 92% 0.84 (0.69-0.99)† 
Strength of agreement considered *good, †very good, ‡perfect 
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the cases, BMD cytology in 16/50 (32%) cases, and in 4/50 cases (8%) the smears 
appeared to be more severe than BMD. 
Of the 50 self-collected genital samples 25 (50%) tested positive for (probable) high-
risk genotypes by the HPV SPF10 Line Blot 25. Of these 25 samples 23 also tested 
positive for (probable) hr-HPV in the cervical smear obtained by the physician. 
Twenty-four of the 50 samples (48%) were negative to (probable) high-risk HPV 
genotypes in both self-collected and physician smear. In 22 of the 50 (44%) cervical 
smears obtained by the physician hr-HPV types were detected, 21 cases also tested 
hr-HPV positive in the self-obtained sample. The overall agreement between self-
sampling and the cervical smear taken by the physician for high-risk HPV was 92% 
(κ-value: 0.84), Table I. Taking both probable high-risk (i.e. 53 or 66) and hr-HPV 
genotypes into account the overall agreement increased to 94% (k-value: 0.88), 
Table II. 
The agreement of HPV DNA detection between the self-obtained and the physician 
obtained sample increased with the severity of the lesion detected in the LBC. For 
the probable high-risk and the high-risk genotypes together the agreement was 
93%, 94% and 100% in the 30 smears with normal cytology, the 16 samples with 
BMD cytology and the 4 samples showing cytology more severe than BMD, respec-
tively. Regarding the defined hr-HPV genotypes the agreement was 90%, 94% and 
100%, respectively.
The frequencies of the probable high-risk and high-risk HPV genotypes detected by 
both methods are summarized in Table III. Taking the samples of all 50 women into 
account, including those negative to probable high-risk and hr-HPV DNA, 40 samples 
(80%) were concordant, 7 (14%) were compatible, and 3 (6%) samples were 
discordant. Of the 40 concordant samples 24 showed no (probable) high-risk HPV 
DNA in both self- and physician obtained samples. The remaining 16 concordant 
samples were hr-HPV positive and showed identical genotypes in the two samples, 
see samples no. 1-16 in Table IV. The seven compatible sample-sets, i.e., showing one 
or more comparative HPV genotypes between the samples, were multiple infections 
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Table II  Probable high-risk and hr-HPV detection for corresponding genital  
self-sampled smears and MD obtained cervical smears 
Table III  Distribution of HPV-genotypes in genital self-sampled smears and  
cervical smears taken by the physician 
MD-sampling Self-sampling Agreement, κ-value and 95% CI
    Positive Negative  
Normal  Positive 9 0 
cytology Negative 2 19 
 Total 11 19 93.3%, 0.85 (0.65-1.05)*
BMD  Positive 10 1 
cytology Negative 0 5 
 Total 10 6 93.8%, 0.86 (0.60-1.12)*  
>BMD   Positive 4 0 
cytology Negative 0 0 
 Total 4 0 100%, 1.00 (1.00-1.00)†
Overall  Positive 23 1 
 Negative 2 24 
 Total 25 25 94% 0.88 (0.75-1.01)* 
Strength of agreement considered *very good, †perfect 
Oncogenic Potential HPV Genotype  Infection frequency 
  Self-sampling MD-sampling
 16 5  5
 18 2  2
 31 5  4
 33 0  2
 35 0  0
 39 1  1
High-risk 45 0  0
 51 3  1
 52 3  4
 56 2  2
 58 1  1
 59 2  1
 68/73* 2  2
 53† 2  1
Probable high-risk
 66 4  3
*HPV SPF10 Line Blot 25 does not distinguish between HPV 68 and HPV 73, since bothtypes are detected by a single 
probe; †Oncogenic potential of HPV 53 is controversial
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when considering both samples. In 6 self-obtained and 5 MD-obtained samples a hr-
HPV type was detected, see Table IV samples no. 17-22. In 3 cases the MD-obtained 
sample did contain a specific hr-HPV genotype that was found in the self-obtained 
sample, and in three other cases the self-obtained sample did not contain a hr-HPV 
type. In one compatible sample-set only probable hr-HPV types were detected. In the 
three discordant cases a hr-HPV genotype was detected in either one of the samples, 
sample no. 23-25 in Table IV. In two samples the MD-smear did not contain a hr-HPV 
type in contrast to the self-obtained sample. Whereas in one sample-set only the 
MD-obtained sample contained a high-risk genotype. 
The average ß-globin of the self-obtained samples was 4.5E+4 (±3.0E+4), whereas 
the average ß-globin of the samples taken by the physician was 6.4E+3 (±6.1E+3). 
This difference was statistically significant P<0.001 (Unpaired t-test).
Table IV gives a summary of the 25 sample-sets that contained at least one high-risk 
HPV genotype in either one or both samples, 16 concordant samples, 6 compatible, 
and 3 discordant sample-sets. In case a sample contained HPV 16, 18, 31, and/or 33 the 
viral loads per scrape per genotype are given. Although numbers of samples with a 
viral load were too small for proper statistical analysis, the loads show little variance 
between the self-obtained and the MD obtained sample in case the viral loads could 
be detected. In five samples however, the viral load was too low for detection using 
the real-time PCR method and could thus not be detected. In four cases it concerned 
a genotype which was only detected in either one of the samples and in 1 case it 
concerned HPV 31 which was detected in both genital-self and MD obtained sample. 
Discussion 
Several studies have already shown that cervicovaginal self-sampling is highly 
representative for the HPV status of the cervix.8-14 Despite a difference in the self-
sampling methods, all these earlier studies have used a liquid sample storage and 
transport medium. Due to legislations the logistics for these potentially hazardous 
liquid-based techniques will be difficult to organize and therefore expensive. 
Implementation of liquid-based at-home self-sampling of population-based screening 
non-responders might thus be delayed or even impossible. 
The present study shows that HPV detection and genotyping in self-obtained genital 
samples that are subsequently applied to dried fluid spots (DFS) is very well possible. 
Moreover, this method shows a high overall agreement with HPV detection in 
physician-obtained cervical LBC. All but three DFS hr-HPV positive samples were also 
hr-HPV positive in the MD-smear, whereas only one DFS hr-HPV negative sample 
appeared to be hr-HPV positive in the MD-smear. Leading to a overall agreement 
between the two methods of 92%, and 94% taking the high-risk and probable hr-
HPV genotypes into account. 
The HPV SPF10 Line Blot 25 test has previously shown good concordance with various 
other assays.23,26,27 However, this assay is known for its high analytical sensitivity 
level, i.e. the test result is positive even if a little amount of HPV copies is present. 
This feature might explain the undetectable viral load in some samples found positive 
for certain HPV genotypes by the assay. Since, a high analytical sensitivity is not 
equal to a high clinical sensitivity or clinical relevance28, genital self-sampled dried 
fluid spots ought to be assessed using other commercially available HPV detection 
and genotyping tests with lesser analytical sensitivity as well, e.g. Hybrid Capture II. 
Although the viral load could not be determined for all genotypes, the agreement 
between the samples in this study would be higher when excluding the samples 
with a known undetectable viral load, 96% κ-value of 0.92 (95% CI 0.81-1.03).
Also high concordance between specific HPV genotypes assessed in the self-sample 
and the cervical smear by the physician signifies that the samples self-obtained by 
the patients are representative for the genotypes that infect the cervix. Moreover, 
the amount of ß-globin found was significantly higher in the self-obtained samples 
(t-test, P<0.001), implying that limited cell count and adequacy in self-obtained 
samples is no limitation. The higher ß-globin might be due to the fact that the 
cervico-vaginal self-sampling brush with unknown volume was directly applied to 
the DFS, whereas the smear obtained by the physician was rinsed in 20 mL LBC and 
homogenised before analysis, as the procedure requires. The difference could also be 
explained by the fact that 500 µL homogenised LBC is used for DNA isolation, while 
the complete DFS paper was processed.
In four of the 7 compatible samples additional genotypes were detected in the self-
obtained samples. These additional types could arrive from the vaginal epithelium 
7
146 147
which might be infected with other HPV genotypes. Especially self-sampling with 
brushes is susceptible to obtaining cells different than cervical epithelial cells. The 
impact of these vaginal or non-cervical localized genotypes in the pathogenesis of 
cervical dysplasia is unknown. 
The dried fluid spots used in this study are neither hazardous nor inflammable; 
applying genital scrapes on these filter papers can solve storage and transportation 
problems. Since this technique could be applicable to at-home self-sampling, it could 
imply an incentive for decreasing non-compliance of the population-based screening. 
Especially women not participating due to fear might be persuaded to actually 
participate. Moreover, since self-sampling can be done by the patient and only the 
women who are persistently hr-HPV positive ought to be examined, less physicians 
and MD-time is needed, which will eventually reduce costs. 
Dried fluid spots (i.e. dried blood) have already been used for decades in the 
postnatal screening of certain congenital disorders and diseases. Dried blood spots 
have also been successfully used in studies detecting and genetically characterizing 
measles virus strains.29 Additionally, at-home collection for HIV testing using DFS has 
been considered feasible and acceptable in a high-risk cohort30, but also viral load 
and genotypic-resistance assessments in HIV-positive patients appear to be possible. 
The air-dried samples are stable at room temperature for months up to years and 
various studies have demonstrated conserved stability of virus particles under 
suboptimal conditions using filter papers.29,31,32 Cervical or genital samples obtained 
in developing countries could therefore be spotted on DFS filter paper and send to 
designated central laboratories for analysis. This could simplify the introduction of 
organised HPV-based cervical screening programmes in developing countries as well.
Regarding to cytological assessment the existing self-sampling methods have 
repetitively shown to be no alternative for the classic Pap smear.8,11 Also, the DFS self-
sampling method is unsuitable for cytological cervical cancer screening. 
In conclusion, HPV detection and genotyping on self-sampled cervicovaginal samples 
using a Viba-brush®‚ and dried fluid spots is very well possible and the results are 
highly representative for the cervical HPV status. The dried fluid spot technique is 
non-hazardous and the samples are allowed regular mailing. This suggests that the 
DFS method might be applicable to at-home self-sampling in the population-based 
screening non-responders, for the introduction of a primary HPV-based cervical 
cancer screening, and for establishing cervical cancer screening programmes in 
developing countries.
7
Table IV  Overview of the sample-sets containing at least one hr-HPV genotype  
in either one or both samples including viral load for HPV 16, 18, 31,  
and/or 33
 HPV genotype   Viral load (16, 18, 31, or 33)
    Concordant
 Self- MD- 
compatible 
Self MD Self MD
 sampling sampling 
discordant
 
1 31 31 Concordant 1.5 • 107 8.1 • 107  
2 52 52 Concordant    
3 18 18 Concordant 2.7 • 107 7.4 • 106  
4 68/73 68/73 Concordant    
5 18 18 Concordant 2.0 • 106 1.7 • 104  
6 56, 66 56, 66 Concordant    
7 16, 53 16, 53 Concordant 5.9 • 105 1.1 • 105  
8 16 16 Concordant 2.7 • 106 3.5 • 105  
9 16 16 Concordant 7.9 • 104 1.6 • 106  
10 58 58 Concordant    
11 56 56 Concordant    
12 39 39 Concordant    
13 59 59 Concordant    
14 52 52 Concordant     
15 68/73 68/73 Concordant    
16 51 51 Concordant    
17 31 31, 52 Compatible 7.7 • 104 9.6 • 102  
18 16, 59, 66 16 Compatible 5.0 • 104 2.8 • 105  
19 51, 66 66 Compatible    
20 16 16, 31 Compatible 5.0 • 105  1.2 • 104  LND
    (HPV 16) (HPV 16)  (HPV 31)
21 31 31, 33 Compatible LND LND  1.9 • 104
    (HPV 31) (HPV 31)  (HPV 33)
22 31, 52 52 Compatible LND   
23 31 - Discordant LND   
24 51 - Discordant    
25 - 33 Discordant  LND
LND: viral load not detectable
(HPV SPF10 Line Blot 25  
genotyping test)
(copies/scrape)
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Managing abnormal cervical cytology  
In developed countries well-organised cervical cancer screening programmes, based 
on Pap (Papanicolaou) smears, have resulted in a significant decrease in the incidence 
of cervical carcinomas. For decades, however, the management of cervical cytological 
abnormalities has been subject for debate. Thereby, important issues are addressed 
such as (i) the progressiveness of cervical lesions and (ii) factors influencing the 
success rates of organised screening-programmes. 
(i) The majority of all cytological abnormalities detected through screening are not 
progressive in behaviour and will not lead to cervical carcinoma. However, those 
susceptible to malignant progression should be detected in an early, pre-malignant 
stage. Previous studies suggest that additional biomarkers like human papilloma-
virus (HPV) can be valuable in the early-detection of the pre-malignancies that are 
truly progressive. Indeed, in chapter 6 of this thesis we have shown that a logistic 
regression model based on a combination of biomarkers indicative for proliferation 
and numerical chromosome aberrations (i.e., Ki-67 labelling index and chromosome 
indexes, respectively), can correctly classify the biological behaviour in a high 
percentage of HPV-positive equivocal smears. 
(ii) The success rate of screening-programmes on the other hand highly depends on 
the patients’ participation rate, the experience of physicians and cytologists, and the 
sensitivity and specificity of the tests used. Improving these features will ultimately 
lead to a higher success rate. Improving patient information on cervical cancer, its 
precursors, its risk factors, and the necessity of early detection, for instance, could 
encourage the screening programmes’ non-responders to participate.1 Whereas, 
training of involved medical professionals will increase their experience and 
awareness, and subsequently the overall success rate of the programmes. The 
interpretation of cervical cytology however remains highly subjective and susceptible 
to disturbing factors such as fatigue. The low sensitivity of conventional cytological 
tests for the detection of high-grade CIN can be increased through the introduction 
of liquid-based cytology (LBC). This technique has also shown to significantly reduce 
unsatisfactory smears, it is faster and more efficient, and the interpretation of LBC 
is associated with fewer screening errors.2,3 Furthermore, it offers the opportunity 
for other diagnostic analyses, e.g., HPV and P16 assessment.
The success rate of screening-programmes could benefit even more by assessing 
high-risk HPV (hr-HPV) in cervical smears. After all, the clinical value of HPV DNA 
testing in the management of cervical cancer is increasingly being acknowledged4, 
and the sensitivity of hr-HPV testing for detecting high-grade CIN or worse is 20-
40% higher compared to cytology. Specificity however lags behind, being 5-10% 
lower than that of cervical cytology5,6, so HPV-positive women could be falsely 
judged having a high-grade CIN based on HPV detection alone. 
Only recently the Dutch Pathology association (NVVP) followed the health-care 
policies from other countries by approving additional high-risk HPV testing. All 
smears persistently (i.e., after a 6 months interval) showing borderline and mild 
dysplasia (BMD), and, even the BMD smears that have normalized after 6 months, 
are subjected to hr-HPV detection, see also the flowchart of the Dutch Pathology 
association (Figure 3) in the first chapter of this thesis. In case of a negative hr-HPV 
test, the patient suffering a persistent BMD smear is not referred to the gynaecolo-
gist, whereas, the patient with the normalized smear can return to the regular 
cervical screening programme. This triage is solely designed for the follow-up 
management of equivocal smears from the population-based screening-programme 
and not for first-time equivocal smears within the screening programme. The main 
reasons for this ‘negative triage’ of follow-up smears are to reduce the number of 
repeated cytological smears and the colposcopy referrals.
Implementation or integration of immediate HPV detection in the screening-
programme is not yet issued. Hence, a major question to be addressed in the near 
future is whether hr-HPV testing should be used as an immediate triage-tool for 
first-time BMD cytology in the regular population-based screening, thus without 
awaiting the repeated cytology after 6 months. Since logistical and technical issues 
will not be the major problem in any highly developed country, sophisticated 
analyses deliberating costs, effectiveness, and health-care benefits of such an 
immediate hr-HPV triage ought to answer this question. 
After implementation of hr-HPV testing in addition to cytological screening, a 
population-based screening programme entirely based on hr-HPV detection is 
suggested to be the next rational step. Major concern regarding primary and 
exclusively HPV testing is the expected higher referral rate for colposcopy due to its 
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low specificity. Therefore high-risk HPV positive women should be reassessed after 
6 months and only in case of hr-HPV persistence the women will undergo a cytology 
triage. Considering primary HPV-testing, cervicovaginal self-sampling should be 
addressed as well. Various studies have shown that hr-HPV detecting in self-obtained 
samples is highly concordant to HPV assessments in cervical smears. Implementing 
these techniques has shown to encourage a large group of non-responders to 
participate in the population-based cervical cancer screening.7 
Regardless the primary or triage position of HPV assessment in the population-based 
screening policy, the importance of genotyping genital HPV infections has to be 
addressed as well. Distinguishing equivocal smears that are HPV 16 positive from 
smears positive for any other hr-HPV genotype, for instance, is already regarded 
essential since, HPV 16 positive equivocal smear have a 30-fold higher risk for 
developing high-grade CIN or worse than those infected with any other hr-HPV 
genotype.8 Moreover, the association between hr-HPV persistence and high-grade 
CIN development is based on genotype specific persistence, consequently a ‘hr-HPV 
on/off ’ detection does not sufficiently cover the need and adequate HPV genotyping 
is necessary. Also, the significance of infections harbouring multiple genotypes -
suggesting repetitive exposure and association with an increased risk for progressive 
disease- remains undetermined and can merely be challenged using assays that are 
able to detect and distinguish multiple genotypes in a sample in a single run. 
Chapters 4 and 7 of this thesis specifically studied and compared the presence of 
HPV genotypes in various cervical samples and could not have been performed 
without an accurate genotyping test. All these issues are considered prospects for 
HPV genotyping. At the 23rd International Papillomavirus conference it was shown 
that in addition to the clinical use for genotyping assays, epidemiological studies -
essential in addressing the burden of HPV infections- can only be performed using 
accurate and reproducible genotyping assays.9 The value of individual genotyping 
assays can merely be assessed through comparative studies. In chapter 5 of this 
thesis two commercially available genotyping assays (SPF10 INNO LiPA and the Roche 
LINEAR ARRAY) were compared and considered highly equivalent. 
For both HPV detection assay and genotyping assay the clinical and the analytical 
relevance are going to play a significant role in the ultimate decision which test to 
use for future screening and/or triage purposes.10
Nevertheless, even if the ultimate hr-HPV test or genotyping assay, with high 
sensitivity, specificity, and positive and negative predictive value, is used in addition 
to the ideal algorithm, merely the developed countries -since money and logistics are 
available- will take advantage of this improvement in patient management. The 
benefits that can be yielded from less significant and cheaper advances in healthcare 
are relatively higher in developing countries than in the developed ones. In India, 
Kenya, and Peru for instance three lifetime hr-HPV tests could reduce the lifetime 
risk of cervical cancer by 60%. Whereas shortening the cytology-screening interval 
from 3 to 2 years in well-developed countries would lead to a reduction in lifetime 
risk of cancer from 80% to approximately 88%. The costs of this latter improvement 
would however be 20-fold higher per year of life saved compared to the first 
development.11 
Another example of less significant, low cost, and easy applicable development in 
cervical cancer prevention is the use of genital self-sampling as described in chapter 
7 of this thesis. The self-sampling method using dried fluid spots has shown to be 
highly concordant to HPV assessments in cervical smears. In developed countries this 
and other methods could encourage population-based screening non-responders to 
participate in a more anonymous setting and might increase the availability of 
cervical cancer prevention in developing countries.
Secondary prevention in the form of a well-organised cervical cancer-screening 
programme is, and probably will however remain unavailable in most of the 
developing countries. Therefore, in addition to various therapeutic interventions (i.e. 
tertiary prevention), prophylactic vaccination (primary prevention) may provide a 
convenient alternative conquering HPV associated genital neoplasia, hereby 
refraining from an organised screening programme. 
HPV vaccination
Early data already suggested that L1 virus-like particles (VLP) vaccines can potentially 
reduce worldwide cervical cancer rates. In all phase II trials the different intramuscular 
administered vaccines available for testing were well tolerated and no serious 
vaccine-related adverse events were reported.12-15 The vaccines have thus met the 
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demands of an ideal vaccine that is generally administered to individuals who would 
have never had developed cervical cancer even without the vaccine. It concerns a 
monovalent hr-HPV 16 vaccine14, a bivalent vaccine against hr-HPV 16 and 1812,13 and a 
quadrivalent vaccine against lr-HPV 6 and 11 and hr-HPV 16 and 18.15 The generated 
immune responses are robust, durable, of 20-100 times greater magnitude than 
those caused by a natural infections. Persistent HPV infections were prevented in 
89-100%, whereas the effectiveness against incident infections in young women 
was approximately 90% for HPV 16 and 18 (see for review Quint 2006).16 In HPV 
positive women the HPV vaccine does not seem to speed viral clearance (A. 
Hildesheim, R. Herrero, Abstr. 23rd IPV Conference, abstr. PL1-1, 2006). The quadriva-
lent vaccine also seems to prevent abnormal cytology, CIN lesions, and even pre-
malignant vaginal and vulvar lesions (J. Paavonen, Abstr. 23rd IPV Conference, abstr. 
PL1-2, 2006). 
Recently, a significant cross protection against other high-risk HPV genotypes, i.e. 
HPV 31 and 45 has been observed.13 Since HPV 16 and 18 together account for 69.8-
77.1% of the cervical cancers worldwide, cross protection of multivalent vaccines 
could lower the worldwide incidence of cervical cancer by an additional 8%.16 Phase 
III studies however should definitively elucidate these questions. Although, the 
protectiveness of the vaccine is promising and has shown to be effective for at least 
48 months13, true long-term protection and effectiveness, re-boost strategies, and 
cost-effectiveness need to be studied in large-scale trials with long-term follow-up. 
Based on the published randomized controlled trials regarding the HPV vaccines, 
health policy makers recommended vaccinating young adolescents prior to the 
onset of their sexual active life, in order for a vaccination programme to become 
successful. Taira and colleagues calculated that in case i) the HPV 16/18 vaccine 
reduces the chance of an infection by 90%, ii) only 12 year old girls are vaccinated, 
and iii) the conventional screening is continued, the risk of developing cervical cancer 
would decrease by 89%.17 In contrast, the lifetime risk for cervical cancer is reduced 
by 58-70% in the current 5-yearly Dutch screening protocol.1,18 Broadening the 
vaccination age will reduce HPV related disease even more, but will also increase 
costs. Providing the per-woman cost of the vaccine is less than $25, mathematical 
models have predicted that prophylactic vaccination will be cost-effective, and 
might even be cost saving.19 In countries with well-organised secondary prevention 
programmes, screening policies should be modified considerably in order to generate 
a cost-effective cervical cancer prevention management after the introduction of 
HPV vaccines. 
Besides effectiveness of vaccines, approval of national governments and registration 
authorities are important issues to be addressed when introducing the vaccine. Also, 
ethical considerations will presumably be more pronounced in case of a vaccination 
for a STD. Despite extensive research on the effectiveness of the various vaccines, 
and the approval of the quadrivalent vaccine for women aged 9-26 by both the FDA 
and the European Commission, neither the Dutch Minister of Health nor the Dutch 
National Institute for Public Health and the Environment (RIVM) have yet taken 
position concerning this issue (personal communication). 
As the HPV vaccines will be implemented as a primary prevention for cervical cancer, 
the suggested vaccination policies are predominantly focussed on girls and young 
women. However, since most young adolescents are not yet aware of their sexual 
preferences, i.e. hetero-, homo-, or bisexual, vaccination programmes should also 
consider targeting boys before HPV-exposure.20 According to Meijer and colleagues, 
the prevention of penile lesions through vaccination would result in a considerable 
reduction of viral transmissibility to sexual partners, consequently lowering HPV 
related disease (C.J. Meijer, M.C.G. Bleeker, F.J. Voorhorst, P.J.F. Snijders, Abstr. 23rd IPV 
Conference, abstr. PS 26-4, 2006). Moreover, in addition to cervical cancer, hr-HPV 16 
and 18 are also the most frequently detected genotypes in anal carcinomas, anal 
sexual activity is practised in at least 33% of the heterosexual and 80% of the male 
homosexual couples, and the incidence of anal carcinoma is rising.20 Although less 
frequently occurring, HPV 16 may also be aetiologically important in tonsillar 
cancerous development21, and may represent an alternative pathway in carcino-
genesis to the established factors of tobacco smoke and alcohol (ab)use.22 
Sexual activities and sexual preferences are in general non-beloved and frequently 
avoided conversation and discussion issues. This is presumably why HPV knowledge 
and the awareness of the association with cervical cancer is extremely low in the 
general population.23 In contrast to the quadrivalent vaccine which is marketed as a 
vaccine against HPV, the bivalent vaccine will be promoted as a primary prevention 
of cervical cancer. Giving recipients full information about the vaccine’s purpose will 
also necessitate teaching them about sex, the sexual viral transmissibility, and the 
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oral and genital cancer risks. Educating health-care workers is highly necessary as 
well (S. Moorthy, Abstr 23rd IPV Conference, abstr PS1-6, 2006).
The post-vaccination era of cervical cancer screening 
The introduction of HPV vaccines will have a global impact as a preventive strategy 
for cervical cancer.6 Ultimately, successful prophylactic vaccines will make secondary 
preventative efforts by means of cervical screening redundant, and thus cause 
reallocation of money from secondary prevention to primary prevention. But even 
with a high vaccination rate, a reduction of cervical cancer burden is not expected 
for at least 20 years. Moreover, although two prophylactic vaccines have shown 
cross-protection for other HPV genotypes than originally designed for, protection 
does not include all high-risk genotypes. On the contrary to the 100% efficacy found 
in the vaccination phase II studies, Franco and colleagues recently suggested that 
the protection for the targeted types cannot be expected absolute.6 Taken the above 
and the vaccine non-responders into account, screening for pre-malignant CIN 
cannot be discontinued after the introduction of the first generation vaccines. 
On June 8, 2006 the U.S. FDA approved Merck’s quadrivalent vaccine GARDASILTM for 
9- to 26-year old girls and women. The European Commission licensed the same 
vaccine, now by Sanofi Pasteur MSD (a joint venture between Sanofi Pasteur and 
Merck & Co.), on September 22 for the 25 member countries of the EU. GlaxoSmithKline’s 
bivalent CervarixTM will most likely follow late 2007 targeting the same age group. 
Consequently, it will take decades before the true effects in this entire cohort can be 
verified. And since group immunity will definitely not occur, women aged 27 and 
above can -at the start of the vaccination programme- never benefit directly from 
the programme, they will be compelled to the regular cervical screening programmes. 
These women might also benefit from “catch-up” immunization even if they have 
already been infected with a genotype included in the vaccine. Large trials in women 
aged 24 and older are currently conducted and will address these issues.
Clearly the conventional population-based cervical cancer-screening programmes 
will not be abolished in the short run. But concerning the future, these programmes 
ought to be thoroughly re-evaluated, an aspect which was largely neglected in the 
studies regarding prophylactic HPV vaccinations. In the post-vaccination era a 
decrease in the prevalence of cervical abnormalities will ultimately lead to a decrease 
of the positive predictive value of cervical cytology. This will successively cause an 
increase in false-positive diagnoses in women who screen positive, resulting in 
unnecessary referrals6 and increased anxiety.24 Addition of HPV testing could be 
beneficial for the efficacy of the existing approach of many screening programmes10, 
in pre- and post-vaccination eras. But adding an extra assay and a vaccine will be too 
costly for public-health budgets in numerous countries. Whether primary HPV 
assessment is efficient and cost-effective in an HPV vaccinated population, should 
be one of the research priorities for the near future. 
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Summary
Chapter 1
Cervical cytological pathology is not uncommon. Prevention of cervical cancer by 
detection of the disease in an early and pre-malignant stage is practised globally 
either through population-based screening programmes or more optimistically non-
organised ones. High-grade cervical intraepithelial neoplasia (CIN) detected by 
cervical cytological screening are extensively visualised by colposcopy and 
successively treated by, for instance, large loop electro-surgical excision of the 
transformation zone (LLETZ). Persistent infections with certain high-risk human 
papillomavirus (hr-HPV) genotypes play a significant, but not determinative, role in 
cervical cancer carcinogenesis. The HPV-induced oncogenesis is suggested to be a 
multi-step process in which the integration of viral DNA in the human genome is the 
established key-event. Next to the assessment of markers indicative for cell-
proliferation and parameters related to aberration of chromosome aberration, are 
the detection and genotyping of HPV infections in cervical smears also suggested to 
become highly established tools in assessing the risk of progression of cervical 
abnormalities. Apart from the above, features such as the clinical and analytical 
sensitivity of a HPV test and the sense and feasibility of genital self-sampling are 
discussed in chapter 1.
Chapter 2
Genital infections with human papillomavirus (HPV) are amongst the most common 
sexually transmitted diseases (STD) worldwide. In the vast majority of adolescents 
and young adults an HPV infection is transient and will not lead to detected cervical 
abnormalities. Another highly prevalent STD, Chlamydia trachomatis, is more 
prevalent in subfertile women than in the general population and the leading cause 
of tubal factor subfertility. One could hypothesise that since the prevalence of 
C. trachomatis is higher in subfertile women, these women are more likely to have 
HPV-induced cervical abnormalities compared to the general population. Chapter 2 
describes a retrospective case-control study assessing the smears of 669 cases, i.e. 
women visiting the fertility clinic for in vitro fertilisation (IVF), and 77055 women 
attending the population-based screening programme for cervical cancer, i.e. the 
controls. Significantly more cases had an abnormal cervical smear compared to the 
controls. The chance that a high-grade cervical lesion is detected is a woman eligible 
for in vitro fertilisation is twice as high compared to a woman in the general 
population. Since cytological abnormalities are induced or enhanced by highly 
prevalent STDs that are related to promiscuous precarious sexual activity, taken a 
cervical smear, as part of the fertility screening in women, should be common 
practice, most certainly before they undergo expensive IVF treatment. 
Chapter 3
Early treatment of cervical intraepithelial neoplasia (CIN) significantly reduces the 
risk of invasive cancerous progression of the lesion. One of the most widely used 
methods effectively treating high-grade CIN is the electro-surgical large loop 
excision of the transformation zone (LLETZ). This procedure has a high success rate, 
while maintaining anatomy and function of the cervix. Chapter 3 gives an overview 
of 22 years experience in treating high-grade CIN and the subsequent cytological 
follow-up as performed at our outpatient clinic. The vast majority of the women 
with a high-grade cervical lesion have shown to be adequately treated, since the 
follow-up of at least 2 years showed no repetitive lesion. In less than 10% of the 
women a high-grade repetitive lesion was detected and subsequently treated. In 
80% these repetitive lesions recurred within 2 years and were therefore considered 
residual CIN. The remaining 20% repetitive high-grade CIN were regarded as 
recurrent lesions. More than half of the recurrent lesions appeared more than 5 years 
postoperatively, suggesting that adequate and long-term cytological follow-up is 
compulsory. Although not assessed in the present study, previous studies have 
recommended using hr-HPV detection as a more sensitive follow-up tool. 
Chapter 4
Chapter 3 has already shown that the LLETZ is a well-established treatment for high-
grade CIN. It has also been postulated that LLETZ is responsible for the elimination 
of HPV, the infectious agent causing CIN. Most studies on HPV detection after a 
LLETZ procedure have merely focussed on the persistence of high-risk (hr-)HPV to 
identify women at risk for residual or recurrent disease. The appearance and or 
significance of new hr-HPV types detected after treatment has not been extensively 
studied. The presence of hr-HPV in 85 high-grade squamous cervical LLETZ biopsies 
and in the first follow-up smear was determined. In 94% of the LLETZ biopsies hr-
HPV was detected compared to 35% hr-HPV positive follow-up scrapes. Twenty of 
the 80 hr-HPV positive women (25%) had the same hr-HPV genotypes in their follow-
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up smears as was found in the corresponding biopsies. In the follow-up smear of 13 
women a new hr-HPV genotype was detected and HPV 18 was newly detected in 8 
of them. The remarkably high presence of newly detected HPV 18 genotypes may 
argue for a release or re-activation of this virus from proximal layers of the cervical 
canal incised during surgery.
Chapter 5
Accurate genotyping of human papillomavirus (HPV) is important in order to i) 
monitor the efficacy of multivalent vaccines and surgical treatment, ii) study the 
epidemiology of HPV infections worldwide, and iii) assess the oncogenic potential of 
high-risk HPV genotypes. Various HPV detection and genotyping assays have been 
developed to meet this demand. In chapter 5 the Roche LINEAR ARRAY a recently 
developed genotyping assay based on a well-known primer set (PGMY 09/11) is 
compared to a more established and highly sensitive genotyping assay (the SPF10-
INNO LiPA). The samples used for comparison showed identical results in both assays 
in 81% of the cases. In 11% of the samples the tests showed comparable but not 
identical results, whereas in 8% no resemblance was observed. The differences 
found could be attributable to a variation in analytical sensitivity for certain 
genotypes in the assays used or to low copy numbers in particular samples. Despite 
the differences, the two assays can be regarded highly comparable and reprodu-
cible.
Chapter 6
High-grade pre-malignant cervical lesions are effectively treated by LLETZ (chapter 3 
and 4). However, not every high-grade CIN would have progressed towards cervical 
carcinoma if left in situ. Biological behaviour, i.e. progression and regression, of CIN 
cannot be predicted using conventional cytology or histology. Since HPV integration 
into the human genome marks the onset of carcinogenesis, parameters as HPV or 
makers indicating proliferation, genetic instability and chromosomal aberration may 
be of predictive value assessing the progressive and regressive behaviour of CIN. In 
chapter 6 logistic regression models based on the progression marker Ki-67 labelling 
index (MIB1) and chromosome aberration parameters (chromosome index and 
aneusomy) for chromosome 1 are used to study the biological behaviour of CIN 
lesions. Patients referred to the gynaecologist having two consecutive equivocal 
smears were assessed for this study. In the in-take smears of 42 women showing 
regression and 31 women showing progression (maximal CIN 3) in the follow-up the 
above-mentioned parameters were assessed. A multi-parameter logistic regression 
model containing the parameters Ki-67 labelling index, chromosome index for 
chromosome 1, and the fraction of cells with 4 copies of chromosome 1 per nucleus 
appeared to be the best predicting model, classifying 93.2% of the samples correctly 
(AUC 0.96±0.02). If applied to women with a borderline or mild dysplastic smear 
who are hr-HPV positive the logistic regression model correctly triaged the ones 
showing progression. So, short-term pro- and regressive behaviour is highly 
predictable using a model combing these parameters. Although laborious, the model 
can be useful further triaging hr-HPV positive women with equivocal smears, 
reducing colposcopy referral rate even more. 
Chapter 7
Previous research has undoubtedly shown that hr-HPV testing in cervical cancer 
screening has a beneficial effect in patient management. Moreover, it is suggested 
to increase the success rate of population-based screening programmes. Since 
women who do not participate in these programmes have a higher risk of developing 
cervical cancer. The introduction of cervicovaginal self-sampling might increase the 
participation rate and can thus reduce cancer incidence. In chapter 7 we have 
assessed the possibility to detect and genotype (probable) hr-HPV-DNA using self-
sampled genital smears that were subsequently applied to specific filter papers. 
These filter papers allow easy storage and transport. The HPV results were compared 
to a cervical smear taken by a trained physician using the HPV SPF10 Line Blot 25 assay. 
The overall agreement between self- and physician obtained sample was 96% 
(κ-value: 0.92). This study shows that HPV detection and even genotyping in self-
obtained genital samples using filter papers is very well possible. Compared to other 
self-sampling devices the filter paper method is not dependent on liquid storage 
methods that are potentially inflammable, hazardous and are not always allowed 
regular mailing.
Chapter 8
The last chapter focuses on the importance of the early-detection and the 
management of abnormal cervical cytology, the problems associated with it 
(sensitivity and specificity issues), and possible solutions for these problems in the 
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near future (implementing additional or new bio parameters). Moreover, this chapter 
briefly issues the introduction of the recently approved HPV vaccines and the impact 
this might have on HPV associated cancers. These vaccines will most certainly have 
a global impact as a primary preventive strategy for cervical cancer. This emphasizes 
the importance of cervical cancer screening in the post-vaccination era.
Samenvatting
Hoofdstuk 1
Afwijkende cervix cytologie is een omvangrijk probleem. Over de gehele wereld 
wordt getracht baarmoederhalskanker (cervix kanker) te voorkomen door de ziekte 
in een vroeg en nog goedaardig stadium te detecteren. Dit geschiedt veelal in een 
door het land/de regio georganiseerd preventief bevolkingsonderzoek, maar ook 
door minder grootsopgezette, meer opportunistische detectie worden afwijkingen 
van de cervix gevonden. De niet-kwaadaardige cervix afwijkingen, ook wel hoog-
gradige cervicaal intra-epitheliale neoplasiën (CIN) genoemd, worden meestal 
opgespoord door middel van uitstrijkjes, vervolgens uitgebreid in kaart gebracht 
door middel van een kolposcopisch onderzoek en indien noodzakelijk behandeld door 
een diathermische lisexcisie van de overgangszone. Aanhoudende infecties met 
bepaalde hoog-risico humaan papillomavirus (HPV) genotypen spelen een belangrijke, 
maar niet alles bepalende, rol in de carcinogenese van het cervixcarcinoom, ofwel de 
ontwikkeling van baarmoederhalskanker. De door HPV geïnduceerde carcinogenese 
is met zekerheid een proces met meerdere elkaar deels overlappende fasen. Hierbij is 
voor de versmelting (integratie) van het virale genetische materiaal met het humane 
materiaal de een hoofdrol weggelegd. Naast diverse testen (b.v. celproliferatie 
markers en parameters welke afwijkingen in chromosomen kunnen bepalen) welke 
indirect de voortgang van de carcinogenese kunnen nagaan, zullen methoden om 
HPV te detecteren en te genotyperen in de nabije toekomst zeer belangrijk worden 
om een progressie risico-inschatting van bepaalde cervix afwijkingen te maken. 
Naast het hierboven geschrevene, zullen aspecten als klinische en analytische 
gevoeligheid van HPV testen, en de zin en mogelijkheden van genitale HPV 
zelfsampling aan de orde komen in hoofdstuk 1. 
Hoofdstuk 2
Genitale humaan papillomavirus (HPV) infecties zijn een van de meest voorkomende 
seksueel overdraagbare aandoeningen (SOA) wereldwijd. Bij de meerderheid van de 
adolescenten en jong volwassenen is deze infectie van voorbijgaande aard en zal ze 
niet leiden tot detecteerbare afwijkingen van de baarmoederhals. Een andere veel 
voorkomende SOA is Chlamydia trachomatis. Chlamydia wordt vaker gevonden bij 
subfertiele vrouwen dan bij vrouwen in de algemene bevolking en is in veel gevallen 
de veroorzaker van verklevingen in de eileiders hetgeen leidt tot “tubafactor 
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subfertiliteit”. Hypothetisch kan het zijn dat gezien de hoge prevalentie van 
C. trachomatis, subfertiele vrouwen vaker HPV geïnduceerde cervix afwijkingen 
hebben in vergelijking met vrouwen uit de algemene bevolking. Hoofdstuk 2 
beschrijft een retrospectieve studie waarbij de uitstrijkjes van 669 subfertiele 
vrouwen in aanmerking komend voor in vitro fertilisatie (IVF) en 77055 vrouwen uit 
het bevolkingsonderzoek screening voor baarmoederhalskanker werden onderzocht. 
Het blijkt dat de subfertiele vrouwen beduidend vaker een afwijkend uitstrijkje 
hadden dan de vrouwen uit de algemene bevolking. De kans dat een hoog-gradige 
cervicale intraepitheliale neoplasie wordt gevonden in een vrouw die in aanmerking 
komt voor IVF is twee maal zo hoog als voor een vrouw in de normale bevolking. 
Cytologische cervix afwijkingen worden geïnduceerd dan wel bevorderd door veel 
voorkomende SOA’s welke op hun beurt worden veroorzaakt door onveilig en 
promiscue seksuele activiteiten. Het is derhalve raadzaam om bij elke vrouw die 
wordt gescreend in het kader van een oriënterend fertiliteitonderzoek een uitstrijkje 
te maken, vooral bij degenen die kostbare IVF behandelingen zullen ondergaan. 
Hoofdstuk 3
Vroegtijdige behandeling van CIN reduceert de kans op progressieve ontwikkeling 
van deze afwijking tot cervixcarcinoom aanzienlijk. Een veel gebruikte behandelings-
methode is de diathermische lisexcisie van de transformatiezone (Eng.: Large Loop 
Excision of the Transformation zone, LLETZ). Deze methode is erg succesvol en 
behoudt de anatomie en functie van de cervix. Hoofdstuk 3 laat een overzicht zien 
van 22 jaar ervaring met de LLETZ behandeling van hoog-gradige CIN en de cytologi-
sche follow-up van de behandelde patiënten. Gezien het lage percentage herhaalde 
afwijkingen in de gehele groep met een minimale follow-up van 2 jaar, blijkt dat de 
meerderheid van de behandelde patiënten een adequate behandeling hebben 
ondergaan. Slechts in 8.5% van de patiënten werd een herhaalde afwijking gevonden 
en wederom behandeld. Ongeveer 80% van deze afwijkingen ontstond binnen twee 
jaar na de initiële LLETZ procedure en kan daarom als residu laesie worden 
beschouwd. De overige 20% kan worden betiteld als zijnde een recidief afwijking. 
Meer dan de helft van deze recidieven ontstond meer dan 5 jaar postoperatief, 
hetgeen suggereert dat langdurige strikte follow-up onontbeerlijk is. Eerdere en 
latere studies hebben overigens aangetoond dat de bepaling van hr-HPV in de 
follow-up gebruikt kan worden als gevoeligere marker voor de detectie van residu/
recidief CIN. 
Hoofdstuk 4
In hoofdstuk 3 is reeds naar voren gekomen dat de LLETZ een veel gebruikte en 
beproefde methode is voor de behandeling van hooggradige cervicale afwijkingen. 
Er wordt gesuggereerd dat LLETZ verantwoordelijk is voor het elimineren van HPV. 
Waar de meeste studies hebben gekeken naar de aanwezigheid van hoog-risico HPV 
na behandeling teneinde vrouwen op te sporen die een verhoogd risico zouden 
hebben op residue of recidief laesie, hebben wij voornamelijk het voorkomen van 
nieuwe HPV typen na LLETZ bestudeerd. In totaal werden 85 hoog-gradige CIN 
laesies en hun follow-up controle uitstrijkjes geanalyseerd op het voorkomen van 
HPV. Bij 20 patienten werd hetzelfde HPV genotype gevonden in laesie en follow-up 
uistrijk, terwijl bij 13 personen een nieuw HPV type werd ontdekt. Hierbij werd in 
maarliefst 8 uitstrijkjes HPV 18 gevonden. Dit opmerkelijke gegeven pleit voor het 
vrijkomen of re-activeren van het virus uit proximale lagen van het cervicale kanaal 
geincideerd tijdens de LLETZ behandeling. 
Hoofdstuk 5
Het correct kunnen genotyperen van het humaan papillomavirus is van belang ten 
einde 1) de doeltreffendheid te kunnen bepalen van multivalente vaccins en chirur-
gische behandelingen van CIN, 2) de epidemiologische verdeling van HPV over de 
wereld gedegen te kunnen bestuderen, en 3) het oncologische potentieel van hoog-
risico HPV genotypen te kunnen observeren. Diverse HPV testen zijn ontwikkeld om 
aan deze eis te voldoen. In hoofdstuk 6 wordt de LINEAR ARRAY van Roche een recent 
ontwikkelde genotyperingstest, welke is gebaseerd op een bekende primerset (PGMY 
09/11) vergeleken met een bestaande en hooggevoelige genotyperingstest (de SPF10-
INNO LiPA). Bij 81% van de monsters werden identieke resultaten gevonden tussen 
de twee testen, in 11% waren er grote, maar niet identieke, overeenkomsten, en in 8% 
werd er geen enkele overeenkomst tussen de testen ontdekt. De gevonden verschillen 
zouden kunnen worden verklaard door een variatie in analytische sensitiviteit voor 
bepaalde genotypen in een test of door een lage virale load in bepaalde monsters. 
Ondanks de gevonden verschillen kunnen de twee testen statistisch gezien worden 
aangemerkt als erg goed vergelijkbaar en reproduceerbaar.
Hoofdstuk 6
Hoog-gradige premaligniteiten van de cervix kunnen effectief worden behandeld 
door middel van een LLETZ (zie hoofdstuk 3). Niet elke onbehandelde hoog-gradige 
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CIN laesie zou echter een progressieve ontwikkeling tot cervixcarcinoom hebben 
doorgemaakt. Biologische gedrag, i.e. progressie en regressie, van CIN kan niet 
worden voorspeld door conventionele markers als cytologie en histologie. Integratie 
van HPV DNA in het humane genoom markeert het begin van de carcinogenese. 
Daarom zouden parameters als HPV of markers die duiden op cel proliferatie, 
genetische instabiliteit en chromosomale afwijkingen van voorspellende waarde 
kunnen zijn bij het beoordelen van progressief en regressief gedrag. In hoofdstuk 7 
wordt een logistisch regressiemodel gebruikt om het biologisch gedrag van CIN te 
bestuderen. Het model is gebaseerd op de progressiemarker Ki-67 labelingsindex en 
parameters voor chromosoom 1 afwijkingen (chromosoom index en aneusomie). Al 
de genoemde parameters werden in de inclusie uitstrijkjes van 73 patiënten bepaald. 
Deze patiënten werden verwezen naar de gynaecoloog in verband met het hebben 
van twee licht afwijkende uitstrijkjes. Van deze patiënten lieten er 42 in de follow-up 
regressie zien en 31 progressie (maximaal CIN 3). Het opgestelde model met de 
parameters Ki-67 labelingsindex, chromosoom index voor chromosoom 1 en de 
fractie cellen met 4 kopieën van chromosoom 1 in de nucleus bleek biologisch gedrag 
het best te voorspellen. Het gedrag van ruim 93% werd correct voorspeld (oppervlakte 
onder de ROC-curve 0.96±0.02). Indien het model enkel werd toegepast bij hr-HPV 
positieve vrouwen met een klasse 2 of klasse 3a geringe dysplasie uitstrijkje dan 
werden progressie en regressie eveneens correct voorspeld. Korte termijn pro- en 
regressief gedrag is dus goed voorspelbaar gebruik makend van een model met de 
aangegeven parameters. Het model kan erg het aantal verwijzingen voor kolposco-
pisch onderzoek aanzienlijk verlagen indien het naast de triage met hr-HPV wordt 
toegepast bij vrouwen met licht afwijkende uitstrijkjes. 
Hoofdstuk 7
Het staat onomstotelijk vast dat hoog-risico HPV testen in baarmoederhalskanker-
screening van voordeel kan zijn in de management van de patienten. Vrouwen die 
niet deelnemen aan de screening hebben een verhoogd risico op het krijgen van 
baarmoederhalskanker. De introductie van cervicovaginale zelfsampling kan het 
aantal deelnemers vergroten en zo de incidentie van baarmoederhalskanker verlagen. 
Hoofdstuk 7 beschrijft een studie waarin we hebben gekeken naar de mogelijkheid 
van HPV genotypering in zelf afgenomen uitstrijkjes die vervolgens op speciale 
filtreerpapiertjes worden gebracht. Deze zelfsampling monsters werden vergeleken 
met de HPV inhoud van de uitstrijkjes genomen door een arts. De overeenkomst 
tussen de samples was 96%. Detectie en zelfs genotypering van HPV gebruik 
makend van zelfsampling en filtreerpapiertjes is dus goed mogelijk en het materiaal 
blijkt overeenkomstig met dat van het “officiele” uitstrijkje. In vergelijking met 
andere bekende methoden van zelfsampling is de filtreerpapier methode onafhan-
kelijk van vloeistoffen die vaak licht ontvlambaar en potentieel infectieus zijn en niet 
altijd via de reguliere weg verstuurd mogen worden. 
Hoofdstuk 8
Het laatste hoofdstuk bespreekt het belang van de vroege opsporing en de 
behandeling van afwijkende cervixcytologie, de sensitiviteit- en specificiteits-
problemen die hiermee samengaan en de mogelijke oplossingen voor deze problemen 
(het implementeren van additionele of nieuwe parameters). Daarnaast komen in dit 
hoofdstuk de recent geintroduceerde HPV vaccins ter sprake. Omdat deze vaccins 
vrijwel zeker een rol gaan spelen in de primaire preventie van baarmoederhalskanker, 
wordt het belang van baarmoederhalskankerscreening in het post-vaccinatie tijdperk 
eveneens uiteengezet. 
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Abbreviations
 
ALTS ASCUS-LSIL Triage Study
ASC-US Atypical squamous cells of undetermined significance
BMD borderline and mild dysplasia
BNC Borderline nuclear changes
CI Chromosome index
CIN Cervical intraepithelial neoplasia
DEIA DNA enzyme immuno assay
DFS Dried fluid spots
DNA Desoxyribo nucleic acid
E Early region (E1-E7 in HPV genome)
et al. et alii, and others
HPV Human Papillomavirus
hr-HPV High-risk Human Papillomavirus
HSIL High-grade squamous intraepithelial lesion
IVF In vitro fertilisation 
L Late region (L1 and L2 in HPV genome)
LA LINEAR ARRAY
LBC Liquid based cytology
LiPA Line probe assay
LLETZ Large loop excision of the transformation zone
lr-HPV Low-risk Human Papillomavirus
LSIL Low-grade squamous intraepithelial lesion
NA Nucleic acid
NPV Negative predictive value
ORF Open reading frames
PCR Polymerase chain reaction
PPV Positive predictive value
pRb Retinoblastoma protein
PSP Population-based screening programme
SCJ Squamo-columnar junction
STI Sexually transmittable infection
TZ Transformation zone
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handigheid geïntroduceerd, welke ik met zijn goedkeuring graag overneem: de 
alfabetische dankwoordenlijst. Gemak dient per slot van rekening de mens en de 
vrijgekomen tijd kan worden besteed aan het lezen van een van de andere hoofdstukken.
An erster Stelle: Mein dank an Dich, Carolina, Mi vida, meine liebste. Danke dass Du 
Dich so sehr für meine (Doctor) arbeit interesiert und eingesetzt hast. Du hast zwar 
immer gesagt, dass du keine Ahnung davon hättest, aber trotzdem warst Du stets 
sehr kritisch und interessiert. Ich weiß nicht, ob es Dir immer bewußt war, aber Du 
bedeutest mir wirklich viel viel mehr als meine Arbeit...” 
A(N)IOS Eindhoven: Anika, Annemarie, Ashley, Audrey, Evelyn, Helen, Huy, Ilse, 
Judith, Katrien, Marieke en René dank dat jullie waar nodig af en toe voor me wilden 
inspringen en voor jullie getoonde interesse in het onderzoek. Alle anderen, heel 
hartelijk dank voor de gezellige en zeer leerzame werksfeer.
A(N)IOS Nijmegen: Met de meeste van jullie heb ik nog nooit samen mogen werken, 
iets wat weldra gaat veranderen, ik kijk hier erg naar uit. Dank aan degene die zo nu 
en dan eens een praatje kwam maken in de kantoortuin, de niet-klinisch werkende 
artsonderzoeker voelt zich dan meer gerespecteerd en “pars pro toto”. 
Avoort van der, Irene: a.k.a. PHI-31, dank dat je samen met PHI-18 mijn paranimf wil 
zijn, iets waar ik erg trots op ben. Samen de co-schappen doorlopen, de interesse 
voor de gynaecologie duidelijk laten blijken, onderzoek gaan doen, als jonge dokters 
onze eerste SEH patiënt gered in het vliegtuig en zelfs samen een hotelkamer 
gedeeld, ’t moet niet gekker worden... Dank voor al je hulp “and for being a friend”. 
Zie ook kantoortuin en vrienden.
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Bakkers, Judith: Dank dat je me wegwijs hebt willen en kunnen maken in het lab, 
zonder je expertise, logische redeneren en werklust was dit werk niet tot stand 
gekomen. Zie MMB-lab.
Bekkers, Ruud: Terwijl jij met je gezin in Australië zat, ben ik doorgegaan op “ jouw” 
onderzoekslijn. Bij terugkomst verraste je enthousiasme me totaal, je vond het 
geweldig dat de lijn werd voortgezet. Uit onze samenwerking ontstonden weer tal 
van nieuwe ideeën, onderzoeks-projecten voor studenten en zelfs een promotie-
plaats. Dank voor je kritische noten, hulp en gezelligheid (m.n. in Istanbul). 
Bulten, Hans: Met klassieke muziek op de achtergrond en de sigarenlucht in de 
gordijnen heb jij de cytologie en histologie van cervicale afwijkingen een heel stuk 
duidelijker gemaakt, zonder deze kennis was e.e.a. niet zo voortvarend gegaan. 
Familie: Lieve pap, mam en Joost, een paar keer slechts heb ik jullie moeten uitleggen 
waar ik mee bezig was en dat het in opkomst zijnde HPV-vaccin niet ten koste zou 
gaan van mijn baan. Prima, want daardoor besefte ik meer en meer dat de wereld 
van onderzoek niet zaligmakend was en dat de vertaalslag naar “de leek” niet 
eenvoudig, maar wel essentieel is. Dank jullie voor alle steun in al die jaren studie en 
onderzoek. Het is heerlijk te weten dat er altijd dierbaren zijn die m.n. interesse 
hebben in de persoon en niet in hetgeen hij gepubliceerd heeft. 
Gynaecologen, Eindhoven: Drs Boll, dr van Dop, dr Hasaart, dr Hermans, drs Kuppens, 
dr v/d Putten, dr Schoot en dr Struijk, dank voor de leerzame en prettige tijd tot dusver.
Ham van, Maaike: A.k.a. PHI-18. Waar je me eerst begeleidde tijdens m’n co-schap 
(toen nog “U” en “dokter van Ham”), werd je later een onderzoeksmaatje (“ je” en 
“PHI-18”) en nu zelfs paranimf. Na de onderzoeksbesprekingen konden we onze 
frustraties mooi bij elkaar kwijt, raar dat deze besprekingen later separaat werden 
gevoerd, je was echt te dominant! 
Dankzij jou, of liever dankzij Mees (dus JC dien ik ook te betrekken in dit dankwoord) 
kon ik ons eerste stuk presenteren in Vancouver, hetgeen Mees beroemd heeft 
gemaakt in de HPV-wereld.  Maaike, dank voor al je hulp bij het “doen” van onderzoek, 
bij het bekritiseren van de manuscripten en presentaties, voor het relativeren van 
“onderzoek doen” en m.n. voor de samenwerking. Succes met je eigen aanstaande 
promotie. 
Kantoortuin: Angèle, Anika, Annemarie, Arno, Bea, Charlotte, Esther, Gwendolyn, 
Ineke, Irene, Nel, Nienke, Sabine en Willianne plots waren we tot elkander veroordeeld 
in de kantoortuin. Ondanks onze aanvankelijke scepsis heeft deze “verantwoorde 
vorm van kantoorindeling” veel gezelligheid, kantoorhumor en productiviteit te 
weeg gebracht. Dank voor alles en iedereen succes met jullie onderzoeken en andere 
werkzaamheden. Voor sommigen: Tot in de kliniek.
Kuijpers, Judith: En dan wordt je ineens aan zo’n artsonderzoeker gekoppeld...even 
wennen voor ons beide. Maar uiteindelijk heeft onze samenwerking dan heel wat 
vruchten afgeworpen. Het is daarom erg jammer dat de experimenten waarvoor jij 
bent terug gekomen op 2e kerstdag (diep diep respect) niet tot het gewenste 
resultaat hebben mogen leiden. Judith, dank voor de vele werkzaamheden die je hebt 
verricht in het lab, zodat ik me meer kon toeleggen op het schrijven. Enne, nee ik ben 
echt niet boos op je dat je een hele lade met geïsoleerde DNA-samples hebt 
weggegooid! Zie tevens MMB-lab.
Lenselink, Charlotte: Als nieuwe onderzoekster werd je vrij snel met al “mijn” stage-
studenten opgescheept. Dit gaf mij meer lucht en jou genoeg stof voor publicaties. 
Gelukkig loopt je eigen project inmiddels ook, en hoe. Het doet me wel pijn te zien 
dat anderen de taak van helpdesk hebben overgenomen! Dank voor de samenwerking 
en het erg gezellige congres in Praag. Zie ook kantoortuin. 
Massuger, Leon: Op slinkse wijze wist je me te overtuigen dat een AIO-schap 
verstandiger was dan een AGNIO-schap. Het onderzoek wat je in de aanbieding had 
was al praktisch klaar en Willem Melchers zou een uitstekende co-promotor zijn. 
Hoe kon ik zo’n vertrouwen in je hebben...je had gelijk. Elk gesprek met jou leidt op 
onnavolgbare wijze tot nieuwe ideeën en zo wist je me weer te overtuigende zaken 
nog eens vanuit een andere kant te benaderen. Ik kijk uit naar de kliniek en hoop dat 
je me daar net zo weet te interesseren en motiveren.
Medeauteurs: Jan Hendriks, Jan Kremer, Bas Keijser en Hebste Shirango dank voor de 
samenwerking bij de diverse artikelen. 
Melchers, Willem: Na onze eerste ontmoeting was ik wat huiverig, je was wel heel erg 
direct, maar tevens eerlijk. Eigenschappen die ik tijdens mijn co-schappen weinig was 
tegengekomen, maar enorm in je waardeer. Tactisch van je om in de eerste correcties 
een blauwe pen te gebruiken, anders had m’n zelfvertrouwen echt een deuk opgelopen. 
Willem, ik heb veel van je geleerd, niet alleen wetenschappelijk, ook qua bejegening, 
wijnkeuze en sigaren, hiervoor mijn oprechte dank. Tot slot: Ja, je hebt vaak gelijk. 
En als er een zou bestaan, zou jij ‘m verdienen de “Harry Mulisch bescheidenheidbokaal”. 
MMB-lab: De weg door het UMC kon ik de eerste weken niet eens vinden, laat staan 
mijn weg door het lab. En dan al die technieken, voorschriften, bepalingen, samples, 
coderingen. Gonneke, Judith B, Judith K, Sandra, Karin en alle anderen duizend maal 
dank voor jullie hulp, geduld en m.n. gezelligheid.
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Nissen, Loes: Zelf was ik net begonnen en jij werd al mij gekoppeld, hetgeen soms 
ten koste ging van de samenwerking. Maar mede dankzij jouw werkzaamheden werd 
hoofdstuk 2 een feit en een publicatie. Zie ook Stage-studenten.
PA-lab: Alle medewerkers die zich hebben bezig gehouden met het verzamelen, 
bestickeren en zoeken van de Thinprep-potjes en histologieblokjes en het kleuren 
van histologiepreparaten hartelijk dank voor jullie belangeloze medewerking.
Patiënten: Alle anomieme patiënten die belangeloos hebben meegewerkt aan de 
diverse onderzoeken wil via deze weg hartelijk danken. Zonder jullie (en jullie 
uitstrijkjes) had ik dit proefschrift nooit kunnen maken.” 
Siebers, Bert: Behalve gezellig keuvelen over hardlooptrainingen, 7-heuvelenloop en 
marathons ben je van onschatbare waarde gebleken bij de tal van zoekvragen in de 
PA databases. Heel erg bedankt voor je hulp en veel succes bij je promotieonderzoek. 
Zie PA-lab
Stage-studenten: Annemiek, Channa, Evelien, Loes, Marloes en Lucille. Vol 
enthousiasme hebben jullie je gestort op de diverse stageprojecten. Ondanks dat de 
begeleiding niet altijd optimaal was, mede gezien een wisseling van begeleidend 
artsonderzoeker, zijn jullie bevindingen zo waardevol dat sommige tot een presentatie 
of zelfs publicatie hebben geleid. Dank voor de samenwerking en succes met jullie 
carrière als arts/onderzoeker.
Struijk, Nel: Je databestand leek ondoorgrondelijk, toch hebben we het kunnen 
opschonen en zelfs publiceren in een overzicht van 22 jaar LLETZ in Nijmegen. Nel, 
dank je voor je hulp van het verzamelen van data tot de interpretatie van colposcopie-
beelden op de poli. Tevens bedankt voor de gezellige praatjes over kunst, spijzen, 
dranken en reizen. Zie ook kantoortuin.
Vrienden: The boys van Maastricht en alle andere vrienden, mijn excuses dat ik niet 
altijd tijd had voor weekendjes weg en gezelligheid. Gelukkig hebben jullie allemaal 
begrip gehad voor de situatie. Als ik deze promotie tot goed einde heb gebracht, 
gaan we met z’n allen bieren en ik beloof jullie niet nog een studie te doen of titel te 
gaan halen...
Wilde, Peter de: Je wiskundige benadering van ziekteprocessen is uniek en voor velen 
met moeite te volgen. Eens zal niemand meer opkijken van (voorspellende) modellen 
in ziekte. Ik ben dan op de hoogte dankzij de tijd die je hebt willen investeren in mij 
en in hoofdstuk 6. 
9
182 183
Bibliography
Lenselink CH, Gerrits MM, Melchers WJ, Massuger LF, Van Hamont D, Bekkers RL. Parental 
acceptance of Human Papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol. 2007
Van Ham MA, Van Hamont D, Bekkers RL, Bulten J, Melchers WJ, Massuger LF. Prevalence of HPV 
18 after a large loop excision of the cervical transformation zone. J Med Virol 79:314-9, 2007
Van Hamont D, Van Ham MA, Bakkers JM, Massuger LF, Melchers WJ. The utility of HPV genotyping 
for the diagnoses and epidemiology of HPV infections: evaluation of the SPF10-INNO LiPA HPV 
genotyping test and the Roche LINEAR ARRAY® HPV Genotyping test. J Clin Microbiol 44:3122-9, 
2006
Van Hamont D, Nissen LH, Siebers AG, Hendriks JC, Melchers WJ, Kremer JA, Massuger LF. 
Abnormal cervical cytology in women eligible for IVF. Hum Reprod 21:2359-63, 2006 
Van Hamont D, Van Ham MA, Struik-van der Zanden PH, Keijser KG, Bulten J, Melchers WJ, 
Massuger LF. Long-term follow-up after large loop excision of the transformation zone: evaluation 
of 22 years treatment of high-grade cervical intraepithelial neoplasia. Int J Gynecol Cancer 16:615-
9, 2006 
Van Hamont D, Voermans NC, Boerman RH, Cruysberg JR. Visuele hallucinaties bij intacte 
realiteitstoetsing: pseudo-hallucinaties. Tijdschr Neurol Neurochir 106:262-8, 2005
Van Hamont D, Harvey CR, Massicotte D, Frew R, Peronnet F, Rehrer NJ. Reduction in muscle 
glycogen and protein utilization with glucose feeding during exercise. Int J Sport Nutr Exerc 
Metab 15:350-65, 2005 
Rietjens GJ, Kuipers H, Adam JJ, Saris WH, Van Breda E, Van Hamont D, Keizer HA. Physiological, 
biochemical and psychological markers of strenuous training-induced fatigue. Int J Sport Med 
26:16-26, 2005
Curriculum Vitae
Op 16 januari 1975 werd Dennis van Hamont in Moedervreugd te Goirle geboren. 
Na aanvankelijk een carrière als Paus te hebben geambieerd, is Dennis via de 
Norbertus MAVO, HAVO en VWO (beide Theresialyceum te Tilburg) Bewegings-
wetenschappen gaan studeren aan de Universiteit Maastricht (prof. dr. Harm Kuipers 
en dr. Hans Keizer). Tijdens zijn verblijf in Nieuw Zeeland voor een wetenschappelijke 
stage aan Otago University in Dunedin (dr. Nancy Rehrer), ontmoette hij Carolina, 
met wie hij binnenkort zal trouwen. 
Na vier maal te zijn uitgeloot voor Geneeskunde, was het de vijfde keer raak. Aan de 
Katholieke Universiteit Nijmegen kon in maart 2000 een lang gekoesterde droom in 
vervulling gaan. Zo werd met de nodige vrijstellingen in januari 2003 het doctoraal 
examen Geneeskunde gehaald. 
Reeds tijdens het co-schap Gynaecologie werd hij door dr. Leon Massuger (toen nog 
dr.) gestrikt voor de wetenschap. Direct na het behalen van het artsexamen aan het 
Universtair Medisch Centrum St Radboud, startte Dennis in september 2004 als 
artsonderzoeker via de afdelingen Medische Microbiologie (dr. Willem Melchers) en 
Verloskunde en Gynaecologie (inmiddels prof. dr. Leon Massuger) aan een onderzoeks-
project wat uiteindelijk heeft geleid tot dit proefschrift. 
Sinds oktober 2006 is hij als AIOS (arts-assistent in opleiding tot specialist) 
Gynaecologie werkzaam in het Catharina Ziekenhuis te Eindhoven (opleider dr. Tom 
Hasaart) binnen het opleidingscluster Nijmegen (opleider mw. prof. dr. Didi Braat). 
De paranimfen
Irene van der Avoort
Maaike van Ham
9

